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SUMMARY 
 
Migraine is characterised by pulsating, unilateral headache that is worsened by movement. It 
is often accompanied by altered sensitivity to light and sound and gastrointestinal symptoms 
(nausea, vomiting). This common disabling condition, affecting 10-15% of the population in 
Australia, the United Sates of America and Germany, is associated with loss of productivity 
and increased family and economic burden. The causes of migraine headache are yet to be 
fully elucidated. The neurovascular theory and altered central modulation, involving the 
trigeminal nerve and higher brain centres, explain the pain and other symptoms, and have 
guided the symptomatic management for abolishing acute attacks and for prevention. These 
medications, including non-steroid anti-inflammatory drugs, ergots, tripan, antidepressants 
and anticonvulsants, are effective, however are associated with a range of unwanted side 
effects. 
 
Globally, the increasing use of complementary and alternative therapies including 
acupuncture has generated broad interest from academia, governments, healthcare 
professionals and the community. The recent advancement on the understanding of the 
neurophysiologic actions of acupuncture, such as its anti-inflammation and central pain 
modulation effects, has provided the base for its increased use for pain management. There 
has been a number of randomised controlled trials (RCTs) that evaluated the benefits of 
acupuncture for migraine over the last two decades. These studies, originated from different 
countries, have produced conflicting evidence due to a range of methodological and reporting 
deficiencies, including, but not limited to, small sample size and inappropriate outcome 
measures. Furthermore, systematic reviews on acupuncture for headache failed to adequately 
represent non-English studies such as those were conducted in China, where acupuncture was 
originated and widely used.  
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The objectives of this study were to: 1) systematically review the current state of evidence 
from English and East Asian literature of acupuncture for migraine; and, 2) design and 
conduct a RCT that addresses the key identified methodological problems from the systematic 
review (SR), to determine the short- and long-term effect and safety of acupuncture for 
patients with migraine. 
 
To address Objective 1, two SRs were conducted guided by the “Cochrane Handbook for 
Systematic Reviews of Interventions”. Major English and Chinese, Japanese and Korean 
databases were searched and studies were selected and assessed using pre-defined criteria. 
Fifteen English and 17 Chinese studies were selected for the English and East Asian review, 
respectively. Overall, findings of these two reviews supported the value of acupuncture in the 
treatment and prevention of migraine when compared with western medications (English 
studies: RR 1.19; 95% CI 0.98 to 1.46; Chinese studies: RR 1.55; 95% CI 1.27 to 1.88). 
However, there was insufficient data for a meta-analysis to determine the effectiveness of 
acupuncture when compared with no treatment. Furthermore, conflicting findings were 
reported with respect to the specific effect of acupuncture for migraine in studies that 
compared real and “sham/placebo” acupuncture (English studies: RR 1.07, 95% CI 0.93 to 
1.25). 
 
When compared with the studies published in English, Chinese studies appeared to have a 
higher frequency of acupuncture treatment, lower methodological quality, and more 
commonly use pharmacotherapy as a comparator (See Publication 1).  
 
The SRs also revealed that there was limited evaluation of acupuncture for frequent migraine, 
a more debilitating form of headache.  
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To address Objective 2, a randomised, sham acupuncture controlled trial was conducted for 
frequent migraine incorporating the Chinese medicine differentiation diagnosis for acupoint 
selection. Nested in this trial was an evaluation of, the effect of acupuncture on cranial 
pressure pain threshold (PPT) and its relationship with features of migraines, such as migraine 
attacks and intensity.  
 
Fifty participants met the selection criteria were randomly allocated to receive real (RA, 26 
subjects) and sham (SA, 24 subjects) acupuncture for a total of 16 sessions over 20 weeks in a 
gradually decreasing frequency. Formula and supplementary acupoints were used. The same 
registered acupuncturist, not involved in outcome assessment, performed all RA and SA 
treatments. Participants were blinded from treatment allocation. Upon completion of the 
treatment period, participants were followed up for further assessment at three months and 
one year. Intention to treat analysis was employed to deal with missing data and dropouts (2, 
1 and 22 drop-out/s at the end the treatment, three months and one-year follow-up periods, 
respectively).  
 
At baseline (four weeks), the two groups were comparable with respect to demographic data 
and migraine characteristics. At the end of the treatment period (20th week), the mean (SD) 
migraine attack days per four weeks decreased from 11.81 (5.76) to 5.17 (5.02) in the RA 
group and from 12.41 (6.4) to 10.08 (7.11) in SA (Group difference: p = .008). Intensity of 
migraine assessed using a Six-point Likert scale was lower in the RA (2.18 ±1.05) than that in 
the SA group (2.93 ± 0.61, p = 0.004). However, there was no statistically significant 
difference between the two groups with respect to Migraine Specific Quality of Life 
(MSQOL). Medication consumption was reduced in the RA group. Group differences were 
shown at the end of the three-month follow up, but not at the one-year follow up. No severe 
adverse event was reported. Blinding was successful through the credibility test. 
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At the end of the treatment period, there was significant group difference in the percentile 
change of PPTs detected at the bilateral points of TaiYang (Ex-HN5) which is located on the 
temporal areas (228.48% vs. -0.66 % in the left and 92.69% vs. -2.52% in the right).   
 
The major limitation of this RCT was a smaller than anticipated sample size due to difficulties 
experienced for subject recruitment. The strict inclusion and exclusion criteria with the long 
treatment and follow-up periods might have contributed to this outcome. Other challenges 
such as participants’ experience in the trial (See Publication 2) and types of controls were 
discussed.     
 
In conclusion, this study demonstrates that acupuncture is a potentially effective and safe 
option for adult patients with frequent migraine headache with the effects lasting up to three 
months after the termination of the treatment. Further studies are needed to confirm these 
therapeutic benefits with adequate sample sizes, preferably in a multi-centric setting. Future 
studies also need to investigate the anti-migraine mechanisms of acupuncture.   
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CHAPTER ONE: INTRODUCTION 
 
Migraine, a chronic neurovascular disorder, is characterized by recurring severe headaches 
and a series of autonomic and neurological symptoms such as vomiting, nausea, light 
sensitivity and sound sensitivity (Ferrari, 1998). The prevalence of migraine is high, involving 
16% of the Australian population (Heywood et al., 1998), 13% of the population in the United 
States of America (Lipton et al., 2000b), 11% of the population in Germany (Göbel et al., 
1994), and 8.4% to 12.7% of the population in different Asian countries and areas including 
China, Japan, Korean and Malaysia (Wang, 2003). Furthermore, migraine is ranked as the 19th 
disease worldwide to cause disability (Headache Classification Subcommittee of the 
International Headache Society, 2004), affecting a high percentage of adults in the productive 
phase of their life. Migraine is therefore associated with a loss of daily activity. Migraine 
results in high social and economic costs (Pradalier et al., 2004, Bigal et al., 2003).  
 
Due to the complexity and unclear mechanisms of migraine, no “cure” approach exists. To 
date, the pharmacologic management used in the treatment of migraine can be divided into 
two groups: agents that abolish the acute migraine, including normal analgesic and specific 
drugs like ergotamine; and prophylactic drugs that are taken regularly, such as methysergide. 
The principle of pharmacologic management of acute pain is to use safe, effective and 
inexpensive medication as first line agents. If the initial agent does not work a more expensive 
second-line migraine-specific medication is then used. For patients who experience two or 
more attacks per month or have contraindications to, or fail to respond to, acute treatment, 
preventive therapy is employed (Snow et al., 2002). Although these pharmacologic products 
provide some relief to migraine sufferers, they are not without risks. Risks of using the 
pharmacologic products can include low blood pressure, decreased libido, nausea, depression, 
sedation, dry mouth, sleepiness, increased appetite, weight gain and kidney damage. Due to 
these possible side effects, a relevant proportion of patients prefer non-pharmacologic or 
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complementary therapies for migraine which can address the limitations associated with 
existing medical approaches. 
 
According to the Guidelines of the Non-Pharmacologic Management of Migraine in Clinical 
Practice (Pryse-Phillips et al., 1998), a range of approaches can be used for managing 
migraine. Acupuncture is one such therapy increasingly used by patients and physicians 
(Larner, 2005). A recent study reported that migraine patients were likely to incorporate 
complementary and alternative medicine (CAM) into their treatment plans and the 
percentages of CAM users in chronic migraineurs and episodic migraineurs were 50% and 
27% respectively (Rossi et al., 2005). In 1998, the National Institutes of Health in America 
(NIH) stated that acupuncture could be a useful adjunct treatment or an acceptable alternative 
for several health conditions, including headache (NIH Consensus Conference, 1998). The 
conclusion of the NIH has been endorsed by the World Health Organisation (WHO)(2003). 
 
Acupuncture is a technique of traditional Chinese medicine (TCM) and is based on the 
meridian theory. Acupuncture has been used in China to deal with illnesses for thousands of 
years. Having originated in China, acupuncture is now widely practiced by traditionally 
trained acupuncturists, medical doctors and physiotherapists in Western countries. According 
to TCM principles, the fundamental purpose of acupuncture treatment is to balance the state 
of a patients’ blood and Qi. Since the 1970’s, a series of studies have been conducted to 
explore the possible mechanisms of action for acupuncture, such as it acting through the 
diffuse noxious inhibitory control system (Carlsson, 2002); producing endogenous opioid 
peptides (McLennan et al., 1977, Han et al., 1979); and its anti-inflammation effect (Lao et al., 
2004, Lao et al., 2001). However, despite these studies, how acupuncture works is still not 
known. 
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Clinical trials have shown that acupuncture is an effective alternative treatment for 
tension-type headache (Endres et al., 2007a, Xue et al., 2004, Melchart et al., 2005), and 
chronic headache (Vickers et al., 2004a). To date, there have been a number of systematic 
reviews on the use of acupuncture for chronic pain in general (ter Riet et al., 1990, Patel et al., 
1989); headaches as a whole (Manias et al., 2000, Melchart et al., 1999); idiopathic headache 
(Melchart et al., 2001) and migraine in particular (Scott and Deare, 2006, Griggs and Jensen, 
2006b) as well as tension-type headache (Davis et al., 2008).  
 
However, there are a number of major issues associated with current migraine literature. 
Firstly, the results appear conflicting: Pintov (1997) supported the effectiveness of 
acupuncture in migraine patients when compared with sham acupuncture. However, Linde 
and her colleagues (2004) found no difference in effectiveness between real and sham 
acupuncture in treating migraines.  
 
Secondly, evidence from East Asian studies is significantly lacking in reviews published in 
English; this is most likely due to language barriers. For example, in the two available SRs on 
migraine (Scott and Deare, 2006) and headache as a whole (Melchart et al., 2001), only one 
Chinese study was included. East Asia is one of the regions where acupuncture is most widely 
used, especially China, where acupuncture is considered the mainstream medicine. Due to the 
widespread use of acupuncture in East Asia, data from these areas is extremely important in 
determining the effectiveness and safety of acupuncture for migraine. 
 
Thirdly, the quality of these trials is often low. According to Jadad scoring, a score of 3 or 
more (which equates to 60% or more of the maximum possible score) in a study is indicative 
of high quality. However, the median of Jadad scoring in the two SRs (Melchart et al., 2001, 
Scott and Deare, 2006) were 1.5 and 2.3 respectively, indicating poor quality. Furthermore, 
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less than half of the studies in Scott and Deare’s SR selected the acupoints according to 
Chinese medicine individual syndrome differentiation; this is against the principles of 
Chinese medicine. It is also unknown whether East Asian literatures suffer from the same 
flaws.  
 
Fourthly, the outcome measures often rely on patient’s reporting. Other measures such as 
medication consumption, recommended by the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT) (Dworkin et al., 2005) and IHS (2000), need to be 
assessed. Pressure pain threshold (PPT), reflecting the individual’s sensitivity to pain, is often 
assessed with an algometry and is widely used in pain studies. Although lower PPTs have 
been observed in tension-type headache sufferers (Schoenen et al., 1991, Bendtsen et al., 1996, 
Ashina et al., 2005), there are few studies investigating the relationship between migraine and 
PPTs and the effect acupuncture has on them.  
 
Hence, to date, the exact role of acupuncture in migraine treatment is not clear. It is important 
to review the effectiveness of acupuncture treatment for migraine in English and East Asian 
literature and to evaluate the effectivness and safety of acupuncture for symptomatic relief of 
migraine and improvements in quality of life through a well-designed RCT.  
 
This thesis includes the following chapters: 
 
Chapter Two describes the epidemiological data of migraine; impacts on patients; current 
available knowledge on diagnosis, management approaches; clinical measurements and 
mechanisms of migraine and acupuncture. 
 
Chapter Three provides the general methods of the systematic review, including background, 
search strategies, criteria for identifying studies, quality assessment and data analysis. 
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Chapter Four and Five present the results of systematic reviews (SRs) of literature included in 
English and East Asian databases, respectively. Chapter Four also compares the results of the 
two reviews and the current reviews on published data. Those SRs showed various 
shortcomings in current research, and identified that frequent migraine was an area requiring 
further study.   
 
Chapter Six describes the general methods of the clinical trial, including recruitment, 
selection criteria, trial procedures, outcome measures, data collection and analysis.  
 
Chapters Seven and Eight report the short- and long-term effects of acupuncture on migraine, 
respectively. The data was analyzed using intention-to-treat analysis. The limitations of the 
present clinical study are discussed. 
 
Chapter Nine presents the data of PPTs measured in migraine patients before and after 
acupuncture, as well as discussing its relevance to the characteristics of migraine. 
 
Chapter Ten, the final chapter, discusses the strengths and limitations of the whole project, 
outlines the overall evidence and provides recommendations for future research and clinical 
practice. 
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1    Migraine Headache 
Migraine is a common, disabling, and typically unilateral headache disorder with symptoms 
such as nausea, vomiting, phonophobia or photophobia. It is ranked by the World Health 
Organization as the 19th disease world-wide to cause disability (IHS, 2004).  
Epidemiological studies have documented its high prevalence and high socioeconomic and 
personal impacts. Approximately 16% of Australians suffer from migraine in its chronic and 
acute forms (Heywood et al., 1998) while 0.32-0.48 million Australians (1.6-2.4%) suffer 
from chronic migraine (Castillo et al., 1999). A similar situation applies in other countries; 
13% of the population in the United States of America (USA) (Lipton et al., 2000b) and 11% 
of the population in Germany (Göbel et al., 1994) suffer from migraine. A review of the 
recent epidemiologic studies of headache in Asia reported consistent findings, that the 
prevalence ranged from 8.4% to 12.7% (Wang, 2003). 
 
The condition of migraine is associated with significant economic and social impacts, such as 
the loss of productivity, increased family burdens and economic costs to society. For example, 
91% of migraineurs reported some level of functional impairment. Fifty-three percent of those 
who experienced severe headaches reported significant impairments on activities and as 
requiring bed rest (Lipton et al., 2001). Another group of investigators estimated that 
migraineurs in the USA spent more than three million days in bed each month due to pain 
(Stang and Osterhaus, 1993). Furthermore, the peak prevalence of migraine occurs in those 
aged between 25 and 55 years in the United State (Lipton et al., 2001), between 25 and 50 
years in China (Guo et al., 1993) i.e., during the most productive years of one’s life. An 
Austrian survey reported 6.8 million working days per year were lost due to working people 
suffering from migraine (Lampl et al., 2003). Migraine affects not only migraineurs’ personal 
quality of life (QoL) but also that of the whole family. For example, it has been reported that 
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90% of migraineurs postponed their household work due to migraine, 30% had to cancel 
family and social activities during their last migraine attack, and two-thirds feared letting 
others down (Clarke et al., 1996). A survey conducted by the University of New South Wales 
estimated the major direct and indirect costs (including medical costs, social services, 
treatment time, work absence and productivity losses at work) of migraine as a whole in 
Australia from 1989 to 1990 was between 302 million to 721 million dollars (Parry, 1992).  
 
2.2    Diagnosis of Migraine  
According to the classifications of the International Headache Society (IHS), there are two 
major sub-types of migraine: migraine without aura (MO) and migraine with aura (MA). MO, 
or “common migraine”, is the most common subtype of migraine, affecting about 58% of 
migraineurs. It has a higher average attack frequency and is usually more disabling than MA 
(IHS, 2004). MA, or "classic migraine", is the form of migraine characterised by headache 
attacks being preceded by neurological manifestations called "aura"; MA affects around 28% 
of migraineurs (Russell et al., 1995b). The other types of migraine, such as retinal migraine 
and probable migraine occupy the remaining 14%. The 2nd edition of International 
Classification of Headache Disorders (2004) provides clear diagnostic criteria for all 
sub-types of migraine (Appendix 1). A new sub-type called chronic migraine (CM) is 
included. Chronic migraine (CM) refers to MO or MA with a frequency of more than 15 
headache days each month for three months.   
 
2.3    Mechanisms of Migraine  
2.3.1   Migraine and Genetics 
Generally, migraine is a neurovascular reaction in response to sudden changes in the internal 
or external environment, such as emotional stress or overload of afferent systems by excessive 
light, noise or other stimulation. The exact mechanism of migraine is not clear. However, 
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genetic disposition has been implicated. In recent years, scientists have found that genetic and 
environmental factors may contribute to migraine via population-based studies (Russell and 
Olesen, 1995, Ulrich et al., 1999).  
 
A survey (Mulder et al., 2003) of six countries participating in the migraine GenomEUtwin 
project and involving a total number of 29,717 twin pairs found that genetic variance 
(heritability) plays a significant determining role in migraine in both sexes and in all countries. 
Estimates of heritability for migraine ranged from 34% to 57% with the lowest estimates in 
Australia and the highest estimates in Finland, the Netherlands, and Denmark. It is argued that 
genes could predispose the carriers to migraine recurrence by setting the brainstem pain 
pathways in a hypersensitive state thereby lowering the threshold for the manifestation of 
migraine. This could enhance a migraine sufferer’s sensitivity to environmental factors, 
resulting in an increased frequency of attacks. Indeed, stress, weather changes, menstrual 
cycle, and excessive sunlight are the leading trigger factors (Robbins, 1994); lack of sleep and 
alcohol use can also increase the number of attacks.  
 
2.3.2   Biochemistry and Migraine 
In terms of pathophysiology, each individual has a hereditary migraine threshold that depends 
on the susceptibility of the balance between excitation and inhibition in the nervous system. 
On a biochemical basis, such a balance may be influenced by magnesium deficiency, 
excitatory amino acids, monoamines, opioids and other factors (Donma and Donma, 2002). In 
the past few years, the fundamental role for magnesium in pathophysiologic mechanisms of 
migraine has become evident via a series of studies. A reduced magnesium level has been 
found in the serum of migraineurs with or without aura during the migraine-free period, and 
the magnesium level was further reduced in the attack (Gallai et al., 1992). A later study 
(Boska et al., 2002) confirmed that the magnesium deficiency may contribute to the brain 
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cortex hyperexcitability and the pathogenesis of migraine syndromes associated with 
neurologic symptoms, such as auras. On the other hand, Martinez and his colleagues (1992) 
found the plasma levels of amino acids in migraine patients during attacks were significantly 
lower than people suffering from stress, which plays a excitation role in migraine attacks. 
 
The biochemical mechanisms of migraine is believed to be related to the following changes: 
increased extracellular potassium and intracellular sodium, calcium, and chloride; excessive 
release of excitatory amino acids; alterations in serotonin; abnormalities in catecholamines 
and endogenous opioids; decline in magnesium levels and increase in intracellular calcium; 
abnormalities in nitric oxide formation and function; and alterations in neuropeptides 
(Packard and Ham, 1997). 
 
2.3.3   Mechanisms of Aura in Migraine 
The typical aura is photophobia, which is a visual image of scintillating or shining 
crenellated-shapes, usually within one visual field lasting 5 to 20 minutes. Leao (1944) 
believed that genetic or environmental fluctuations in neurotransmitter composition can 
trigger a cortical spreading depression (CSD), which is a gradually spreading depolarization 
of cortical cellular elements followed by repolarization. The migraine aura is evoked by this 
series of aberrant spreads crossing the cerebral cortex. This theory was also supported by 
other scientists (Lauritzen, 1987). Drugs that can inhibit the development of CSD provide 
treatment for aura, such as the Amitriptyline (Elavil), a tricyclic anti-depressant (Silberstein, 
2006). 
 
During the CSD process, extracellular potassium (K+) increases up to 60-80mmol, which is 
enough to depolarize nerve endings around pial blood vessels, thereby releasing vasoactive 
peptides, such as calcitonin-gene related peptide (CGRP). Furthermore, vasoactive peptides 
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induce neurogenic inflammation, which causes pain. The NSAID drugs can reduce 
inflammation, which, in turn, eliminates headache. Afferent pain impulses are modulated in 
the spinal cord and higher centres. If there is an active antinociceptive system, the migraine 
aura may occur alone without a headache phase (Olesen, 1993).  
 
2.3.4   Hypothesis and Mechanisms of Migraine  
Prior to an attack, some migraine sufferers experience an “aura”, consisting of visual 
disturbances such as partial vision loss, the appearance of “special effects” and distortion of 
objects. Other symptoms at this stage include vertigo (motion sickness or dizziness), 
imbalance, confusion, numbness, pallor face and cold hands. During a migraine attack, the 
patients often feel nausea and vomit and being hypersensitive to light and sound. The 
headache is often worsened by physical activities. Resting in a dark room often helps relieve 
the pain.  
 
The early hypothesis of migraine is the vascular theory, introduced by Wolff (1963). This 
theory considers that the dilated blood vessels stimulate perivascular pain sensitive nerve 
endings thereby eliciting pain. Based on this hypothesis vasoconstrictor drugs like Ergotamine 
are used for migraine treatment. Nevertheless, the purely vascular theory apparently 
weakened when the blood flow changes in migraine could be produced by direct electrical 
stimulation of brainstem structures (Lance et al., 1983). The vascular theory alone might not 
be sufficient to explain migraine.  
 
Current studies support that both neural and vascular elements contribute to migraine (Lance 
and Goadsby, 2005). The neurovascular hypothesis is the basis when considering the 
pathophysiology and therapeutics of migraine.  
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Figure 1 illustrates the mechanism of the migraine and the actions of anti-migraine agents and 
prophylaxis medications. Firstly, trigger factors, such as stress, hypoglycemia or tyramine can 
initiate the release of epinephrine and noradrenaline, which induces increasing platelet 
aggregation (Holmsen, 1986). Secondary to platelet aggregation, pain-sensitizing agents, such 
as serotonin, bradykinin and histamine are released from platelets, basophils and mast cells 
(Dalessio, 1979). Bradykinin stimulate the release of prostaglandins and e-leukotriene, 
resulting in the sensitization of high-threshold mechanoreceptors in the perivascular 
trigeminal nerve causing pain (Theisler, 1990, Moskowitz, 1984). This process is also called 
inflammation reaction. Consequently, some non-steroidal anti-inflammatory drugs (NSAIDs) 
can be used for acute pain at this stage. 
 
Secondly, activated platelets also increases the release of serotonin (5-HT), causing cerebral 
vasoconstriction (Vinken et al., 1985), thereby leading to reduced infusion of internal carotid 
artery oligemia and cerebral ischemia (Anthony, 1986). At this stage, CSD is found in 
patients experiencing aura (Leao, 1944). After the ischemia stage, the serotonin levels 
automatically fall. Because serotonin is a potent vasoconstrictor, there is a reactive hyperemia 
with vasodilatation. Intracranial vasodilatation activates the “stretch receptors” in the wall of 
the blood vessels, stimulating the perivascular trigeminal nerves fibers. Nociceptive peptides 
such as substance P (SP), calcitonin gene-related peptide (CGRP), prostaglandins, vasoactive 
intestinal polypeptide (VIP), and neuropeptide Y were released as a part of axon reflex, 
leading to vasodilatation, increasing permeation of the vessels. (De Vries et al., 1999, Villalón 
et al., 2002). The process is called neurogenic inflammation (Edvinsson et al., 1987). 
Meanwhile, these peptides further reinforce vasodilation and perivascular nerve activity 
(Saxena, 1994), causing peripheral and central sensitization, resulting in enhanced pain 
(Goadsby et al., 2002, Silberstein, 2004).  Meanwhile, the trigeminal cranial nerve conveys 
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nocicpetive information to central trigeminal nuclei that, in turn, relay the pain signals to 
higher centres where headache is perceived (Edvinsson, 2004).  
 
Thirdly, some studies indicate that the brainstem might have a “migraine generator”. Once the 
“generator” is switched on due to unknown reasons, the cerebral blood flow changes, 
followed by the CSD (Weiller et al., 1995).
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Figure 1: Diagram of the mechanism of migraine 
        indicates the mechanisms of anti-migraine medications for the treatment of acute 
attack;      indicates the mechanisms of preventive medications  
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2.4    Current Western Pharmacotherapy 
At present there is no cure for migraine. Current treatment for migraine is symptomatic 
management, such as a reduction of the frequency, duration and severity of the attacks. 
Medications used for acute migraine includes non-specific drugs, such as acetaminophen, 
aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), opiates for pain and antiemetic 
drugs to reduce vomiting; migraine-specific drugs include Ergots and serotonin 
(5-hydroxy-tryptamine, 5-HT) agonists known as the Triptans. For chronic migraine sufferers, 
preventative drug therapy can be used for prophylactic purposes to reduce the frequency, 
duration, and severity of future attacks. These drugs include β-adrenergic blockers, 
anti-depressants, anti-convulsants, calcium channel blockers, serotonin antagonists, and 
NSAIDs; their mechanisms are explained as follows. 
 
2.4.1    Drugs for Acute Pain 
Most mild migraine sufferers self-medicate using non-prescription analgesics. Two major 
classes of such medications exist on the market: acetaminophen and non-steroidal 
anti-inflammatory drugs (NSAIDs). NSAIDs have two subgroups, aspirin and non-aspirin. 
The drugs in this class, which inhibit sterile inflammation, are used to reduce the intensity of 
the pain or eliminate the pain. 
 
Acetaminophen (brand name: Tylenol): The exact mechanism of action regarding 
Acetaminophen is not well understood. However, it is believed that it relieves pain by 
inhibiting the prostaglandin synthesis, which causes inflammation and pain. However, the 
effectiveness of acetaminophen for migraine is controversial (Lipton et al., 2000a, Diamond, 
1976). Consequently, the American Academy of Family Physicians does not recommend 
acetaminophen alone for migraine attacks (Snow et al., 2002). 
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NSAIDs are the first-line choice in treating migraine attacks. They work by blocking 
cyclooxygenase (COX) which is crucial for the production of prostaglandins, and peripherally 
blocking pain impulse generation. NSAIDs have two classes, namely “selective” and 
“nonselective”. “Selective” NSAIDs block COX-2 only and “nonselective” NSAIDs block 
COX-1 and COX-2. COX-2 is the enzyme responsible for inflammation and fever; COX-1 
has other functions such as protecting the gastric mucosa from the acid that the stomach 
naturally produces. However, most popular NSAIDs for migraine, such as Aspirin, Ibuprofen, 
and Naproxen, are nonselective. An example of a selective NSAID is Celebrex. One of the 
problems with nonselective NSAIDs is that they block both types of the COX enzymes; while 
inflammation and pain is reduced, so are some of the beneficial effects of prostaglandins such 
as protection of the stomach lining. The selective NSAIDs are a newer type of analgesic and 
are always recommended to people with stomach problems. Clinical studies have 
demonstrated the effectiveness of various NSAIDs for migraine, such as aspirin (Hakkarainen 
et al., 1979, Boureau et al., 1994, Tfelt-Hansen and Olesen, 1984); ibuprofen 
(Havanka-Kanniainen, 1989, Kloster et al., 1992); naproxen sodium (Sargent et al., 1988, 
Landy et al., 2007), and tolfenamic acid (Myllylä et al., 1998, Larsen et al., 1990). However, 
NSAIDs produce good responses only in cases of mild migraine. For those migraines 
associated with moderate-to-severe headache, migraine-specific drugs should be used. 
 
Opioids alone are not recommended for mild migraineurs because of the risk of dependence 
and aggravation of gastrointestinal symptoms. However, the combination of aspirin with 
codeine may be used for severe migraine (Lipton et al., 1998).  
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2.4.2   Migraine-Specific Drugs 
Ergotamine is a vasoconstrictor and acts on 5-HT receptors, alpha-adrenergic receptors and 
dopaminergic receptors (Goodman and Gilman, 2001). It is generally believed to exert its 
anti-migraine effect via being a 5-HT receptor agonist. The vascular theory of migraine 
considers that dilated arteries can stimulate the perivascular nociceptors, thereby causing 
migraine. Ergotamine constricts the dilated arteries to reduce the stimulation to perivascular 
nociceptors. Although Ergotamine has been used for treating migraine for more than 50 years, 
evidence of efficiency is insufficient. Moreover, it was considered to be useful only in a small 
numbers of migraineurs. Further to this, a number of side effects have been reported in 
medical literature, including myocardial infarction, ischaemia of limb extremities, and fibrotic 
changes. Long-term use has led to reported cases of ergotamine-induced headache, vascular 
reactivity, and sub-clinical ergotism. Consequently, following a systematic review by an 
European expert group in 2000 (Dahlöf, 1993, Tfelt-Hansen et al., 2000) it is recommended 
that Ergotamine should not be used until further clinical data becomes available.  
 
Sumatriptan is 5-HT1 agonists. It relieves headache in 50-75% of migraineurs, and improves 
migraine symptoms such as vomiting, nausea, photophobia and phonophobia. Unlike 
Ergotamine, Sumatriptan can selectively act on one type of the 5HT1 receptors located in the 
cranial vascular bed, thereby reducing inflammation and constricting the blood vessels. 
Furthermore, it has been demonstrated to produce high response rates in mild, moderate or 
even severe migraines and is superior to the effect of Ergotamine plus Caffeine or Aspirin 
plus Metoclopramide (Cady et al., 2000). There is good evidence for the efficacy of 
Sumatriptan (Russell et al., 1995a, Ryan et al., 1997), although it is associated with AEs, such 
as throat and chest pain.  
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2.4.3   Drugs for Migraine Symptoms 
Antiemetic drugs, such as Metoclopramide and Domperidone, can be used orally to reduce 
vomiting and nausea when patients feel the first symptoms of migraine and are then taken 
every 6-8 hours. Metoclopramide can increase the gastric motility, thereby normalizing the 
absorption of other drugs. A controlled study demonstrated that the combination of 
Tolfenamic acid (NSAID) and Metoclopramide is significantly better than Tolfenamic acid 
alone in treating migraine attacks (Tokola et al., 1984). However, a neuroleptic type of 
antiemetic, such as Tiethylperazine and Chlorpromazine, cannot normalize the absorption of 
drugs. Therefore, for these two neuroleptic drugs, oral administration should be avoided. 
Clinically, the first treatment of an attack is antimetic drugs administered orally or via 
intramuscular injection depending on the severity of nausea or vomiting, then followed by the 
painkillers (Tfelt-hansen, 1993). The AEs of antiemetic drugs are acute dystonia and 
drowsiness. 
 
2.4.4   Prophylactic Drugs for Migraine 
Prophylactic medications are taken daily in order to reduce the frequency and duration of 
migraine attacks. They are given to patients who suffer from migraine for two or more times 
per month and have associated disability lasting three or more days per month (Snow et al., 
2002). There are several classes of prophylactics such as beta-andrenoreceptor blockers 
(propranolol, timolol), antidepressants (amitriptyline), anticonvulsants (sodium valproate), 
calcium-channel blockers (nimodipine), 5-HT receptors antagonists (methysergide) and 
NSAIDs (naproxen), which can be used for different stages of migraine. Silbestein (2006) 
reviewed evidence of the effectiveness of migraine preventive drugs and found the 
beta-andrenoreceptor blockers decrease sympathetic activities and prevent vasoconstriction; 
calcium channel blockers can prevent migraine attacks by inhibiting CSD; both 
antidepressants and anticonvulsants inhibit CSD and enhance anti-nociception; NSAIDs block 
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the production of prostaglandin, therefore reducing central sensitization. Preventative drugs 
should be chosen with caution. Physicians should be aware of the co-morbidity of the 
migraineurs in order to avoid AEs brought by these agents such as beta-blockers for asthma 
sufferers or calcium channel blockers for patients with low blood pressure. 
 
2.4.5   Pharmacotherapy: Strength and Weakness  
Effective pharmacologic management of migraine is challenging due to the complexity of 
migraine and the difficulty of selecting proper treatments from a large variety of 
pharmaceutical products. A clinical guideline (Snow et al., 2002) for pharmacologic 
management of migraine has been produced by the American Society of Internal Medicine 
based on a comprehensive review of the scientific literature. Based upon that guideline, 
NSAIDs are considered as the first choice for mild-to-moderate migraine, or even severe 
attacks that have responded to NSAIDs. However, for patients whose migraines are always 
moderate-to-severe in intensity, migraine-specific drugs like Sumatriptan should be taken 
upon feeling the first symptoms of migraine. Opioids are strong analgesics, but should only be 
used when sedation effects are not a concern or the risk of abuse has been addressed. 
Moreover, concerning the disability issue, patients with two or more severe attacks per month 
are suggested to take preventative therapy. 
 
There are a few limitations with current pharmacotherapy management. Firstly, many patients 
dislike taking medications for a long term, as such medications are not always optimal and 
associated with AEs such as low blood pressure, decreased libido, nausea, depression, 
sedation, dry mouth, and increased appetite and weight. Secondly, nearly half of all migraine 
sufferers treat themselves with over the counter medications (Lipton et al., 2002). Overuse of 
medicines is common in chronic migraine sufferers, and the overuse of medicines is likely to 
lower the pain threshold necessary to trigger further migraine attacks (Eric and Eross, 2006). 
Nearly 80% of chronic migraineurs overuse symptomatic medications (Mathew, 1993). When 
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non-prescriptive drugs for acute pains are used as often as three times a week, patients may 
experience a gradual shift from episodic migraine to chronic migraine (Snow et al., 2002). A 
headache study conducted on 216 patients overusing medication found that 4% were 
overusing Ergots, 6% Narcotics, 20% Triptans, 29% simple Analgesics (pain relievers) and 
42% combination of Analgesics (Eric and Eross, 2006). 
 
As discussed above, current pharmacology management involves some side effects such as 
the changes in heart rate, vasodilation in cutaneous blood vessels, vasoconstriction in the 
external carotid bed and gastrointestinal effects, etc. (Saxena and Villalón, 1990b, Saxena and 
Villalón, 1990a). Future medications are aimed at identifying drugs that do not impact on 
5-HT receptors as to reduce their cardiovascular side effects. CGRP receptor antagonists 
could be the ideal candidate (Maassenvandenbrink and Chan, 2008). 
 
2.5    Non-pharmacological Treatment Approaches for Migraine 
Due to the above risk and side effect of existing pharmacological approaches, many people 
seek “natural” treatment. Furthermore, some experts pointed out that the pharmacological 
therapy should only be applied if non-pharmacological management is ineffective (Olesen, 
1993). Non-pharmacological treatments aim to avoid the trigger of migraine, like stress, 
weather, fasting, dietary factor and sleep and to reduce the frequency, duration and intensity. 
They include psychological management, physical management, acupuncture, and other 
complementary therapies. 
   
2.5.1   Psychological Management 
Psychological management includes relaxation training, biofeedback and cognitive 
behavioural therapy. Since the beginning of 1970s, a series of psychological approaches have 
been developed for headaches including migraine (Rains et al., 2005), There are two groups, 
namely, physiologically oriented techniques and cognitive behaviourally oriented methods. 
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The former includes the various types of biofeedback treatment. The latter encompasses a 
series of forms of relaxation training (progressive relaxation training, autogenic training, 
hypnosis), transcendental meditation and cognitive-behavioural therapy (Martin et al., 2007). 
In 2002, The Association for Applied Psychophysiology and Biofeedback classified 
psychological treatment into five levels of efficacy, level one being not supported by evidence 
and level five being efficacious and specific (LaVaque et al., 2002, Moss and Gunkelman, 
2002). It is concluded that these psychological therapies including temperature, muscle 
tension and pulse biofeedback are efficacious for migraine, and are ranked at level 4 (Yucha 
and Gilbert, 2004). 
 
2.5.1.1   Biofeedback (BFB) 
Biofeedback theory is based on the idea that the autonomic nervous system can come under 
voluntary control through operant conditioning. Biofeedback therapy involves the recording 
and displaying small changes in the status of involuntary biological functions that are related 
to the recurrent disease, such as pulse, skin temperature and breathing patterns. Patients are 
instructed to use various techniques to change the levels of the parameter using the feedback 
from the display as a guide to avoid the onset of the disease. Migraineurs can monitor one of 
the three parameters and regulate then by warming their hands, reducing sweating, slowing 
down breathing and lowering muscle tension. The most commonly used methods of BFB for 
migraine are peripheral skin temperature feedback (TEMP-FB), blood-volume-pulse feedback 
(BVP-FB) and electromyography feedback (EMG-FB). The effectiveness of biofeedback for 
migraine had been demonstrated when compared with control conditions in frequency and 
perceived self-efficacy in a meta-analysis study (Nestoriuc and Martin, 2007). Nestoriuc and 
Martin also found that BVP feedback (weighted mean effect size = 0.68) was more effective 
than TEMP (0.52) and EMG feedback (0.5).  
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Biofeedback can be used by itself or in combination with relaxation training. Furthermore, the 
combination of biofeedback and home training has been shown to be more effective than 
biofeedback alone (Nestoriuc and Martin, 2007). Meta-analysis suggests that relaxation is as 
effective as biofeedback (Blanchard et al., 1980, Penzien et al., 1985). 
 
2.5.1.2   Progressive Relaxation Training 
Progressive relaxation, also named progressive muscle relaxation, was developed by an 
American Physician, Edmund Jacobson in 1929 (Sadock et al., 2007). It is based on a 
principle of muscle physiology. The process of progressive relaxation is simply that of 
isolating and contracting specific muscles or muscle groups, one at a time, creating tenseness 
for 8-10 seconds, and then letting the muscle relax and the tenseness go. Jacobson used the 
word “tenseness” rather than “tension” to emphasise the patient’s role in tensing the muscles 
(Sadock et al., 2007). This method can relax the deep level of muscles. There are many 
parallels with autogenic training, which was developed independently. 
 
2.5.1.3   Autogenic Training and Hypnosis 
Autogenic training emerged from German, developed by Dr. Johannes Schultz. This method 
was first published in 1932 (Schultz and Luthe, 1959). It is a method of self-suggestion, 
which directs patient’s attention to specific bodily areas that reflect a relaxed state. Such 
phrases include heaviness, warmth, cardiac regulation, breathing adjustment, solar plexus and 
forehead. For example, “my solar plexus is warm”.  
 
Hypnosis, firstly described as a therapeutic modality in the18th century by Anton Franz Anton 
Mesmer (Sadock et al., 2007). It is currently understood as a normal activity of a normal mind 
through which attention is more focused, critical judgment is partially suspended, and 
peripheral awareness is diminished. Hypnosis reduces distress as it does in pain disorders. A 
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meta-analysis of largely uncontrolled trials suggested that hypnosis combined with 
cognitive-behavioural therapy (CBT) can enhance the outcomes of migraine when compared 
with using CBT alone (Kirsch et al., 1995). To date, some clinicians use hypnosis to facilitate 
relaxation or use tape-recorded exercise to allow patients to practice relaxation on their own.  
 
2.5.1.4   Cognitive - Behavioural Therapy 
Cognitive therapy and behavioural therapy are two independent therapies. Cognitive therapy 
was developed by an American psychiatrist, Aaron Temkin Beck in the 1960s. It is based on 
the idea that our thought can create our mood, thereby influencing/affecting some diseases. 
Behavioural therapy involves changing the behaviours of patients to reduce dysfunction and 
to improve quality of life. These two therapies go hand in hand; behavioural techniques can 
test and change maladaptive and inaccurate cognitions. Consequently, they are combined to 
be adopted in clinic, and named cognitive-behavioural therapy (CBT). Generally, CBT can 
help patients identify and modify maladaptive responses that may trigger or aggravate a 
migraine headache (Pryse-Phillips et al., 1998). 
 
CBT consists of self-monitoring, education, relaxation training and pain-management 
strategies, including rational emotive behavioural therapy, rational behavioural therapy, 
rational living therapy, cognitive therapy and dialectic behavioural therapy. In general, CBT 
teaches patients how to change their maladaptive thought, incorrect beliefs and fears to 
prevent patients form illnesses. In migraine, CBT aims to calm down patients’ emotion. 
Psychologists and patients can work together to plan when and what the migraineur should do 
to prevent or reduce pain, if the migraine is coming. They then develop alternative behaviours 
to try in the same situation in the hope that changing the behaviour will change the migraine. 
For example, they work together to make a migraineur’s daily plan for restricting salt, 
decreasing water retention and eliminating trigger diets.  
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The effectiveness of CBT for migraine has been supported by some studies (Knapp and Florin, 
1981, Sorbi and Tellegen, 1986, Richardson and McGrath, 1989). CBT is ranked at the 
second level, B, by the Canadian Headache Society (Pryse-Phillips et al., 1998). According to 
this society, there are six levels of evidence ranging from A to F, with A being good evidence 
to recommend the clinical preventative action and F being insufficient evidence. 
 
2.5.2   Physical Management 
Physical management is a common part of pain management programs, which include 
transcutaneous electrical stimulation (TENS), Yoga, cervical manipulation, hyperbaric 
oxygen, and even occlusal adjustment. 
 
TENS is a non-invasive, electronic device with few known side effects. A TENS unit consists 
of a pulse generator, transformer, frequency and intensity controls and a number of electrodes. 
It can produce electrical signals used to stimulate nerves through unbroken skin to decrease 
pain perception. TENS has been used for a series of pain conditions, including migraine 
(Solomon and Guglielmo, 1985, Carroll et al., 2001, Sheftell et al., 1989).  
 
Yoga originated in India, associated with diversified postures, which couples physical 
exercise with breathing to produce relaxation. It is a popular form of mind-body therapy, and 
has been used to deal with the emotional aspects of chronic pain in term of reducing anxiety 
and depression (Kim et al., 2005, Kakigi et al., 2005). In a randomised controlled trial, Yoga 
has shown to reduce the frequency of migraine from 10.22 days per months to 4.56 days, 
much better than the self-care group from 9.82 to 10.18 days (John et al., 2007).  
 
Cervical manipulation directs short or long-term high velocity thrusts at one or more joints of 
the upper seven spines, which can increase β-endorphin levels (Buchmann et al., 2005). 
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β-endorphin is believed to be 50 times more powerful than morphine and hence unmatched 
for their ability to control pain (Terrett and Vernon, 1984). Milne conducted a study in 150 
migraineurs, and found that cervical manipulation is useful for terminating ongoing migraine 
attacks (Milne, 1989). Other studies have also demonstrated that this therapy can reduce the 
severity of pain in migraine attacks (Parker, 1978, Wight, 1972). Furthermore, Vernon (1982) 
has shown manipulation to be effective in ameliorating autonomic symptoms associated with 
migraine, such as nausea and vomiting. .  
 
Occlusal adjustment is a dental procedure used to adjust a patient's biting surfaces, thereby 
relieving muscle tension in the jaw. Based on the belief that migraine is related to the tension 
of that area, this therapy might reduce migraine pain. However, a study conducted in Finland, 
did not report any benefits of occlusal adjustment for migraineurs compared with mock 
occlusal adjustment (Forssell et al., 1985). 
 
Hyperbaric oxygen therapy is a new form of physical approach. It has been theorized that the 
increased levels of oxygen in the blood act as a vasoconstrictor of cerebral vessels, thereby 
alleviating headache pain. Patients are placed a hyperbaric chamber (100% oxygen, delivered 
at greater than normal atmospheric conditions) to increase pressurization of the blood gases. 
However, the effectiveness for migraine is still conflicting in RCTs (Eftedal et al., 2004, 
Wilson et al., 1998, Myers and Myers, 1995). 
 
2.5.3   Complementary Therapy 
Complementary therapy includes massage, osteopathy, chiropractic, herbal medicine and 
acupuncture. The theory of massage is quite similar to physiotherapy, aiming to release the 
tension of muscle to prevent and reduce headache. Osteopathy and chiropractic are based on 
the misalignments of the vertebrae that can cause migraine, although there is no evidence for 
this hypothesis. They all apply some specific techniques to adjust the misalignments. To date, 
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the most popular medicinal herb in western country for migraine is feverfew, and its effect for 
migraine has been demonstrated by some RCTs (Pfaffenrath et al., 2002, Diener et al., 2005).  
 
2.6    Chinese Medicine’s Understanding of Migraine and Its Treatment 
2.6.1    Introduction 
Traditional Chinese Medicine (TCM) utilizes a philosophic understanding of nature, such as 
Yin, Yang and the Five Element theory, to explain health and illness. Other key concepts 
include the Zang-Fu (Visceral organ), Qi, Blood, Body Fluid and meridian Theories (Liu and 
Dong, 1998). One of the most outstanding characteristics in TCM is its holistic view. Most of 
the traditional theories and principles of TCM are founded not upon anatomy but rather upon 
functional activities and interaction with other Zang-Fu organs. For instance, when TCM says 
Liver Qi stagnation, it does not refer to the Liver organ the same way as Western medicine 
does. Liver in Chinese medicine is like the “hinge” of a door, regulating the Qi flow in the 
whole body. Part of this function is manifested in its interaction with the stomach and spleen 
in digestion. It also stores blood and is therefore involved in menstruation. Liver Qi stagnation 
refers to a set of signs and symptoms including indigestion, nausea, pain in the hypochondriac 
area, nervousness, and possible premenstrual tension in females.  
 
TCM also holds the view that health exists when Yin and Yang within the human body and 
between the human body and the external environment are kept in a normal, dynamic balance. 
Once the balance is impaired, a disease will result. The ultimate principles of treatment are to 
balance Yin and Yang, encourage the free flow of Qi and harmonize the relationship between 
the body and its environment. 
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2.6.2    Pathogenesis in Traditional Chinese Medicine 
Migraine in TCM is called “Tou Feng” or “Lei Tou Feng” (Hu and Zhang, 1997) due to its 
severe pain and sudden onset feature. Based on the manifestation, there are 4-8 types of 
migraine sub-type. Four of them are most commonly seen as types suitable for acupuncture 
treatment. 
     
2.6.2.1   Ascending Hyperactivity of Liver Yang and Liver Wind Up Surge   
The head is the confluence of all Yang Qi. When the Liver becomes hyperactive it is unable 
to store blood and thus leads to symptoms of blood and Yin deficiency. The latter cannot root 
Yang due to a loss of the balance between the two, therefore Yang Qi rises to disturb the brain, 
causing a throbbing headache. Other diagnostic criteria of this type of migraine are irritability; 
dizziness; distending pain; lassitude in the lower back and legs; feeling heavy in the head; 
bitter taste in mouth; red tongue body and yellow dry coating; string-taut or rapid pulse. 
 
2.6.2.2   Deficiency of Both Qi and Blood 
Blood is considered as the base substance that nourishes the brain, which is provided by Qi. If 
insufficient Qi cannot take blood to the brain or the insufficient blood fails to nourish the 
brain, headache may occur. This type of headache usually has the following symptoms: pale 
or sallow complexion; shortness of breath after slight physical exertion; weak limbs; pale 
tongue with white and thin coating; deep, thready and feeble pulse.   
 
2.6.2.3 Wind Phlegm Blocking the Meridians  
The lung, spleen and kidney may cause retention of excessive fluids in the body. If the 
excessive fluid accumulates in a certain part of the body and congeals, phlegm is formed. 
Phlegm blocks the meridians located in the head, leading to headache. The features of this 
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type of migraine are chest distress; corpulent tongue body with tooth-prints; white and greasy 
tongue coating; deep and taut or deep and slippery pulse. 
 
2.6.2.4 Blood Stasis 
As mentioned above, one of the functions of Qi is to allow the blood to flow freely. Stagnated 
Qi causes blood stasis, which in turn becomes a pathogenic factor that causes various 
disorders including headache. This type of migraine involves stabbing pain; cyanotic lips and 
nails; purplish tongue with thin white coating; deep, thready or thready-sluggish pulse. 
 
In general, during an attack there is always an involvement of Liver Yang and Liver wind. In 
between attacks, the underlying pathology, such as phlegm, blood stasis, Liver Yin and Blood 
deficiency or Qi and Blood deficiency manifest more clearly.  
 
2.6.3    Treatment of Migraine in Chinese Medicine  
The principle of treatment is based on the diagnosis, which determines the nature of a 
condition as deficient or excessive. The aim of treatment is to restore the balance of Qi and 
blood, the balance of Yin and Yang and the balance of the organs. In general, it is enhancing 
and strengthening the deficient syndromes through the elimination and dispelling of the 
excessive pathogens in order to bring the patient back to the state of equilibrium that is 
postulated to exist prior to illness. 
 
According to the four pathogenesis of TCM, the principle of treating migraine is pacifying the 
liver to subdue Yang Qi; tonifying Qi and replenishing blood; extinguishing wind and 
resolving phlegm and activating blood and resolving stasis. 
 
The detailed information regarding the acupoint selection for the different four sub-groups is 
described in Section 6.4.3.2 . 
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2.7    Acupuncture for Migraine  
2.7.1   History of Acupuncture 
Acupuncture, a technique of traditional Chinese medicine, based on the meridian theory, has 
been used in China for thousands of years for treating diseases. It originated in China, and has 
been developed into different types, namely, Classical Chinese, Japanese and Korean 
acupunctures. To date, acupuncture is widely practiced by traditionally trained acupuncturists, 
medical doctors and physiotherapists in western countries. In the contrast to traditional 
Chinese acupuncture method with inserting needles into the traditional acupoints, medical 
acupuncturists always prefer to choose trigger points or choose points according to neural 
anatomy for treatment.  
 
In the early 19th century, acupuncture was introduced to the west, mainly Europe and America. 
By the 1970s it began to capture the public interest and become to be widely practiced, 
especially for pain relief (Mann et al., 1973). Since then western scientists began to publish 
researches into acupuncture (Bache, 1826, Berliozs, 1816, Churchill, 1821, Cloquet, 1826). 
The World Health Organization (WHO) has endorsed the effectiveness of acupuncture in 
relieving postoperative pain, nausea during pregnancy, nausea and vomiting resulting from 
chemotherapy, and dental pain, anxiety, panic disorders and insomnia (WHO, 2003).  
 
Scientists are researching the mechanisms and assessing the efficacy of acupuncture.  
 
2.7.2   Mechanisms of Acupuncture for Anti-migraine 
There are several theories explaining the mechanisms of acupuncture analgesia (AA). One of 
the earliest theories was that acupuncture meridians and acupoints were related to the nerves 
and blood vessels (Chan, 1984). However, so far, no unifying and persuadable theory has 
been proposed. The following theories have been supported by empirical data; they are 
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Melzack’s gate control theory (segmental inhibition), endorphin hypothesis, diffuse noxious 
inhibitory control (DNIC), regulation of the autonomic system and the anti-inflammation 
effect.  
 
Acupuncture needling is an invasive procedure, stimulating the Aδ afferent nerves, and 
possiblely Aβ fibres, resulting a cascade of reaction at the spinal and supraspinal levels.  
First, Aδ and Aβ afferent fibres end primarily in the most superficial zone and neck of the 
dorsal horn of the spinal grey matter (Kumazawa and Perl, 1978), in turn activate inhibitory 
interneurons and stimulate the release of γ-amino butyric acid (GABA). The latter produces 
pre-synaptic inhibition on spinal transmission interneurons (T). T neurons are also activated 
by inputs from unmyelinated afferent fibres (C), primarily activated by noxious stimulation, 
and transmit nociceptive information. Thus, at the segmental level, activation of large 
myelinated afferent fibres inhibits the input from C fibres directly and indirectly via the spinal 
grey matter of the dorsal horn. This is part of the gate control theory (Melzack and Wall, 
1996), explaining the segmental effects of acupuncture. This hypothesis has been supported 
by a recent study in which electroacupuncture (EA) with low intensity increased the 
homotopic, but not heterotopic pain threshold (Xu et al., 2003). This study suggest that local 
acupuncture-induced analgesia is effective with activation of large afferent fibers, whereas 
heterotopic acupuncture-induced analgesia is only effective with intensities strong enough to 
excite small afferent fibers. Local analgesic effects of acupoint stimulation involve segmental 
inhibition, whereas systemic analgesic effects of acupoint stimulation are involved in 
contra-lateral effects. The latter may recruit the diffuse noxious inhibitory controls (DNIC) 
system. The specific function of an acupoint is determined by the anatomical relationship 
between the disease focus and the segmental location of the acupoint. 
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Second, the signals from the Aδ afferent fibres are relayed to the suprapsinal centres, leading 
to the release of endogenous opioid peptides. A few lines of evidence support this 
hypothesis.1) AA is blocked or reversed by naloxone, an endogenous opioid antagonist. 
(Cheng and Pomeranz, 1980, Fine et al., 1988, Han et al., 1986); 2) Similar brain regions are 
involved in both morphine and acupuncture analgesia. AA was significantly attenuated by 
microinjection of naloxone into the nucleus accumbens, amygdala, habenula and 
periaqueductal gray matter (PAG) of the rabbit, areas that are involved in morphine analgesia; 
3) The release of the types of opioid neuropeptides depends on the frequency of EA with high 
frequency EA (100 Hz) stimulating the release of dynorphin and lower frequency EA of 
enkephalin and β-endorphin (2 and 15 Hz) (Han, 2003a, Han, 2003b).  
 
Two major descending inhibition pathways, serotonin (5-HT) and nonepinephrine, are also 
involved in AA. Upon acupuncture stimulation, 5-HT is released from nucleus raphe magnus, 
and descends in the dorsolateral funiculus to terminate directly on enkephalin-neurons which 
then produces post-synaptic inhibition on transmission neurons at the segment where the 
painful stimulation comes (White and Ernst, 1999). The nonepinephrine pathway descends 
from the hypothalamus and induces inhibition on transmission neurons at the dorsal horn via 
the dorsal lateral funiculus as the serotonin pathway does (Han, 2003a). Acupuncture 
activates the descending inhibition system so that reduces pain.    
 
Third, diffuse noxious inhibition controls (DNICs) may explain the non-segmental effects of 
AA (Le Bars et al., 1991). The dorsal horn neurons are inhibited by nociceptive afferent 
signals applied to heterotopic part of the body. This action is likely due to the inhibition of 
acupuncture on wide dynamic range neurons (Hashimoto and Aikawa, 1993).   
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Four, acupuncture has a strong anti-inflammation effect. Numerous studies have shown that 
EA reduces acute and chronic inflammation and attenuates both heat and mechanical 
hyperalgesia in animals (Zhang et al., 2004a, Zhang et al., 2004b, Zhang et al., 2005a, Zhang 
et al., 2005b, Zhang et al., 2005c). In particular, EA of low frequency has a strong 
anti-inflammation effect whereas that of a high frequency reduces pain (Lao et al., 2004). 
 
Finally, Acupuncture regulates the autonomic nervous system. Bakers and colleagues found 
that acupuncture reduced lower frequency band of heart rate variability of migraine patients, 
indicating an inhibition on the sympathetic nervous system (Bäcker et al., 2008). Furthermore, 
acupuncture-like stimulation has been shown to improve the cortical cerebral blood flow 
(CBF) of rats (Uchida et al., 2002). In migraine subjects, the CBF is reduced at the posterior 
pole of the brain and the area of low blood flow spreads gradually, resulting in the cerebral 
ischemia that causes the headache (Olesen, 1993). Increasing in the CBF can potentially 
relieve headache and prevent migraine attack.  
 
Acupuncture operates on the multi systems of pain control. Based on the neural mechanism, 
acupuncture could abolish migraine via segmental and general pain inhibition systems. It 
might also prevent migraine via its effects on anti-inflammation, regulation of sympathetic 
nervous system and enhancing descending inhibition.   
 
2.7.3   Current Clinical Research of Acupuncture for Headache 
Clinical trials have shown that acupuncture is an effective alternative treatment for 
tension-type headache (Endres et al., 2007a, Xue et al., 2004, Melchart et al., 2005), and 
chronic headache (Vickers et al., 2004a). To date, there have been a number of systematic 
reviews on the use of acupuncture for chronic pain in general (ter Riet et al., 1990, Patel et al., 
1989); headaches as a whole (Manias et al., 2000, Melchart et al., 1999); idiopathic headache 
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(Melchart et al., 2001) and migraine in particular (Scott and Deare, 2006, Griggs and Jensen, 
2006b) as well as tension-type headache (Davis et al., 2008). However, there are a number of 
major issues associated with current migraine literature. Firstly, the results appear conflicting: 
Pintov (1997) supported the effectiveness of acupuncture in migraine patients when compared 
with sham acupuncture. However, Linde and her colleagues (2004) found no difference in 
effectiveness between real and sham acupuncture in treating migraines. Secondly, the quality 
of part of available trials is low, as most of these studies suffered from problems of either 
small sample size (usually less than 50), or inappropriate choice of instruments for outcome 
measure, or non-adherence to the IHS classification of migraine headaches in the inclusion 
criteria. Thirdly, according to Scott and Deare’s SR (2006), less than half of the included 
studies selected the acupoints according to Chinese medicine individual syndrome 
differentiation; this is against the principles of Chinese medicine. Therefore, to date, use of 
acupuncture for migraine, though promising, still suffers from insufficient quality in design 
which undermines the validity of the clinical trials. Further research is warranted to strengthen 
or refute the available evidence. 
 
2.8    Assessments of Migraine 
Assessment of treatment outcomes is very important for both practitioners and researchers. In 
measuring any pain complaints, the patient as a whole should be considered, not just the pain 
itself, because pain impacts on the physical, psychological and socials aspects of patients’ life 
(Seres, 2003). Theisler (1990) pointed out that successful treatment should reduce patients’ 
headache activity as measured by the frequency, intensity and duration, eliminate or reduce 
reliance on medications and on headache’s interference with the activities of daily living, 
improve patients’ ability to cope with the headache problem, and  reduce over-utilization of 
the health care system. All in all, the above aspects can be summed up into four domains, 
namely pain dimensions, pain quality, medication consumption and functional impact.  
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2.8.1   Pain Dimensions 
Migraine, like other pain conditions, is subjective, without reliable objective markers. So far, 
subjective ratings of self-reported head pain using various scales are regarded as the “gold 
standard”. Because changes in headache can occur on various dimensions, data from the 
changes can be summarised in the following ways: frequency, intensity, duration and 
headache index. 
 
2.8.1.1   Frequency 
Researchers always record either the number of the days with migraine or the migraine-free 
days in a 4-week period to assess the frequency of migraine. These are recorded with a diary.  
 
2.8.1.2   Intensity 
There are many measurements of pain intensity, and can be grouped into three broad types: 
verbal rating scales (VRSs; e.g., “none”, “mild”, “moderate”, “severe”); numerical rating 
scales (NRSs; e.g. four-grade scale, from 0 to 4 corresponds to no headache, mild pain, 
moderate pain and severe pain); and sisual analogue scales (VASs; e.g. a 10-cm line anchored 
by “no pain” and “pain as bad as it could be”). Each type has been used in clinical trials to 
investigate the effects of a treatment on pain. Among these methods, VAS and VRS are the 
most frequently used measurements. Their variability and reliability have been evaluated 
(Corran et al., 1991). VAS is recognized to be more sensitive than VRS, reflecting changes in 
the intensity of pain more precisely (Deschamps et al., 1988, Ohnhaus and Adler, 1975). 
However, it can be difficult for old individuals to use (Carlsson, 1983).  
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2.8.1.3   Duration 
Duration means the length of time in hours between migraine onset and offset. The original 
measurement was a grid card (Figure 2), and x-axis and y-axis reflect the duration and 
intensity, respectively. This original form does not measure the two dements separately.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A sample of grid diary 
 
In 1977, Epstein and Abel (1977) noted that most patients did not record headache 
continuously via directly observing patients; rather, they would like to periodically fill in later 
by recalling the headaches. Hence, Epstein and Abel modified the procedure to record 
patients’ situation four times per day: wakeup, lunch, dinner and bedtime. Later, Collins and 
Martin (1980) compared this modified format with a bihourly schedule and found they 
yielded fairly equivalent results. Although the Epstein’s new format is convenient for patients 
and provides reliable and valid data, it does have some demerits. For instance, clinicians and 
researchers, who chose either frequency or duration as the primary interest, found this format 
did not provide the exact data of frequency and duration. Since then, several modification to 
the Epstein’s format have been proposed in order to improve adherence and accuracy, until 
researchers decided to separate these two dimensions. To date, the widely used measurement 
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of duration is a 24-hour scale (Figure 3). Patients are required to draw a line representing a 
period of time within 24 hours that they experienced pain. 
 
 
 
Figure 3: 24-hour scale of duration 
 
2.8.1.4   Headache Index 
Headache index is a composite measure that incorporates all dimensions, calculated by 
summing headache frequency, intensity and duration together (frequency × intensity × 
duration). Headache index can reflect the total suffering of patients, however, it weighs these 
three dimensions in an arbitrary manner, which renders it of little value when comparisons are 
being made across patients. Furthermore, the clinical meaning of changes is not clear based 
on the headache index. In fact, it has been argued that there is no need for headache index, 
because in most cases where there is a decrease in the index value, it is usually due to a 
decrease in frequency of attacks (Tfelt-Hansen et al., 1984). Consequently, IHS community 
recommended this composite measure no longer be used (International Headache Society 
Clinical Trials Subcommittee, 2000). 
 
2.8.2   Pain Quality 
In clinical practice, assessing pain quality is as important as pain intensity, because treatment 
intervention may alter certain qualities of pain while not impacting on pain intensity. The 
items contained in the McGill Pain Questionnaire (MPQ) are designed to access various 
components of pain, such as sensory, affective and evaluative, using 78 adjectives in 20 
categories. MPQ was developed by Melzack and colleagues (Melzack, 1975a). Its validity and 
reliability have been tested extensively in acute and chronic pain (Melzack and Perry, 1975, 
Reading, 1982, Wilkie et al., 1990).  
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2.8.3   Medication Consumption 
Medication consumption has been frequently monitored by clinicians and researchers, even in 
the non-drug trial. It is not only related to the social burden, it is also another way to assess 
behaviours motivated by pain. The direct way of measurement is to request the patients to 
record and count the number of pills consumed. In fact, the simple pill count cannot be 
suitable for some conditions, such as participants take more than one medication in non-drug 
trials; patients switch medication during treatment. In 1976, some medical experts rate the 
potent weight of analgesics for migraine control (Coyne et al., 1976). Later on Blanchard and 
Andrasik (1985) modified that potent weight into a “1 to 7” list and summarised a medication 
index, which multiplies the number of pill count by the respective potency value. Based on 
that, scientists developed the medication quantification scale (MQS) of pain for both clinical 
and research purposes in 1992, and has been updated to version III in 2003. The MQS covers 
simple analgesics, opioids, anti-depressants to steroids (Harden et al., 2005). The reliability, 
validity and sensitivity of the MQS have been demonstrated (Guck et al., 1999a, Stormo et al., 
1998), Furthermore, it has been used as a standard measurement to validate other 
measurements (Guck et al., 1999b). IHS guidelines committees recommend that the 
medication consumption should be recorded and as a secondary effect parameter.  
 
2.8.4   Functional Impact 
Until last decade, researchers have begun to note that the effectiveness of a treatment for pain 
disorders, is not only determined by the degree of pain reduction, but also in the improvement 
of impacted functioning (Portenoy, 1991, Turk et al., 1993). Especially for migraineurs, the 
impact can be more serious than some other diseases, such as hypertension, diabetes, 
gastrointestinal disorders (Andrasik, 2001), and other types of headache (Kryst and Scherl, 
1994). So far, a number of scales are available for assessing the functional impact, without 
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reliability and validity issues, such as the SF-36 (Ware, 2000), the Beck Depression Inventory 
(BDI) (Flor et al., 1992) and the Migraine Disability Assessment Questionnaire (Stewart et al., 
1999b, Stewart et al., 1999a).  
 
Most recently, researchers began to focus on scales specific to migraine or headache in 
general. Migraine Specific Quality of Life Questionnaire (MSQOL) was developed by Glaxo 
Wellcome Inc. to assess the effect of migraine treatment. Although MSQOL takes the SF-36 
as the basis, the dimensions of MSQOL had been demonstrated to have low-to-modest 
correlations with the two component scores of the SF-36 and were modestly to moderately 
correlated with migraine symptoms (Martin et al., 2000). Moreover, the validity and 
reliability of the MSQOL have been confirmed by a few studies (Cole et al., 2007, Martin et 
al., 2000).  
 
MSQOL contains three aspects, namely role function-restrictive (question 1-7), role 
function-preventive (questionnaire8-11) and emotional function (questionnaire 12-14). Each 
dimension is scored from 0-100 and a higher score indicates better health. The use of tools 
assessing headache impact or disability is increasingly being recommended by generalized 
headache management guidelines (Dowson, 2001, Dowson et al., 2002). 
 
2.9    Pressure Pain Threshold (PPT) 
2.9.1   Introduction 
The term pain threshold refers to the minimum intensity or duration of a sensory stimulus at 
which it becomes painful as interpreted by the subject (Cook, 2006). For instance, the 
temperature, the pressure, or the duration of muscle being ischaemia, at which a change from 
ordinary sensation to pain occurs, is the pain threshold. It is clearly different to the term “pain 
tolerance”, which refers to the degree of pain that a subject can tolerate. Pressure pain 
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threshold is most commonly tested. It has been used as the outcome measure for testing the 
efficacy of analgesics or other specific therapies mainly for clinical purposes (Tunks et al., 
1988, Meyer et al., 2008), such as manual oscillation for rheumatoid arthritis (Dhondt et al., 
1999) and evaluating activity of 3alpha-hydroxysteroid oxido-reductase in sciatic nerve injury 
(Meyer et al., 2008). 
 
2.9.2   Thermal Pain Threshold (TPT) 
Noxious thermal pain threshold includes heat and cold TPTs. Females (Riley et al., 1998, 
Edwards et al., 2004), non-white races (Edwards and Fillingim, 1999, Campbell et al., 2005) 
and younger people (Bravenboer et al., 1992) have lower TPT.  Moreover, TPT has been 
reported to vary among different areas of the body (Chery-Croze and Duclaux, 1980, Melzack 
and Wall, 1962); and increases with decreased stimulation area (Defrin and Urca, 1996, 
Defrin et al., 2002). Apart from the above factors, TPT is also affected by some external 
factors. Kundermann and his colleagues (2004) found sleep deprivation produces a significant 
decrease in heat pain threshold in healthy volunteers. In addition, a study involving 13 healthy 
subjects revealed that electroacupuncture can increase heat pain threshold (HPT) (Leung et al., 
2005). 
 
TPT as a laboratory-based assessment has been researched in headache patients. Patients with 
cluster headache reported a reduced cold pain threshold (CPT) and increased HPT on the 
affected side compared with the contralateral asymptomatic side (Ellrich et al., 2006). Patients 
with tension-type headache experienced a significant decrease in HPT measured in the 
temporal region, but reported normal HPT in the hand during the headache attacks (Jensen, 
1996).  
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The reliability and reproducibility of TPT measurements has been demonstrated by studies in 
young adults (Cathcart and Pritchard, 2006, Bravenboer et al., 1992) as well as other age 
groups (Bravenboer et al., 1992). 
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2.9.3   Pressure Pain Threshold (PPT)  
Pressure pain thresholds in the general population vary by age and gender (Jensen et al., 1992). 
Women have lower PPT values than men (Takala, 1990, Chesterton et al., 2003, Garcia et al., 
2007). Moreover, PPT has been detected to be significantly lower in healthy females during 
the premenstrual phases (Isselée et al., 2001). Furthermore, Fischer (1987) has noted that the 
PPT of healthy people varies among different muscles and individuals, and with a wide range 
of values (Davenport, 1969, McMillan, 1995). In 1990, Takala (1990) tested PPT on the 
upper trapezius and levator scapulae muscles finding that even in the same tissue the values of 
PPT in the non-symptomatic population displayed wide variation. A study involving 27 sites 
including the nape, shoulder, arm and lumbar back areas revealed that PPTs were lower in the 
nape region, The PPT values of nape region were 55% of those tested in the lumbosacral 
region, the least sensitive area to pressure (Kosek et al., 1993). Such results are consistent 
with other publications (Fischer, 1987, Hogeweg et al., 1992). 
 
PPT has been used in determining the beneficial effect of physical therapies in the deeper 
tissues (Vernon et al., 1990, Fischer, 1998) such as spinal manipulation for chronic neck pain 
(Vernon et al., 1990) or low back pain (Cote and Mior, 1994); neck muscle training for neck 
pain (Ylinen et al., 2005). 
 
The relationship between PPT and headaches including migraines is not well understood. 
Bovim (1992) compared PPT in cervicogenic headache, migraine, tension-type headache and 
healthy people measured with algometer, and found that there was no significant difference 
between migraine or tension-type headache and healthy controls. However, lower PPTs have 
been observed in cephalic and extra-cephalic muscles in tension-type headache sufferers 
(Schoenen et al., 1991, Bendtsen et al., 1996, Ashina et al., 2005); in the head and at the 
deltoid muscle in cluster headache patients (Bono et al., 1996), when compared with healthy 
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volunteers. In addition, some headache studies reported that compared with the PPT in a 
pain-free state, the PPT during pain was decreased (Drummond, 1986), or unchanged (Jensen 
et al., 1988, Bove and Nilsson, 1999). Furthermore, another study involved cervicogenic 
headache, migraine and tension-type headache as a whole revealed that a lower PPT was 
recorded when the headache was more intense (Sand et al., 1997). Jensen and his colleagues 
(1988) also demonstrated that PPT did not change during the attacks of common migraine as 
well as during headache-free intervals, which is in conflict with another study (Sandrini et al., 
1994) which reported a lower PPT in migraine attacks compared to healthy people. Moreover, 
a recent study revealed significant differences in PPTs of the neck muscles between the 
patients with unilateral migraine and healthy volunteers, and in PPTs of the neck region 
between symptomatic and non-symptomatic sides, however without a significant side 
difference in the cephalic points of these unilateral migraine sufferers 
(Fernández-de-Las-Peñas et al., 2008). In contrast, other studies reported the lower PPTs on 
the symptomatic side than on the non-symptomatic side in the craniofacial area (Bono et al., 
1996) and temporalis muscle (Bono et al., 1996, Ellrich et al., 2006) of cluster headache 
sufferers and in the cranial area of migraine patients (Smith et al., 2006).  
 
In addition, TPT is significantly and strongly correlated with PPT in healthy volunteers 
(McManusa et al., 2006, Bhalang et al., 2005). 
 
2.9.4   Reliability of PPT 
An algometer is a device that measures sensitivity to pain and determines a patient's PPT. It 
was developed in 1988 by the companies 3M and Racia, based on the work of Claude Willer, 
and has been introduced as semi-objective method (Takala, 1990). 
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The high intrarater and interrater reliability of PPT has been demonstrated on cranial and neck 
muscles by studies with healthy individuals (Chung et al., 1992, Antonaci et al., 1998, 
Delaney and McKee, 1993) and on cephalic points of headache patients (Sand et al., 1997).  
 
Some technical issues have been identified as affecting the reliability of PPT assessed with an 
algometer, including sites, reaction time of the rater and the speed in which pressure is 
increased. Jensen and his colleagues (1986) found that measurements of PPT were most 
reliable when the measurement site was flat, wide, and bony as opposed to a soft tissue site 
where the hard rubber tip might slide off the target. However, Kosek (1993) reported no 
consistent differences between PPT values of muscle bellies and bony sites when compared 
within the same body region. The reaction time of the rater and the rate of pressure increase 
were other factors that affected reliability (Jensen et al., 1986). The reliability is enhanced 
when all measurements are taken by one examiner (Nussbaum and Downes, 1998). An 
increasing rate at 1 kg/cm2 is more reliable than 2 kg/cm2 (List et al., 1989), which may be 
due to a certain time being necessary for the patient and rater to react to applied pressure. 
Such rates have been widely used by a series PPT studies (Zaslawski et al., 2003, Fischer, 
1987). 
 
A study testing the reproducibility of PPT in patients with different types of headaches 
revealed that the variability was reported as higher among tension-type headache patients than 
migraine and cervicogenic headache patients (Sand et al., 1997).  
 
Repeatability varies between measurement sites. The most reliable measurements are the 
temporal muscles among the 11 points located in the temporal, sternocleidomastoid insertion 
and frontal region (Sand et al., 1997). A study to determine the number of measurements that 
provided the most precise estimate of PPT was carried out by Ohrbach and Gale (1989), and 
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revealed that PPT increased and decreased unsystematically from measurement to 
measurement. The mean of two readings provided a more reliable estimate of PPT than using 
one reading.   
 
In summary, PPT measured with an algometer has a high intrarater reliability when it is 
measured on the bony sites of head and neck, at 1 kg/cm2 increasing rate and by one rater. 
 
2.10    Research Questions  
Both clinical evidence and neural mechanisms support that acupuncture may benefit migraine 
by abolishing and preventing attacks. There are some weaknesses and gaps in the current 
body of literature. Existing systematic reviews on acupuncture for migraine failed to 
adequately represent non-English studies such as those were conducted in China, Japan and 
Korea. In addition, acupuncture effects on other types of migraine, those with frequent 
headache or menstrual migraine have not been properly examined.   
 
The objectives of this study were to:  
1) systematically review the current state of evidence from English and East Asian literature 
of acupuncture for migraine; and,  
2) design and conduct a RCT that addresses the key identified methodological problems from 
the systematic review (SR), to determine the short- and long-term effect and safety of 
acupuncture for patients with migraine.  
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CHAPTER THREE: METHODOLOGY OF SYSTEMATIC 
REVIEW 
Clinicians, researchers, healthcare providers and relevant policy makers are inundated by the 
amounts of available research and clinical data. Such information should therefore be 
managed and assessed systematically so that appropriate decisions based on the research / 
data can be made. Taking an intervention for migraine as an example, before any healthcare 
provider decides to provide an intervention to a migraine sufferer, the effectiveness of the 
intervention should be evaluated systematically; this is referred to as an ‘evidence-based 
decision’.  
 
Investigating the efficacy of an intervention is not the only aim of a systematic review; 
sometimes due to the limitations of literature, we cannot make a decision at that time. 
Systematic reviews can also assist researchers in finding flaws in the available literature, 
which is useful for the purposes of further research. 
 
Systematic reviews can synthesize the results of multiple primary investigations by using 
appropriate strategies which can limit biases and reduce chance effects so that every single 
right conclusion and decision is based on reliable results (Antman EM, 1992). The usual 
methods of a systematic review include a comprehensive search of all potentially relevant 
studies; the use of explicit, reproducible criteria in the selection of studies for review; 
identifying the evidence; appraising the quality of evidence; synthesizing the data and 
reporting the findings (Cook et al., 1997). A meta-analysis is the statistical method used to 
synthesize, combine and summarise the results of several primary studies in the systematic 
review. 
 
In the past 20 years, guides have been created to help with the critical appraisal (Oxman et al., 
1994) and application (Guyatt et al., 1995) of literatures. Furthermore, an international 
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initiative, called the Cochrane Collaboration, has evolved to help prepare, maintain, and 
disseminate the results of systematic reviews of health care interventions since 1992. 
Presently, the Cochrane reviews are widely accepted as reviews of the highest quality. The 
methods of current systematic reviews followed those recommended by the “Cochrane 
Handbook for Systematic Reviews of Interventions” (Higgins and Green, 2006). 
 
In this project, two systematic reviews were conducted; a systematic review of studies 
included in English databases and a systematic review of studies in East Asian databases. 
Two systematic reviews were conducted as acupuncture is widely accepted as the mainstream 
medicine in most Asian countries, especially in China and Korea, therefore literature from 
these countries is important to the overall understanding of the clinical applications of 
acupuncture. Unfortunately, most studies conducted in these countries are not published in 
English and are often not included in commonly used databases in Western countries, such as 
PubMed. 
 
The aims of the two systematic reviews were: 
1) To assess the efficacy and safety of acupuncture in the treatment of migraine in the 
following comparisons  
Real acupuncture vs sham or placebo acupuncture  
Real acupuncture vs non-acupuncture treatment  
Real acupuncture vs standard therapies  
2) To compare the study design and quality of literature published in these two groups of 
databases, i.e., English and East Asian databases.   
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3.1    Search Strategy for Identification of Studies 
“Acupuncture”, “electro-acupuncture”, “Chinese medicine”, “point-stimulation”, “headache” 
and “migraine” were used as search terms and searched for in selected Chinese, English, 
Japanese and Korean electronic databases from the inception of the databases to August 2006, 
January 2008, January 2008, and May 2007 respectively. The Chinese data was searched and 
assessed by two researchers. The Japanese and Korean data was searched and translated with 
the help of three acupuncture researchers from Korea and Japan who are specialized in 
systematic reviews. The work contributed by Dr. Yamashita Hitoshi, Dr. Junchul Seo and Dr. 
Jae Cheol Kong was acknowledged. The search strategies were explained to the three experts. 
The included databases were chosen by the individuals according to their prior knowledge of 
relevant medical journals and are listed below in Table 1. 
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Table 1: The databases used in different systematic reviews 
Systematic review Database 
Chinese Database 
Vi Pu，www.cqvip.com 
Wan Fang，www.wanfangdata.com.cn 
English Database 
EMBASE, www.embase.com 
PUBMED, www.ncbi.nlm.nih.gov 
Cochrane library, www.theCochraneLibrary.com 
Japanese Database Ichushi Web, www.jamas.or.jp 
Korean Database 
National Assembly Library, www.nanet.go.kr  
KoreaMed, www.koreamed.org 
Journal of Korean Oriental Medicine , www.koms.or.kr 
The Journal of Korean Acupuncture & Moxibustion Society, 
www.acumoxa.or.kr 
The Korean Journal of Meridian & Acupoint, www.acupoint.org 
Oriental Medicine Information System, www.omis.dhu.ac.kr 
 
3.2    Criteria for Considering Studies for Reviews 
3.2.1   Language of Studies 
The full-text of included studies must have been published in Chinese, English, Japanese or 
Korean databases.  
 
3.2.2   Types of Studies 
Studies with a randomized and controlled design were included. Quasi-randomized studies 
(e.g. by the order of admission or date of birth) were also included. Ongoing or unpublished 
studies were excluded.  
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3.2.3   Types of Participants  
 
Participants were migraine patients diagnosed according to the standard criteria, such as those 
recommended by the Ad Hoc committee of the National Institute of Neurological Diseases 
and Blindness (Ad Hoc Committee on Classification of Headache of the National Institute of 
Neurological Dieases and Blindness, 1962) or the International Headache Society (IHS) 
(Headache Classification Subcommittee of the International Headache Society, 2004), for 
participants recruitment. Studies that did not separate migraine patients from those with other 
types of headache, such as tension-type headache, were excluded.  
 
3.2.4   Types of Intervention  
Studies involving needle insertion at acupuncture points, tender points, or trigger points and 
other invasive methods of stimulating these points (e.g. electro-acupuncture) were included. 
Studies examining non-invasive acupuncture, such as laser acupuncture or acupressure were 
excluded as were studies utilizing point-injection. Studies comparing a combined therapy of 
acupuncture and Chinese herbal medicine or Tuina with a control group were included 
because acupuncture was often used together with other therapies in clinical practice.  
Control interventions considered were: 
• No treatment, 
• Sham or placebo acupuncture, or 
• Other active treatments. 
Studies comparing different modalities of acupuncture were excluded, for instance comparing 
manual acupuncture with electroacupuncture. Studies without a valid control group which did 
not allow the effects of acupuncture alone to be assessed (for instance, comparing 
acupuncture with acupuncture plus Qigong) were also excluded. 
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3.2.5   Types of Outcome Measures 
Included studies should report at least one clinically related outcome for migraine, such as the 
frequency or intensity of migraine. Studies using respondent rates to present improvements in 
frequency, intensity or duration were also included. Trials reporting only physiological or 
laboratory parameters as outcome measures, such as electroencephalogram, were excluded.  
 
3.3   Data Extraction 
Information on participants, randomization, blinding, interventions, outcome measures as well 
as results were extracted using the standard form adopted by Melchart and colleagues 
(Melchart et al., 2001). One reviewer extracted the data. Another reviewer checked the 
extraction according to the pre-defined form (Appendix 2). Differences between the reviewers 
were solved through discussion. Extracted data were presented using separate tables. 
 
3.4    Assessment of Quality 
The quality of included studies was assessed independently by two reviewers using a Jadad 
Scale (Jadad et al., 1996), Internal Validity Scale (IVS) (Linde et al., 1997), and the Oxford 
Pain Validity Scale (OPVS) (Smith et al., 2000). Jadad scales and IVS have been used in 
several SRs on acupuncture (Melchart et al., 2001, Melchart et al., 1999). The OPVS was 
designed specifically to examine the internal validity of trials in the field of pain research 
(Smith et al., 2000). In addition, Standards for Reporting Interventions in Controlled Trials of 
Acupuncture (STRICTA) were used to assess the reporting quality of acupuncture 
interventions (MacPherson et al., 2002). In the two systematic reviews conducted (see 
chapters four and five), points awarded for each item of Jadad Scale, IVS and OPVS were 
listed in order for each trial in tables. 
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3.4.1   Jadad Scale 
The Jadad Scale (Jaded et al., 1996) (Table 2) consists of five questions assessing the 
following five aspects: random allocation, description of randomization, double blinding, 
description of double blinding and reporting of drop-outs. The maximum score of the Jadad 
Scale is 5. Studies scoring 3 or more points are considered high quality with 3 points being 
60% of the maximum score. In each category, if “yes” is answered, one point is awarded. If 
“no” is answered, then no points are awarded. The Jadad Scale utilised in this research was 
the latest version. The former version of the Jadad Scale contained three items; it combined 
items 1 and 2 of the current version, and also combined items 3 and 4 of the current version.  
 
Table 2: Scoring of Jadad Scale 
ITEM 
Yes=1; No=0 
SCORE 
Was the study described as randomized?   
Was the randomization described and appropriate?  
Was the study described as double blind?  
Was the method of double blinding appropriate?   
Was there a description of drop-outs and withdrawals?  
 
3.4.2   Internal Validity Scale (IVS) 
The IVS consists of six items (Table 3) which assess the method of allocation, concealment of 
allocation, baseline comparability, blinding patients and evaluators and likelihood of selection 
bias respectively. Each item is scored as 0 (criterion not met or insufficient information 
provided), 0.5 (criterion partially met), or 1 (criterion met). 
Item 1 “Method of allocation to groups”: If the study was titled “randomized study” or 
“randomized trial” or the authors mentioned that “patients were randomized”, 0.5 was given 
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to Item 1. Furthermore, if the study used appreciate allocation approaches another 0.5 was 
given to Item 1. 
Item 2 “Concealment of allocation”: If the paper mentioned “the person who executed the 
allocation sequence was different from the person who recruited participants,” 0.5 was given. 
If the authors described the method of concealment, such as “sealed envelope”, another 0.5 
was given to Item 2.   
Item 3 “Baseline comparability”: If the demographic data was comparable, 0.5 was given. If 
the baseline data of main outcomes was comparable, another 0.5 was given. 
Item 4 “Blinding of patients”: If the paper only mentioned that “participants were blinded”, 
0.5 was given. If the paper described the process of blinding participants or investigated the 
creditability of blinding that was success, another 0.5 was given. 
Item 5 “Blinding of evaluators”: If the paper mentioned blinding the evaluator, 0.5 was given. 
If the paper described the process of blinding the evaluator, another 0.5 was given. 
Item 6 “Likelihood of selection bias”: If the paper mentioned the number of drop-outs or the 
number of participants between baselines and after treatment was presented (thereby enabling 
the calculation of the number of drop-outs) 0.5 was given. If the paper provided detailed 
information (reason, allocation of drop-out, etc) about the drop-out, another 0.5 was given. 
 
Table 3: Scoring of IVS 
ITEM SCORE 
Method of allocation to groups  
Concealment of allocation  
Baseline comparability  
Blinding of patients  
Blinding of evaluators  
Likelihood of selection bias after allocation to groups by drop-outs, etc.  
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3.4.3   Oxford Pain Validity Scale (OPVS) 
The Oxford Pain Validity Scale (OPVS) (Smith et al., 2000), was developed by a pain 
research group and specifically examines five aspects (Table 4) of trial methodology that are 
the sources of biases in the field of pain research: blinding, sample size, outcome measure, 
demonstration of internal sensitivity and data analysis. Generally, OPVS is more 
comprehensive in assessing the quality of clinical trials, as it not only focuses on 
randomization and blinding, but also assesses the outcome measure and data analysis. So far, 
there is no standard cutoff score to determine what constitutes a high quality study. Following 
the Jadad Scale, a study with 60% of the maximum score was considered as high quality. 
 
Table 4: Description of OPVS 
ITEM 
Score 
(circle one 
number per item) 
Was the trial convincingly double-blind? 6 
Was the trial convincingly single-blind or unconvincingly 
double-blind? 
3 
1. 
Blinding 
Was the trial either not blind or the blinding is unclear? 0 
Was the start group start size ≥ 40? 3 
Was the start group start size 30 to 39? 2 
Was the start group start size 20 to 29? 1 
2. 
Size of 
trial 
groups Was the start group start size 10 to 19? 0 
Look at pre hoc list of most desirable outcomes relevant to 
the review question: 
 
Did the paper include results for at least one pre hoc 
desirable outcome, and use the outcome appropriately? 
2 3. 
Outcome 
There were no results for any of the pre hoc desirable 
outcomes, or, a pre hoc desirable outcome was used 
inappropriately. 
0 
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Continued Table 4: Description of OPVS 
ITEM 
Score 
(circle one 
number per 
item) 
Look at the baseline levels for the outcomes relevant to the 
review question: 
 
For all treatment groups, baseline levels were sufficient for 
the trialist to be able to measure a change following the 
intervention (e.g. Enough baseline pain to detect a difference 
between baseline and post-treatment levels). Alternatively, did 
the trial demonstrate internal sensitivity? 
1 
4. 
Demonstra
tion of 
internal 
sensitivity For all treatment groups, baseline levels were insufficient to 
be able to measure a change following the intervention, or, 
baseline levels could not be assessed, or internal sensitivity 
was not demonstrated. 
0 
i. Definition of outcomes  
Did the paper define the relevant outcomes clearly, including 
where relevant, exactly what ‘improved’, ‘successful 
treatment’, etc represented? 
1 
The paper failed to define the outcomes clearly 0 
ii. Data presentation: Location and dispersion  
Did the paper present either mean data with standard 
deviations, or dichotomous outcomes, or median with range, 
or sufficient data to enable extraction of any of these? 
1 
The paper presented none of the above 0 
iii. Statistical Testing  
Did the trialist choose an appropriate statistical test, with 
correction for multiple tests where relevant? 
1 
Inappropriate statistical tests were chosen and/or multiple 
testing was carried out, but with no correction, or, no statistics 
were carried out. 
0 
iv. Handling of Drop-out  
The drop-out rate was either ≤10%, or was > 10% and 
includes an intention-to-treat analysis in which drop-outs 
were included appropriately. 
1 
5. Data 
Analysis 
The drop-out rate was> 10% and drop-out were not included 
in the analysis, or, it is not possible to calculate a drop-out 
rate from data presented in the paper. 
0 
 TOTAL SCORE  
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3.4.4   Allocation Concealment 
In addition, concealment of allocation was assessed using the method recommended by the 
Cochrane Collaboration if the method was adequate, uncertain, inadequate or not mentioned, 
and scored A, B, C and D, appropriately (Higgins and Green, 2006). This method has been 
used by other systematic reviews (Ezzo et al., 2006, Smith et al., 2007). Concealment of 
allocation is the process of concealing assignments of the interventions. “A” refers to studies 
adopting correct concealment methods, such as using centralized randomization or 
sequentially numbered sealed, opaque envelopes. If studies do not report any concealment 
approach, “B” should be coded, and this code should also be used for studies that merely state 
that a list, table or sealed envelopes were used. “C” includes the use of case record numbers, 
dates of birth or day of the week, and any procedure that is entirely transparent before 
allocation, such as an open list of random numbers. “D” refers to studies that clearly state that 
allocation concealment is not used (Higgins and Green, 2006). 
 
3.4.5   Standards for Reporting Interventions in Controlled Trials of Acupuncture 
(STRICTA) 
The STRICTA recommendations (Table 5) were proposed by an international group of 
researchers in acupuncture in an attempt to improve the quality of reporting interventions of 
acupuncture (MacPherson et al., 2002). It is suitable for both western trigger point treatment 
and traditional Chinese acupuncture treatment using manual acupuncture, electro-acupuncture 
or auricular acupuncture. Implementing the STRICTA recommendations amends inadequate 
acupuncture reporting, facilitates the improvement of critical appraisal, and helps researchers 
developing criteria for assessing acupuncture treatment in earlier studies (White and Ernst, 
1998). STRICTA is a qualitative assessment tool and does not have a scoring mechanism. It 
contains the following six items. 
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Table 5: Items of STRICTA 
INTERVENTION ITEM DESCRIPTION 
Style of acupuncture 
Rationale for treatment (e.g. syndrome patterns, segmental 
levels, trigger points) and individualization if used 
Acupuncture 
rationale 
1 
Literature sources to justify rationale 
Points used (uni/bilateral) 
Numbers of needles inserted 
Depths of insertion (e.g. tissue level, mm or cun) 
Responses elicited (e.g. de qi or twitch response) 
Needle stimulation (e.g. manual or electrical) 
Needle retention time 
Needling details 2 
Needle type (gauge, length, and manufacturer or material) 
Number of treatment sessions Treatment 
regimen 
3 
Frequency of treatment 
Co-interventions 4 Other interventions (e.g. moxibustion, cupping, herbs, 
exercises, life-style advice) 
Duration of relevant training 
Length of clinical experience 
Practitioner 
background 
5 
Expertise in specific condition 
Intended effect of control intervention and its appropriateness 
to research question and, if appropriate, blinding of 
participants (e.g. active comparison, minimally active 
penetrating or non-penetrating sham, inert) 
Explanations given to patients of treatment and control 
interventions 
Details of control intervention (precise description, as for 
Item 2 above, and other items if different) 
Control 
intervention(s) 
6 
Sources that justify choice of control 
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3.5    Data Analysis  
Qualitative assessment was used to analyze methodological data. RevMan 4.2 was used for 
meta-analysis. If significant heterogeneity among the trials was detected with I2 statistic (I2 >= 
50%), a random-effects model was used. Otherwise, a fix-effects model was used. For 
continuous data, weighted mean difference (WMD) was calculated. For dichotomous data, 
relative risks were calculated. If different numerical scales were used to assess one outcome 
measure, a standardised mean difference (SMD) was calculated. 
 
We also adopted the method described by van Tulder and colleagues in 2003 for the 
qualitative assessment of the overall evidence. This method classifies the evidence into the 
categories of “strong”, “moderate”, “limited”, “conflicting” or “no evidence” depending on 
the quality, number and results of the studies (van Tulder et al., 2003).  
Strong evidence: Refers to consistent findings in multiple high quality RCTs. 
Moderate evidence: Refers to findings in a single, high quality RCT or consistent findings in 
multiple low-quality trials. 
Limited evidence: Refers to findings in a single low-quality RCT. 
Conflicting evidence: Refers to inconsistent results in multiple RCTs. 
No evidence: Meant no studies were identified. 
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CHAPTER FOUR: SYSTEMIC REVIEW OF ENGLISH 
LITERATURES ON ACUPUNCTURE FOR MIGRAINE 
 
4.1    Introduction 
A systematic review on idiopathic headache, published in 2001, stated the overall 
effectiveness of acupuncture in the treatment of headache was conflicting (Melchart et al., 
2001) as most of the included studies suffered from problems of either small sample size 
(usually less than 50), the inappropriate choice of instruments for measuring outcomes, or, 
non-adherence to the IHS classifications for migraine headaches in the inclusion criteria. The 
latest systematic review (Scott and Deare, 2006) to evaluate the effectiveness of acupuncture 
for migraine alone included studies published before March 2006. The 2006 review also 
found that acupuncture studies for migraine still suffered from the same flaws as the earlier 
systematic review published in 2001. However, according to the 2006 systematic review, the 
methodological quality of acupuncture studies has improved recently. Since the 2006 
systematic review, some high quality clinical trials have been published thus there is a need to 
re-conduct a systematic review to evaluate the efficacy of acupuncture for migraine alone. 
Furthermore, such a review can be compared with the SR in East Asian literatures to explore 
whether any differences exist in RCTs of acupuncture between Western and East Asian 
countries. 
 
4.2    Objective 
Through systematically reviewing English literature, the objectives of this review were to 
determine whether acupuncture was: 
1. More effective than no treatment;  
2. More effective than “sham/placebo” acupuncture; and 
3. As effective as other active interventions for migraine. 
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4.3    Methodology 
The following strategies were conducted. 
 “Acupuncture”, “electroacupuncture”, “point stimulation”, “headache”, “migraine” and 
“chronic migraine” and their combinations were used as text words to search the EMBASE, 
PUBMED and Cochrane Library from their inception to January 2008. 
The following list contains the terms used to search PubMed:  
#1 search acupuncture [tw]  
#2 search electroacupuncture [tw]  
#3 search point stimulation [tw] 
#4 search migraine [tw] 
#5 search chronic migraine [tw] 
#6 search headache [tw] 
#7 search #1or #2 or #3 [tw] 
#8 search #4 or #5 or #6 [tw] 
#9 search #7 and # 8 and Human (MeSH) and clinical trial [pt] 
 
The methodology utilised in this study is described in chapter three. 
 
4.4    Result 
4.4.1   Identification of Studies 
One hundred and five papers were found through the search. Fifty-four studies were excluded 
because they reported either other disease, other kinds of headaches or idiopathic headache as 
a whole. Seven papers did not report clinical relevant outcome measures or were protocols, 
and they were therefore excluded. Nine of the remaining 34 studies were excluded as TENS, 
laser-therapy treatment or other therapies were the active intervention. A further eleven 
studies were excluded for not having a valid control intervention, such as comparing 
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acupuncture plus Western medication with acupuncture plus placebo tablet (Lenhard and 
Waite, 1983), or not being RCTs. Another study was excluded as it was not a clinical trial. 
Two papers did not report original data and used previously published data to conduct further 
analyses (Linde et al., 2007c, Linde et al., 2007a); these two papers were excluded. 
Furthermore, three studies were excluded as they did not use standard diagnostic criteria in 
recruiting participants. Three studies published in German were excluded as we could not 
have them translated. Finally, 15 studies were identified. Figure 4 illustrates the process of 
study identification. 
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our  studies were excluded as not having a valid control intervention, 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Flowchart illustrating the process of study identification.  
 
 
 
 
 
 
105 studies 
 
 
51 studies 
 
 
44 studies 
 
 
35 studies 
 
 
24 studies 
 
 
23 studies 
 
 
21 studies 
 
 
18 studies 
 
 
15 studies 
    
 
54 studies excluded for reporting 
other types of headache 
7 papers did not report the clinical 
relevant outcome measures 
9 used TENS, laser-therapy or 
other therapies as treatment 
One study was not a clinical trial 
Two papers were not original 
studies 
11 studies did not have a valid 
control intervention or not being 
RCTs 
Three studies did not use standard 
diagnostic criteria in recruiting 
participants 
Three studies in Germany were 
excluded for lack of adequate 
translation  
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4.4.2   Description of the Studies 
Data from the 15 included studies was extracted and is summarised in Table 6. One study 
(Pintov et al., 1997) implemented Prensky’s classification to identify participants (Prensky 
and Sommer, 1979); twelve studies adopted the IHS criteria for the diagnosis of migraine, and 
the remaining two trials (Liguori et al., 2000, Dowson et al., 1985) used the Ad Hoc 
Committee’s criteria. In total, 2468 participants (median 81; range 22 - 960) were included in 
this review.  
 
Fourteen of the 15 studies used acupuncture in the treatment group and the remaining one 
study used dry needling (Hesse et al., 1994). Four studies compared acupuncture with 
Western medication and one study compared acupuncture with usual care (avoid acupuncture) 
(Vickers et al., 2004a). Four studies had a three-arm design, comparing acupuncture with 
sham acupuncture or Western medication (Diener et al., 2006);  acupuncture with TENS or 
laser therapy (Allais et al., 2003); acupuncture with placebo Western medication or Western 
medication (Melchart et al., 2003a); acupuncture with sham acupuncture or waiting list (Linde 
et al., 2005a), respectively. Four of the remaining six studies compared acupuncture with 
Western medication. The final two studies used a combination of massage and relaxation 
(Wylie et al., 1997), and mock TENS (Dowson et al., 1985) as the control intervention, 
respectively.  
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Table 6:  Characteristics of the 15 included studies 
Author and 
Date 
Definition 
of 
Participants 
Intervention Sample 
Population 
Outcomes Follow-up Drop-out Quality 
 
AC* 
Acute attacks  
(Melchart et 
al., 2003b) 
IHS Acupuncture 
vs Placebo 
WM vs WM 
Acu: n = 60 
PWM: n =61 
WM: n = 58 
Number of participants in whom a attack was 
prevented 
2 days Not report Jadad: 1-1-0-0-1 
IVS: 1-1-1-0.5-0-1 
OPVS: 0-3-2-1-1-1-1-1 
A 
Prophylactic effects  
(Streng et al., 
2006) 
IHS Acupuncture 
vs Western 
Medication 
(WM) 
Acu: n = 59 
WM: n = 55 
Frequency: headache days; number of attacks; 
days with medication 
Intensity （0-10 scale) 
Quality of life (SF-36) 
Disability (PDI) 
Emotional of pain (SES) 
Depression (ADS) 
Working days lost 
Proportion of treatment respondents: percentage of 
patients with a reduction of >= 50% in migraine 
attacks 
Number of patients with adverse side effects 
Number of drop-out due to side effects 
3 months Acu: n = 2 
WM: n = 17 
Jadad: 1-1-0-0-1 
IVS: 1-1-0.5-0-1-0.5 
OPVS: 3-3-2-0-1-1-1-1 
A 
(Alecrim-An
drade et al., 
2006) 
IHS Acupuncture 
vs Sham 
Acupuncture  
Acu: n = 16 
SA: n = 15 
Frequency: headache days, number of attacks 
Proportion of treatment respondents: percentage of 
patients with a reduction of >=40% and 50% in 
migraine attacks 
Duration: average duration of a migraine attack, 
total duration of pain per diary 
Intensity: average severity (0-3 scale) 
Rate of rescue medication used 
Frequency of nausea and vomiting 
6 months Acu: n = 2 
SA: n = 1 
Jadad: 1-1-1-1-1 
IVS:  1-1-1-1-1-1 
OPVS: 6-2-2-0-1-1-1-1 
A 
(Diener et al., 
2006) 
IHS Acupuncture 
vs SA vs WM 
Acu: n = 313 
SA: n = 339 
WM: n = 308 
Frequency: the difference in migraine days 
Proportion of treatment respondents: percentage of 
patients with a reduction of >= 50% in migraine 
days 
5 months Acu: n = 23 
SA: n = 22 
WM: n = 
121 
Jadad: 1-1-0-0-1 
IVS:  1-1-0.5-0.5-1-0.5 
OPVS: 3-3-2-1-1-1-1-0 
A 
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Intensity (0-100 scale) 
Pain-related impairment 
Quality of life (SF-12) 
Global assessment of therapy (1-6 scale) 
(Linde et al., 
2005a) 
IHS Acupuncture 
vs SA vs 
Waiting list 
Acu: n = 145 
SA: n = 81 
WL: n = 76 
Frequency: headache days; number of attacks; 
days with medication; difference in numbers of 
days with moderate or severe headache 
Intensity（0-10 scale) 
Quality of life (SF-36) 
Disability (PDI); 
Emotional of pain (SES) 
Depression (ADS) 
Working days lost; 
Proportion of treatment respondents: percentage of 
patients with a reduction of >= 50% in migraine 
attacks 
4 months Acu: n = 29 
SA: n = 24 
WL: n = 24 
Jadad: 1-1-0-0-1  
IVS: 1-1-0.5-0.5-1-1 
OPVS: 3-3-2-1-1-1-1-1 
A 
(Linde et al., 
2004) 
IHS Acupuncture 
vs SA 
Acu: n = 17 
SA: n = 14 
Frequency: number of attacks, headache days, 
Intensity (0-10 VAS) 
Medication consumption (total sum) 
6 months Acu: n = 2 
SA: n = 1 
Jadad: 1-0-0-0-1  
IVS: 0.5-0.5-1-0.5-0-1 
OPVS: 3-2-2-1-1-1-1-1 
B 
(Vickers et 
al., 2004a) 
IHS Acupuncture 
vs Usual care 
Acu: n = 161 
UC: n = 140 
Frequency: headache days 
Intensity: average of severity (0-5 scale) 
Quality of life (SF-36) 
Medication consumption 
Proportion of treatment respondents: percentage of 
patients with a reduction of >= 50% in migraine 
days 
12 months Acu: n = 2 
UC: n = 4 
Jadad: 1-1-0-0-1  
IVS: 0.5-1-1-0-1-1 
OPVS: 3-3-2-1-1-1-1-1 
A 
(Allais et al., 
2003) 
IHS Acupuncture 
vs TENS vs 
Lasertherapy 
Acu: n = 20  
Tens: n = 20 
Laser: n = 20 
Frequency: headache days 
Proportion of treatment respondents: percentage of 
patients with a reduction of >= 50% in migraine 
days 
2 months Acu: n = 2  
Tens: n = 2 
Laser: n = 3 
Jadad: 1-1-0-0-1  
IVS: 1-1-1-0-1-1 
OPVS: 3-3-2-1-1-1-1-0 
A 
(Allais et al., 
2002) 
IHS Acupuncture 
vs WM 
Acu: n = 80 
WM: n = 80 
Frequency: number of attacks, days with 
medication 
Intensity: average of severity (0-3 scale) 
Medication consumption 
No Acu: n = 3 
WM: n = 7 
Jadad: 1-1-0-0-1  
IVS: 1-0.5-1-0-1-1 
OPVS: 3-3-2-1-1-1-1-1 
B 
(Liguori et 
al., 2000) 
Ad Hoc Acupuncture 
vs WM  
Acu: n = 60 
WM: n = 60 
Headache index: duration, intensity, quality of life 45 weeks Not report Jadad: 1-0-0-0-0  
IVS: 0.5-0-0-0-0-1 
OPVS: 0-3-2-1-1-1-1-0 
B 
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(Pintov et al., 
1997) 
Prensky Acupuncture 
vs SA 
Acu: n = 12 
SA: n = 10 
Frequency: number of attacks 
Duration 
Intensity (0-10 VAS) 
10 weeks No Jadad: 1-0-1-1-1 
IVS: 1-0-0.5-0.5-1-1 
OPVS: 3-3-2-1-1-1-1-1 
B 
(Wylie et al., 
1997) 
IHS Acupuncture 
vs massage 
plus 
relaxation 
Acu: n = 13 
Control: n = 
14 
Frequency: pain total index, headache index 
Duration: totally hours 
Intensity (1-3 scale) 
Not report Not report  Jadad: 1-0-0-0-0 
IVS:  0.5-0-0-0-1-0 
OPVS: 0-1-2-1-1-1-1-0 
B 
(Hesse et al., 
1994) 
IHS Acupuncture 
plus placebo 
WM vs WM 
Acu + 
Placebo: n = 
40 
WM: n = 41 
Frequency: number of attacks 
Intensity (3-point scale) 
Duration 
Global rating of migraine (intensity, duration and 
symptoms) 
Medication consumption 
No Acu + 
Placebo: n = 
2 
WM: n = 2 
Jadad: 1-0-1-1-1 
IVS:  0.5-0-0.5-0.5-1-1 
OPVS: 6-3-2-1-1-1-1-1 
B 
(Vincent, 
1989a) 
IHS Acupuncture 
vs SA 
Acu: n = 16 
SA: n = 16 
Frequency: headache days 
Intensity (0-5 scale): peak pain, total pain score 
per week 
Medication consumption 
Anxiety scales 
Pain behaviour scale 
1 year Acu: n = 1 
SA: n = 1 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0.5-1-0-1 
OPVS: 3-2-2-1-1-1-1-1 
B 
(Dowson et 
al., 1985) 
Ad Hoc Acupuncture 
vs Mock 
TENS 
Acu: n = 25 
SA: n = 23 
Frequency: self-defined respondent rate 
Intensity (0-6 scale) 
Duration 
Medication consumption 
24 weeks Acu: n = 4 
SA: n = 4 
Jadad: 1-1-0-0-1  
IVS: 1-1-0-0.5-0-1 
OPVS: 3-3-2-1-1-1-1-0 
A 
 
WM = Western Medication; PWM = Placebo Western Medication;  PDI = Pain Disability Index; SES = Schemerzempfindungs-Skala (assessing 
emotional scale) 
ADS = Depression Scale; AC = Allocation Concealment; SA = Sham Acupuncture; WL = Waiting List; UC = Usual Care 
TENS = Transcutaneous Electrical Nerve Stimulation 
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Allocation concealment:  
A: Indicates adequate concealment of the allocation (e.g. by telephone randomisation, or use of consecutively numbered, sealed, opaque envelopes) 
B: Indicates uncertainty about whether the allocation was adequately concealed (e.g. where the method of concealment is not known)  
C: Indicates that the allocation was definitely not adequately concealed (e.g. open random number lists or quasi-randomisation such alternate days, 
odd/even date of birth, or hospital number) 
D: Indicates the score was not assigned, i.e. not used.  
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4.4.3 Quality Assessment 
Jadad, IVS, OPVS and STRICTA were used to assess the quality of the included studies (see 
chapter three for a detailed description of the methods). The results are provided in Table 1. 
Studies scoring 3 or more in Jadad, 3.5 in IVS and 10 in OPVS were considered as high 
quality, which is 60% of the maximum possible score. 
 
The median Jadad score was 3 (range 1-5) out of a possible score of 5; the median IVS was 4 
(range 1.5 - 6) out of 6; and the median OPVS was 12 (range 7 - 16) out of 16. Ten of the 15 
studies were of good quality in Jadad. However two of the five studies with poor quality 
achieved 1 point only in randomization (Wylie et al., 1997, Liguori et al., 2000). Based on the 
IVS, eleven of the included 15 studies were of high quality. There was one study having 1.5 
in IVS (Wylie et al., 1997). In OPVS, 13 papers had 10 or more points and were considered as 
high quality. 
 
All 15 trials were described as randomised studies; consequently, a score of 1 or 0.5 was 
given to item one in Jadad and IVS. In seven studies the method of randomisation was briefly 
mentioned; these were considered as an “unclear” concealment allocation hence “B” was 
coded. Eight trials reported the allocation approaches clearly and the methods were 
appropriate therefore “A: adequate” was coded.  No studies were coded as “C: Inadequate” 
or “D: not used”.  
 
Furthermore, in nine of the 15 studies the participants were blinded and details regarding the 
process of blinding was reported. Two of the nine studies tested the credibility of sham 
control (Alecrim-Andrade et al., 2006, Vincent, 1989a); consequently, 1 or 0.5 points were 
granted to the fourth item of Jadad or IVS. The involvement of blinding the assessor was 
reported in nine of 15 studies, thereby scoring 1 in the fifth item of IVS.  
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Two of 15 studies did not report participant drop-outs (Melchart et al., 2003a, Liguori et al., 
2000, Wylie et al., 1997), the other 13 studies gained one point in Jadad for reporting 
drop-outs. In five studies, a drop-out rate over 10% was reported, and three of these studies 
(Diener et al., 2006, Allais et al., 2003, Dowson et al., 1985) did not use the intention-to-treat 
analysis, therefore 0 was given in the last item of OPVS. Two other studies (Liguori et al., 
2000, Wylie et al., 1997) did not report drop-out rates, and therefore did not score any points 
on this item.  
 
In six studies, either the comparability of demographic data or the comparability in baseline 
characteristics of headache data between treatment and control groups was not reported. 
Therefore these six studies scored 0.5 on the 3rd item of IVS on the basis that some did not 
report the comparability of demographic data and some did not report the comparability of the 
headache data (Streng et al., 2006, Diener et al., 2006, Linde et al., 2005a, Pintov et al., 1997, 
Hesse et al., 1994, Vincent, 1989a). 
 
 Eight of the 15 included studies stated that both the demographic data and the outcome 
measures of the baseline were comparable. The remaining three papers (Wylie et al., 1997, 
Liguori et al., 2000, Dowson et al., 1985) did not mention comparability or the data was not 
comparable, therefore 0 was given on the 3rd item of IVS. All of the studies presented mean 
and standard deviations of demographic data or the outcome measures of baseline or 
post-treatment and were awarded one point each for data presentation, and for choosing an 
appropriate statistical test in OPVS. 
 
All in all, the included studies had a moderate quality.  
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4.4.4   STRICTA 
Consistent with the moderate reporting quality, most of the studies also achieved satisfactory 
results in STRICTA, reporting quality of intervention. Only four trials did not provide exact 
acupoints. One study did not provide treatment regimes and merely stated that dry needling 
treatment was conducted on the individual tender trigger points (Hesse et al., 1994).  All 15 
trials gave detailed information for co-interventions and the control interventions. The item 
that had the poorest reporting was information on the background or the qualifications of 
acupuncturists. Seven studies did not include this information. Detailed data about STRICTA 
is given in Table 7. 
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Table 7 Details of acupuncture and control interventions of the 15 included studies 
Author and date 
Study 
Intervention 
Type of 
Acupuncture 
Treatment 
Acupuncture points & 
Needling 
Other 
treatment  
Treatment 
Regime 
Practitioner 
Background 
Control Intervention 
Acute attacks 
(Melchart et al., 
2003b) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
associated 
symptoms of 
migraine 
Ex-HN5, GB8, GB10, GB14, 
GB15, GB20, GB41, GV20, 
LI4, LR3, SJ5 
Complementary points: not 
mentioned 
De Qi mentioned 
No Once only,  
1.5h (range, 
0.5-2.1) 
Experienced 
Chinese 
acupuncturists 
Sumatriptan: 6 mg in 1 
ml NaCl solution 
 
Placebo: 1 ml NaCl 
solution 
Prophylactic effects 
 
(Streng et al., 
2006) 
Acupuncture 
alone  
Formula 
acupuncture plus 
complementary 
points based on 
TCM syndrome 
differentiation 
and location of 
pain 
Ex-HN5, 
GB20, GB40/41/42, GV20, 
LR3, SJ3/5 
Ashi points 
De Qi mentioned  
No 8-15 sessions 
during 12 
weeks 
At least 140 
hours of 
acupuncture 
training 
Metoprolol 100-200 mg 
o.d. daily 
(Alecrim-Andrade 
et al., 2006) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
location of pain 
BL10, GB12, GB20, GB21 
Complementary points: 
BL60, SI3 or BL2, GV23, 
LI4, ST36 or GB8, GB34, 
SJ5 or DU20, LR3, SI3 or 
SP6 or LR3 
De Qi mentioned 
No 2/w for 4 
weeks 
1/w for 8 
weeks 
16 sessions 
during 12 
weeks 
N/A Sham acupuncture: 
minimal acupuncture 
Ex-B1, LU5, SP7, ST37, 
SJ17, SJ20 
16 sessions during 12 
weeks 
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(Diener et al., 
2006) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
TCM syndrome 
differentiation 
and location of 
pain 
Acupoints were not 
mentioned 
Ashi points 
De Qi mentioned 
No 2/w or 10 
sessions 
during 6 
weeks 
At least 140 
hours of 
acupuncture 
training and 2 
years’ 
acupuncturist 
experience 
Sham acupuncture: 
minimal acupuncture on 
unacupoints 
 
Standard migraine 
prophylactic treatment 
(Linde et al., 
2005a) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
TCM syndrome 
differentiation 
Ex-HN5, GB20, GB40/41/42, 
GV20, LR3, SJ3/5 
Complementary points: not 
mentioned 
De Qi mentioned 
No 2/w for 4 
weeks 
1/w for 4 
weeks 
12 sessions 
during 8 
weeks 
At least 140 
hours of 
acupuncture 
training and 
experienced in 
acupuncture 
Sham acupuncture: 
minimal acupuncture on 
unacupoints 
 
Waiting list: without 
prophylactic treatment 
(Linde et al., 
2004) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
location of pain 
GB8, GB20, LI4, LR3, SP6 
Complementary points: BL10 
or Ex-HN5 or GB14 
De Qi mentioned 
No 3/M for 3 
months 
9 sessions 
during 3 
months 
Experienced 
physiotherapist 
Sham acupuncture: blunt 
placebo needles 
(Vickers et al., 
2004a) 
Acupuncture 
alone 
Depending on 
the individual 
discretion of 
acupuncturists 
Not mentioned No 12 sessions 
during 12 
weeks 
A minimum of 
250 hours of 
postgraduate 
training 
Usual care: avoid 
acupuncture 
(Allais et al., 
2003) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
location of pain 
and associated 
symptoms of 
migraine 
Ex-HN5, GB20, GV20, LI4, 
LR3, SP6 
Complementary points: BL10 
or GB14 or GB21 or CV12, 
ST36 or HT7 
De Qi mentioned 
No 2/w for 2 
weeks 
1/w for 6 
weeks 
10 sessions 
during 8 
weeks 
Experienced and 
qualified 
acupuncturists 
TENS: BL2, Ex-HN5, 
GB20, GB21, LI4, SI3 
 
Laser therapy: Ex-HN5, 
GB14, GB20, GV20, 
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(Allais et al., 
2002) 
Acupuncture 
alone 
Formula 
acupuncture 
CV12, Ex-HN5, GB14, 
GB20, GV20, LI4, LR3, PC6, 
SP6, ST36 
De Qi mentioned 
N0 1/w for 8 
weeks 
1/4w for 16 
weeks 
12 sessions 
during 24 
weeks 
 
 
Experienced and 
qualified 
acupuncturists 
Flunarizine 10 mg daily 
for 2 months then, 20 
days per month for 4 
months 
(Liguori et al., 
2000) 
Acupuncture 
alone 
Formula 
acupuncture 
GB5, GB20, GV14, LU7, ST 
8, 
De Qi mentioned 
No 2/w 
10 sessions 
during 7 
weeks 
Not report Flunarizine 90 mg/d 
Nimodipine 90 mg/d 
Dihydroergotamine 10 
mg/d 
Some participants also 
accept TENS as well 
(Pintov et al., 
1997) 
Acupuncture 
alone 
Not report Not report No 1/w for 10 
weeks 
10 sessions 
during 10 
weeks 
Not report Sham acupuncture: 
minimal acupuncture 
(Wylie et al., 
1997) 
Acupuncture 
alone 
Formula 
acupuncture 
based on 
associated 
symptoms of 
migraine plus 
complementary 
points based on 
Ashi points 
Pick up points from the 
following: BL2, GV20, 
Ex-HN5, Ex-HN3, GB14, 
GB20, GB41, KI3, LI4, PC6, 
SJ5, SP6, ST36, ST40 
Complementary points: Ashi 
points 
No 1/ day for 6 
days 
6 sessions 
during 6 days 
Not report Massage plus relaxation 
(Hesse et al., 
1994) 
Dry needling Not specified Individual tender trigger 
points 
Placebo 
tablets 
Not specified Not report Metoprolol 100 mg daily 
for 17 weeks 
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(Vincent, 1989a) 
Acupuncture 
alone 
Formula 
acupuncture plus 
complementary 
points based on 
associated 
symptoms of 
migraine 
Ex-HN5, LR3 
Complementary points: 
GB20/BL10 or 
BL11/GB21/SJ15/SI14/SI15 
No 1/w for 6 
weeks 
6 sessions 
during 6 
weeks 
Not report Sham acupuncture: 
minimal acupuncture on 
unacupoints 
 
(Dowson et al., 
1985) 
Acupuncture 
alone 
Acupoints based 
on associated the 
location of pain 
Not report No 1/w for 6 
weeks 
6 sessions 
during 6 
weeks 
Not report Mock TENS 
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4.4.4.1   Acupuncture Intervention 
Among the 14 studies that used acupuncture as the treatment, 11 trials implemented formula 
acupuncture; one paper did not provide detailed information (Pintov et al., 1997); one study 
allowed the treating acupuncturists to choose acupoints based on individual discretion 
(Vickers et al., 2004a); the remaining study chose acupoints based on the location of pain 
without description of these points (Dowson et al., 1985). Furthermore, nine of 11 formula 
acupuncture trials also included complementary points selected according to the traditional 
Chinese medicine (TCM) syndrome differentiation. The remaining two trials used formula 
points only (Liguori et al., 2000, Allais et al., 2002). 
 
De qi, a sensation of numbness, heaviness, distension or irradiation, was considered as 
essential for clinical efficacy according to traditional Chinese medicine (Shanghai College of 
TCM, 1980) and was reported in nine studies. 
 
The treatment regimen is an essential part of treatment, and includes treatment frequency and 
duration in the STRICTA. The objective of one study was to test the effectiveness of 
acupuncture for acute migraine, therefore the acupuncture treatment was conducted once only 
and was observed for 48 hours (Melchart et al., 2003a). Another study did not report the 
treatment regimen, which used dry needling (Hesse et al., 1994). In the remaining 13 studies, 
the median treatment period was 8 weeks (range 1 – 24 weeks), with an average of 10 
treatment sessions (range 6 - 16). In addition, the frequency of treatment was different among 
the studies. The most frequent treatment, once per day, occurred in Wylie’s study (Wylie et al., 
1997). The study with the least frequent treatment used three treatment sessions per month 
(Linde et al., 1997). There were two (Diener et al., 2006, Liguori et al., 2000) and three 
(Pintov et al., 1997, Vincent, 1989a, Dowson et al., 1985) trials which implemented twice a 
week and weekly treatment, respectively. In four trials, the frequency of treatment reduced 
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during the trial. Three of these four trials used twice a week treatment for two to four weeks, 
followed by weekly treatment for four to eight weeks (Alecrim-Andrade et al., 2006, Linde et 
al., 2005a, Allais et al., 2003); the remaining one study used weekly treatment for eight weeks 
followed by once per four-week treatment for 16 weeks (Allais et al., 2002). The remaining 
three papers did not report the relevant information (Streng et al., 2006, Vickers et al., 2004a, 
Hesse et al., 1994). 
 
The most common acupoints used in trials were: Yintang EX-HN5, Baihui DU 20, Fengchi 
GB20, Hegu LI4, and Taichong LR3. 
 
4.4.4.2   Control Intervention 
In all 15 trials, eight included placebo control, including three three-arm studies (Diener et al., 
2006, Linde et al., 2005a, Melchart et al., 2003a), in which at least one control intervention is 
a placebo. Among these eight trials, one applied mock TENS (Dowson et al., 1985); one used 
intravenous injection with 1 ml NaCl solution as placebo medication (Melchart et al., 2003a); 
the rest six used sham acupuncture, including one study that used minimal acupuncture on 
acupoints (Alecrim-Andrade et al., 2006); three studies used minimal acupuncture on 
non-acupoints; one paper used minimal acupuncture without clear description (Pintov et al., 
1997); and one implemented blunt placebo needles(Linde et al., 2004). 
 
Nine trials included one to two active control interventions. Six of the trials used Western 
medication as the control intervention.  Two trials used usual care (avoid acupuncture) 
(Vickers et al., 2004a) and massage plus relaxation as control (Wylie et al., 1997). The 
remaining study compared acupuncture with TENS and laser therapy separately (Allais et al., 
2003). 
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Prophylactic medications were used by five out of six trials, in which Western medication was 
the control intervention. The remaining study used Sumatriptan for acute attack (Melchart et 
al., 2003a). 
  
4.4.4.3   Follow-up 
One paper did not provide the follow-up information (Wylie et al., 1997). Melchart and his 
colleagues (2003a) wanted to test the efficiency of acupuncture in preventing acute attacks, 
hence no follow-up period was involved. Furthermore, another two trials did not monitor the 
data after treatment was terminated (Allais et al., 2002, Hesse et al., 1994). The median of 
follow-up period in the other 11 studies was six months (ranging from 2.5-12 months). 
 
Due to the length of the follow-up period varying considerably between the remaining studies, 
we could not evaluate the long-term effects of acupuncture. The length of the follow-up 
period ranged between two to twelve months depending on the study, hence the results from 
the follow-up periods did not provide comparable data. The data extracted from last phase of 
treatment was used in the analysis for evaluating the effectiveness of acupuncture.  
 
4.4.5   Outcome Measures  
The outcomes used in these trials were frequency, intensity and duration of migraine, 
medication consumption, quality of life, emotional pain, disability and depression. Fourteen 
of 15 trials monitored the frequency of migraine, using headache days, the numbers of attacks, 
pain-free days or a headache index. The remaining one study tested the immediate effect of 
acupuncture for acute attacks, hence no frequency data was available. All of the 14 studies 
observed the intensity of pain, via a series of measurements, such as 0-10 VAS, 0-100 VAS or 
pain index. Seven trials adopted medication consumption as one of the outcome measures.  
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Pill accounts were used by five studies but only two studies provided this data. A Medication 
Quantification Scale (MQS) was used by two studies. The next common outcomes were 
respondent rate and duration of attacks, which was adopted by six and five studies 
respectively. Quality of life was assessed by five studies, including three of them using SF-36 
and the remaining two employing SF-12.  
 
Due to the inconsistent types of outcome measurements used in the 15 studies, the 
effectiveness of acupuncture in the following aspects were evaluated: the number of days with 
migraine; the number of migraine attacks per month; the intensity of pain as well as patient 
respondent rate. The dates of medication consumption were provided by four studies with 
different control interventions. Consequently, no meta-analysis could be conducted. A similar 
situation also applied to information regarding quality of life.  
 
4.5    Analysis 
Trials were divided into two groups to investigate the acute analgesic and prophylactic effect 
of acupuncture for migraine respectively. Moreover, these two groups contained three 
sub-groups according to the control interventions for analysis. These three sub-groups were 
categorised into i) no treatment ii) “sham/placebo” acupuncture and iii) other interventions. 
 
One study, conducted by Vickers and his colleagues (2004a), used usual care (avoid 
acupuncture) as the control intervention,  is not appropriate to be divided into any 
sub-groups. This study found that acupuncture can prevent migraine attack in frequency, 
intensity as well as can reduce the medication consumption. Furthermore, the effectiveness of 
acupuncture was found to be best in patients who have more than five days with migraine per 
month. 
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4.5.1   The Effectiveness of Acupuncture in Acute Attacks 
4.5.1.1   Acupuncture VS. No Treatment  
There was no study under this comparison.  
 
4.5.1.2   Acupuncture VS. Sham/Placebo Acupuncture  
No study was available in this comparison. 
 
4.5.1.3   Acupuncture VS. Western Medication 
One trial only was conducted by Melchart and his colleagues (2003a) to assess the 
effectiveness of acupuncture for acute attacks. Participants were recruited into the study when 
they felt the first symptom of migraine and were randomised into acupuncture, Western 
medication (Sumatriptan) and placebo (1 ml NaCl solution) groups. The migraine of 
participants was monitored for 48 hours. The researchers found that 1st injection of 
sumatripan injection prevented migraine attacks in 36% of the participants, similar to the 
acupuncture group with a 35% success rate (Figure 5).  
 
4.5.1.4   Acupuncture VS. Other Sham Interventions 
In the study mentioned above, researchers found acupuncture was more effective, and 
prevented the migraine attacks in 35% of the participants in comparison to 18% prevented by 
the placebo injection. The difference between acupuncture and placebo was statistically 
significant (p = 0.04) (RR = 1.94; 95% CI, 1.06-3.07) (Figure 6). 
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Figure 5: Acupuncture vs. Western medication in acute attack 
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Figure 6: Acupuncture vs. placebo injection in acute attack 
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4.5.2   The Effectiveness of Acupuncture as a Prophylactic Treatment 
 
4.5.2.1   Acupuncture VS. No Treatment 
There was only one paper in this comparison (Linde et al., 2005a). A total of 221 participants 
were randomly divided into acupuncture (n = 145) and waiting list (n = 76). Baseline data was 
comparable. Participants in the waiting list group did not receive any prophylactic treatment 
during the 12-week treatment period. After 12-weeks of treatment, acupuncture achieved 
significant improvements in the number of migraine attacks (Figure 7), intensity of migraine 
(Figure 8), medication usage and accompanying symptoms and activities impairment when 
compared with the waiting list (p < 0.001 in all above outcomes).  
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Figure 7: Acupuncture vs. no treatment in the number of migraine attacks 
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Figure 8: Acupuncture vs. no treatment in the intensity of migraine 
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4.5.2.2   Acupuncture VS. Sham/Placebo Acupuncture 
Sham or placebo acupuncture was compared with real acupuncture in seven trials. Two of the 
seven papers did not present any detailed data of pre-planned outcome measurements 
(Alecrim-Andrade et al., 2006, Dowson et al., 1985, Vincent, 1989a), though they stated they 
assessed the frequency and intensity etc. No data can be exacted from the above two papers. 
The remaining five studies presented at least one of the pre-planned outcomes in mean (SD). 
The intensity of migraine was presented in four studies (Linde et al., 2004, Linde et al., 2005a, 
Diener et al., 2006, Pintov et al., 1997). Furthermore, numbers of migraine attacks and global 
responses were reported by three trials. Detailed information is listed in Table 8. 
 
Table 8: Outcome measures included in trials comparing real acupuncture with sham/placebo 
acupuncture 
Reference Intensity Migraine days 
Number of 
Attacks 
Global 
responses 
(Alecrim-Andrade et al., 
2006) 
    
(Diener et al., 2006) √   √ 
(Linde et al., 2005a) √ √ √ √ 
(Linde et al., 2004) √  √  
(Pintov et al., 1997) √  √  
(Vincent, 1989a)     
(Dowson et al., 1985)    √ 
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Three comparisons were conducted to evaluate the effectiveness of acupuncture in relation to 
the intensity of migraine, number of migraine attacks and overall improvement (respondent 
rate). Significant heterogeneity was indicated by I2 statistic (88.4%, 93.5%), and a 
random-effects model was applied to the first two comparisons. Moreover, as different 
measurements were conducted for assessing the intensity of migraine, such as 0-100 VAS or 
0-10 VAS, the standardised mean difference (SMD) was applied in the meta-analysis. As 
indicated in Figure 9, Figure 10 and Figure 11, acupuncture was not statically significantly 
better than sham/placebo acupuncture with regard to the intensity of migraine (p = 0.4, SMD 
-0.25; 95% CI -0.83 to 0.33), number of migraine attacks (p = 0.17, WMD -2.41; 95% CI 
-5.87 to 1.06), and global response (p = 0.35, RR 1.07; 95% CI 0.93 to 1.25). 
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Figure 9: Acupuncture vs. sham/placebo acupuncture in the reduction of intensity of migraine 
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Figure 10: Acupuncture vs. sham/placebo acupuncture in the numbers of migraine attacks 
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Figure 11: Acupuncture vs. sham/placebo acupuncture in global responses 
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4.5.2.3   Acupuncture VS. Western Medication 
Five studies compared acupuncture with Western medication. However, mean data was only 
presented in three studies.  In the remaining two studies, data was presented using a 
headache index (Liguori et al., 2000) and mean data without standard deviation (Hesse et al., 
1994). Consequently meta-analysis was applied to data from three trials (Streng et al., 2006, 
Diener et al., 2006, Allais et al., 2002). The types of outcome measures used in the three 
studies are listed below in Table 9. The drugs used as control intervention in these five studies 
are standard preventive medication, and included four categories: Ca++ channel blocker 
(Nimodipine), antihistamines (Flunarizine), beta receptor blocker (Metoprolol) and 5-HT 
agonist (Sumatriptan).  
 
Table 9: The outcome measures used by studies comparing real acupuncture with Western 
medication 
 
 Intensity Migraine days 
Number of 
Attacks 
Global responses 
(Streng et al., 2006) √ √ √ √ 
(Diener et al., 2006) √   √ 
(Allais et al., 2002)   √  
(Liguori et al., 
2000) 
    
(Hesse et al., 1994)     
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Three comparisons were conducted to evaluate the effectiveness of acupuncture in terms of 
the intensity of migraine, number of migraine attacks and overall improvement (respondent 
rate). The random-effects model was used in comparisons to evaluate the action of 
acupuncture in intensity of migraine, because the I2 statistic was 73.1%. Furthermore, 
inconsistent measurements in assessing the intensity of migraine led to the use of standardised 
mean difference. 
 
Acupuncture was superior to Western medication in preventing migraine attacks (p < 0.01, 
WMD -0.63; 95% CI -0.7 to -0.56) (Figure 12), and at least as effective as Western 
medication in reducing the intensity of migraine (p = 0.06, SMD -0.39; 95% CI -0.79 to 0.01) 
(Figure 13) and global responses (p = 0.08, RR 1.19; 95% CI 0.98 to 1.46) (Figure 14). 
However, there was a trend for a statistically significant difference in these two aspects. 
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Figure 12: Acupuncture vs. Western medication in the numbers of migraine attacks 
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Figure 13: Acupuncture vs. Western medication in the intensity of migraine 
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Figure 14: Acupuncture vs. Western medication in global responses 
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4.6    Discussion 
4.6.1   Summary of the Findings 
To date, only one published study is available on acute attack. This study revealed that 
acupuncture was as effective as Western medicine, and superior to placebo injection, in 
stopping acute attacks. 
 
As to the prophylaxis effect of acupuncture on migraine, three subgroups were identified 
according to different control interventions, namely i) no treatment ii) sham/placebo 
acupuncture iii) Western medication. However, only one corresponding study (Linde et al., 
2005a) was identified regarding the use of acupuncture compared with no treatment; this 
study illustrates the greater effects of acupuncture on different aspects of migraine such as 
intensity, frequency of attack and medication consumption. Furthermore, there is moderate 
evidence from English literature supporting that acupuncture is as effective as Western 
medication for both abolishing and preventing migraine attacks. However, evidence 
supporting the value of acupuncture for the treatment and prevention of migraine when 
compared with sham/placebo acupuncture is conflicting due to the inconsistent results in 
multiple RCTs with moderate quality.  
 
4.6.2   Strengths of This Review  
As stated in the Guidelines for RCT on migraine by IHS (2000), evaluating the effectiveness 
of interventions for migraine should involve measuring different aspects, such as the 
frequency of attack, the number of days with migraine, intensity or respondent rate. This 
systematic review is the first study evaluating the effectiveness of acupuncture on different 
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features of migraine separately, such as intensity and the numbers of migraine attacks. Based 
on the comparisons between acupuncture and Western medication, the numbers of migraine 
attacks (p < 0.01) was more likely to be affected by acupuncture than the intensity of migraine 
(p = 0.06). Similar findings were detected by other studies (Tfelt-Hansen et al., 1984), 
indicating that in most cases where there is a decrease in headache index, this is due to a 
decrease in frequency of attacks. 
 
4.6.3   Weaknesses of This Review  
The major limitation of this SR is that we were not able to search databases in other languages, 
such as French, Italian and German. Moreover, though some non-English studies were 
indexed in the PubMed, we could not access them due to a lack of language assistance. 
However, it is unlikely the missing data would influence our findings. Three papers published 
in German (Heydenreich and Thiessen, 1989) (Schnorrenberger and Baust, 1979, Baust and 
Stürtzbecher, 1978), were published in 1980’s. It is likely they were of poor quality similar to 
other studies produced at that time. 
 
Thirteen studies in Scott and Deare’s review (2006) were not included in the current review. 
The language barrier was not the only contributing factor. The different selection criteria 
might also have contributed to the difference of included studies. For instance, the following 
seven studies of Scott and Deare’s review were not included into our current review as they 
had conducted real acupuncture treatment in both groups and injected naloxone and saline 
respectively to test the effect of naloxone (Lenhard and Waite, 1983); did not report the 
migraine data separately (Loh et al., 1984); used various TCM therapies not limited to 
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acupuncture as treatment (Melchart et al., 2004a); even tested the changes of cerebrovasculr 
response to visual stimulation in migraineurs after acupuncture compared with healthy 
volunteers (Bäcker et al., 2004); did not use either IHS or Ad Hoc’s classification to recruit 
participants (Gao et al., 1999, Ceccherelli, 1987, Agrò et al., 2005). Furthermore, we also 
included four studies, which were not mentioned in Scott and Deare’s SR (Allais et al., 2003, 
Streng et al., 2006, Liguori et al., 2000, Pintov et al., 1997). 
 
4.6.4   Reporting of Outcome Measures  
Fourteen of the 15 included studies aimed to test the prophylactic effect of acupuncture and 
used frequency as the primary outcome. However, two of them combined the frequency with 
intensity of migraine presenting a headache index. Furthermore, the measurements for the 
frequency of migraine varied from study to study. Five studies (Pintov et al., 1997, Allais et 
al., 2002, Streng et al., 2006, Linde et al., 2005a, Linde et al., 2004) adopted the number of 
migraine attacks as the outcome measure.  Four studies (Allais et al., 2003, Vickers et al., 
2004a, Linde et al., 2007c, Streng et al., 2006) used the number of days with migraine. Other 
studies used the percentage of participants with a reduction of 50% or more in migraine 
attacks or migraine days; the difference in migraine days between baseline and after treatment 
(Diener et al., 2006); or headache index and pain total index (Liguori et al., 2000, Wylie et al., 
1997).  In addition, two studies did not present data in mean (SD) (Alecrim-Andrade et al., 
2006, Hesse et al., 1994), and one used self-defined respondent rates (Dowson, 2001). Hence 
the inconsistent measurements and data presentation make it difficult to extract information to 
evaluate the prophylactic effect of acupuncture. The same situation also occurred in the 
outcome assessments of quality of life and medication consumption.  
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Medication consumption is a tool for assessing the effect of acupuncture. Seven trials 
monitored the dosage of medication including analgesic drugs for acute pain and prophylaxis 
anti-migraine medication. These papers however used different methods to calculate and 
present data. Taking Allais’ trial (2002) as an example, the number of analgesic tablets was 
used. In fact, participants in that study not only took analgesics for acute attack, but also took 
anti-migraine medications, such as Sumatriptan, when they felt the first symptoms of 
migraine. Counting one type of medication, but not all medications used by patients, has 
certainly biased the results of Allais’ study.  Furthermore, analgesics vary in strength. For 
instance, Panadeine and Panadeine Forte all belong to compound analgesics, and contain 
Paracetamol 500 mg plus codeine phosphate 8 mg, and Paracetamol 500 mg plus codeine 
phosphate 30 mg respectively. Obviously, the latter is stronger than the former. Four tablets 
of Panadeine Forte are nearly four times stronger than four pills of Panadine and therefore pill 
counting is not an accurate method for assessing medication consumption. To accurately 
measure medication consumption, the Medication Quantification Scale (MQS) published in 
1998 is recommended. However, only one acupuncture study for headache used the MQS 
method (Vickers et al., 2004a). Another study (Vincent, 1989a) used the potency scale, which 
is the basis of the MQS. 
 
Due to the use of a range of outcome measures, each meta-analysis only included one to four 
studies.  
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4.6.5   Heterogeneity of the Studies  
There was a high heterogeneity among eight comparisons. Two comparisons contained one 
study each, consequently no heterogeneity existed.  Three of the remaining six comparisons 
were highly heterogeneous (I 2 > 50%). This is consistent with our findings that studies were 
of various sample sizes, using different treatment regimes, adopting different sham designs, 
and having various outcome measurements without detailed data presentation. Moreover, 
some included trials presented intention-to-treat data whereas others used per protocol data.  
 
The design of sham/placebo acupuncture studies, a disputed issue (Lewith and Machin, 1983), 
varied from one study to another, including invasive or no-invasive needling, and choosing 
acupoints or non-acupoints. This problem is evident that the American Headache Society 
(AHS) emphasises the need for developing a reliable sham/placebo control for acupuncture 
studies in headache(Mauskop, 2001). 
 
4.6.6   A Comparison with Other SRs 
A comparison of findings from our review with those in the two previous SRs in general 
headache (Melchart et al., 2001) and migraine (Scott and Deare, 2006) is presented in Table 
10. The Melchart review focused on general headache and included both English and 
European literature. Melchart also assessed the effectiveness of acupuncture for migraine 
separately. Unfortunately, most of the trials either did not present the detailed data or lacked 
consistent measurements. Scott and Deare’s review focussed on migraines only and used 
studies mainly published in English or European languages. The current systematic review 
identified papers published in English which focussed on migraine only.   
  98 
Table 10: A comparison of our review and two other SRs of acupuncture for migraine. 
 Current English review Melchart et al Scott and Deare 
Sample size 
(median) 
81 37 63 
Frequency of 
treatment (session per 
week) 
mostly 1 - 2 1-2 mostly 1 - 2 
De qi sensation 9 / 15 trials reported 9 / 26 trials reported 
10 / 25 trials 
reported 
Jadad, Median (range) 3 (1 - 5) 1.5 (1 - 4) 2.3 (1 - 5) 
IVS 4 (1.5 - 6) 2.5 (1 - 4) 3 (0.5 - 6) 
Acupoint selection 
67% of the studies chose 
acupoints according to Chinese 
medicine individual syndrome 
differentiation or location of 
pain 
N/A 
44% of the studies 
chose acupoints 
according to 
Chinese medicine 
individual syndrome 
differentiation 
Control intervention 
Waiting list 
Sham/placebo acupuncture 
Western medications 
Physiotherapy (massage and relaxation) 
Sham/placebo acupuncture 
Waiting list 
Western medications 
Standard GP care 
Respondent rate N/A 50% 33% 
Relative risk 
(acupuncture vs 
western medications) 
1.19 (0.98 to 1.46) N/A 
1.38 (1.08 - 1.76) 
Favour acupuncture 
Relative risk 
(acupuncture vs 
sham/placebo 
acupuncture) 
1.07 (0.93 to 1.25) N/A 1.14 (0.98 - 1.34) 
Relative risk 
(acupuncture vs 
waiting list) 
Intensity: WMD -0.8, 95% 
CI (-1.12, -0.48), P < 0.01 
Frequency: WMD -1.90, 
95%CI (-2.47, -1.33), P < 
0.01 
Favour acupuncture 
N/A 
3.17 (2.00 – 5.00) 
Favour acupuncture 
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In general, studies published in the current review had larger sample sizes, were of better 
quality, had a similar frequency of acupuncture treatment and used similar standard control 
interventions. Nine out of 15 studies in our review emphasised the achievement of Deqi 
sensation; this was more frequently than in the Melchart et al review (2001) where only 9 out 
of 26 trials emphasised achievement of Deqi sensation, and in Scott and Deare’s review 
(2006), where only 10 out of 25 studies emphasised achievement of Deqi sensation.  
 
Sixty-seven percent of the English trials (10 out of 15 studies) used semi-standardised 
acupuncture treatment based on Chinese medicine syndrome differentiation or location of 
pain. In comparison, 44% of the trials reported in Scott’s review adopted this method.   
 
We used the outcome measures presented in the studies for the meta-analysis. This is different 
from Scott and Deare’s or Melchart’s SRs in which the percentage of respondents was 
calculated from mean data presented by the authors. Their approach introduces another level 
of complexity to the already heterogeneous data. For instance, respondents could be defined 
as a 50% improvement (Melchart et al 2001) or a 33% improvement (Scott and Deare 2006). 
Furthermore, converting mean and SD to percentage of improvement could be a problem of 
its own. While our approach of using the original data reduced the available studies for 
analysis, it provides a more detailed understanding of how acupuncture could help migraine, 
such as reducing migraine frequency or intensity.  
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4.6. 7   Impacts on the Conclusion  
Differences between the current and Scott and Deare’s reviews could lead to variations in 
conclusion. Both reviews concluded that acupuncture is significantly better than no treatment, 
however acupuncture was  not superior to sham/placebo acupuncture. In this review we 
found that acupuncture was similar to Western medication in preventing migraine when 
respondent rates were used, however acupuncture was slighter better than Western medication 
in reducing the frequency of attacks. Scott and Deare’s review, using the respondent rate, 
concluded that acupuncture was superior to Western medication. This discrepancy might be 
due to the sample size as we only had two studies under this comparison whereas the other 
review has four studies. The conclusions of the two reviews highlight the importance of 
adopting a set of uniform, standard outcome measures in future trials.   
 
4.7    Conclusion 
4.7.1   Implications for Research 
Over all, acupuncture is as effective as Western medication in managing migraine. However, 
due to the lack of consistent measurements in the monitoring of specific aspects of migraine 
(including frequency, intensity, medication consumption or quality of life), the overall 
effectiveness of acupuncture on migraine is still unknown. In the future, researchers are 
encouraged to use standard outcome measurements, adopt appropriate statistical methods, and 
present detailed data. More clinical studies of good quality are urgently needed. Furthermore, 
the cost-effectiveness of acupuncture also needs to be taken into account in future studies.  
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4.7.2   Implication for Clinical Practice 
Acupuncture is an effective alternative to prophylaxis of migraine.  It has few side effects, 
and can be used by patients who do not want, or cannot tolerate, anti-migraine medications. 
Due to the high heterogeneity existing among trials, we cannot recommend an ideal 
acupuncture treatment regime.   
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CHAPTER FIVE: SYSTEMIC REVIEW OF EAST ASIAN 
LITERATURE ON ACUPUNCTURE FOR MIGRAINE 
 
5.1    Introduction  
Currently available systematic reviews (SRs) on the topic of acupuncture and migraine focus 
primarily on published studies undertaken in Western countries; few studies published in 
Asian languages are incorporated into these SRs (Melchart et al., 2001, Griggs and Jensen, 
2006a, Scott and Deare, 2006). The majority of Asian studies are neglected possibly due to 
language difficulties and a lack of access to the relevant databases (Melchart et al., 2001). In 
parts of Asia, such as China, Japan and Korea, acupuncture is widely used and therefore data 
from this region needs to be taken into consideration when determining the effectiveness and 
safety of acupuncture for migraine treatment.  
 
5.2    Objectives 
Through systematically reviewing Chinese, Japanese and Korean literature, the objectives of 
this review were to:  
1) Determine whether acupuncture was 
• More effective than no treatment;  
• More effective than “sham/placebo” acupuncture; and 
• As effective as other interventions for migraine. 
2) Compare East Asian and English literature on acupuncture and migraine.  
 
  103 
5.3    Methodology 
“Acupuncture (针灸)”, “electro-acupuncture（电针）”, “Chinese medicine（中医药疗法）”, 
“point-stimulation（穴位刺激）”, “headache（头痛）” and “ migraine（偏头痛）” were used 
as search parameters. These search terms were used to search the two largest Chinese 
electronic databases Vi Pu (重庆维普，www.cqvip.com, inception 1989) and Wan Fang (万方
数据，www.wanfangdata.com.cn, inception 1982) for papers published from the inception of 
the databases to August 2006. The same search terms were searched for in Ichushi Web 
(Japana Centra Revuo Medicina, www.jamas.or.jp, inception 1983) for papers published from 
its inception to March 2008. The search terms were also searched for in the Korean databases 
The National Assembly Library (www.nanet.go.kr), KoreaMed (www.koreamed.org), Journal 
of Korean Oriental Medicine (www.koms.or.kr), the Journal of Korean Acupuncture & 
Moxibustion Society (www.acumoxa.or.kr), the Korean Journal of Meridian & Acupoint 
(www.acupoint.org) and Oriental Medicine Information System (www.omis.dhu.ac.kr) from 
their inception to May 2007. 
 
Identified papers were selected according to the criteria described in chapter three.  
 
5.4    Results 
5.4.1   Identifying Studies 
In Chinese literature, of 266 papers found, 177 were either not RCTs, used Chinese herbs as 
the active intervention, or did not have a valid control intervention. A further 55 papers were 
excluded because they reported other types of headache. Two researchers assessed the 
remaining 34 papers. Two were excluded because non-invasive acupuncture was used and 
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seven papers were excluded due to the use of point-injection alone as the treatment. A further 
eight papers were eliminated for not providing any clinically relevant outcome measures. 
Finally, a total of 17 studies were included and analyzed. The following flowchart (Figure 15) 
illustrates the process of identifying studies.   
 
 
Figure 15: A flowchart illustrating the process of identifying Chinese studies  
 
The Japanese data was searched through with the help of a Japanese expert. In total 290 
articles were found, however, 289 of these articles were excluded as they were not RCTs. The 
remaining one study used acupuncture to treat neck stiffness, where headache was just an 
accessory symptom, and was therefore also excluded. Thus none of the Japanese studies were 
included in the current systematic review. 
 
266 studies 
89 studies 
34 studies 
25 studies 
17 studies 
177 excluded for not being RCTs, using Chinese herbs as 
the study intervention, or not having a valid control 
intervention. 
55 excluded for reporting other types of headache 
2 excluded for using non-invasive acupuncture treatment  
7 excluded for using point-injection alone as the studied 
intervention 
32 studies 
8 excluded for not providing clinically relevant 
outcome measures 
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The search of Korean literature was conducted by a visiting Korean post-doctorate fellow in 
the Division of Chinese Medicine at RMIT University. The data was translated into English 
by a Korean student studying Chinese medicine in Australia. The data search selection was 
also verified by an Korean expert. Of the fifty-six publications found, 40 were excluded for 
not being a RCTs or because headache was just a symptom of the recruited participants. 
Another 15 publications reported other types of headache conditions or did not report data of 
migraine separately from other types of headache. The remaining one migraine study used 
blood flow of the brain as the measurement, which was not related to the pre-defined clinical 
outcome. This study was excluded. None of the Korean studies were therefore included into 
the current systematic review. The process of the identification of Korean studies is illustrated 
in the following flowchart (Figure 16). 
 
 
Figure 16: A flowchart illustrating the process of Korean study identification 
 
40 excluded for not being RCTs or not relate to 
headache
56 studies
16 studies
1 study
0 study
15 excluded for reporting other types of headache or 
combining migraine with other types of headache 
together
1 excluded for not providing clinically relevant 
outcome measures 
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5.4.2   Description of the Studies 
Table 11 summarises the characteristics of the 17 included Chinese studies. Sixteen trials 
adopted the IHS criteria for the diagnosis of migraine, and one trial used the Ad Hoc 
Committee’s criteria (Li et al., 1998). A total of 2097 participants (median 91; range 62 - 414) 
were included in our review. 
 
All studies compared acupuncture with Western medication treatments. Ten studies used 
acupuncture alone. Six studies used a combined therapy of acupuncture with acupoint 
injection (Liu et al., 2002b), with intravenous injection of a purified Chinese herb (Wang and 
Gao, 2004), with Chinese Tuina (Shao et al., 2005, Lu and Yan, 2004), or with hyperbaric 
oxygen (Wang and Chen, 2004, Liu et al., 2002a). The remaining study compared 
acupuncture plus Western medication with Western medication alone (Wang and Gao, 2004, 
Zhang, 2005).  None of the studies compared acupuncture with no-treatment control or 
sham/placebo acupuncture. 
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Table 11: Characteristics of included studies 
Author and 
Date Intervention 
Sample 
Population ＊ 
Outcomes 
＃ 
Follow-up Drop-out 
No. and percentage of 
respondent 
Treatment vs Control 
Quality Allocation 
concealment ※ 
Acupuncture vs Western medication 
Zhou, J.H. 
(2005) 
Acupuncture vs 
Western 
medication  
Acu: n  = 35 
WM: n  = 35 
▲ 
6 months No 
Treatment: 21 / 35, 60% 
Control: 9 / 35, 25.7% 
Jadad: 1-0-0-0-1 
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 
C 
Cui, R., et al 
(2004) 
Acupuncture vs 
Western 
medication  
Acu: n = 48 
WM: n = 38 
▲ 
3 months No 
Treatment: 28 / 48, 
58.3% 
Control: 17 / 38, 44.7% 
Jadad: 1-0-0-0-1 
IVS:  0.5-0-1-0-0-1 
OPVS: 0-3-2-0-1-0-0-1 
C 
Wang, B. 
(2004) 
Acupuncture vs 
Western 
medication 
Acu: n = 125 
WM: n = 61 
▲ 
N/A No 
Treatment: 100 / 125, 
80% 
Control: 36 / 61, 59% 
Jadad: 1-0-0-0-1 
IVS:  0.5-0-1-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 
B 
Feng S.L., et al 
(2003) 
Acupuncture vs 
Western 
medication 
Acu: n = 35 
WM: n = 27 
▲ 
2 months No 
Treatment: 23 / 35, 
65.7% 
Control: 7 / 27, 25.9% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-0-0-1 
B 
Lao, J.X. 
(2003) 
Electronic 
acupuncture vs 
Western 
medication 
Acu: n = 87 
WM: n = 61 
▲ 
2 months No 
Treatment: 41 / 87, 
47.1% 
Control: 14 / 61, 23% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 B 
Zhou, L.S. 
(2003) 
Acupuncture vs 
Western 
medication 
Acu: n = 43 
WM: n = 20 
▲ 
3 months No 
Treatment: 40 / 43, 93% 
Control: 15 / 20, 75% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-0-0-1 
B 
Zhang, Y.C., et 
al (2002) 
Acupuncture vs 
Western 
medication 
Acu: n = 106 
WM: n = 110 
■ 
1 year No 
Treatment: 63 / 106, 
59.4% 
Control: 24 / 110, 21.8% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 
B 
Liu, K.Y., et al 
(2001) 
Acupuncture vs 
Western 
medication 
Acu: n = 43 
WM: n = 43 
▲ and 
frequency 
and 
duration 
1 months No 
Treatment: 33 / 43, 
76.7% 
Control: 25 / 43, 58.1% 
Frequency: 0.3 ± 1.4 vs 
2.6 ± 1.6 
Duration: 2.54 ± 1.37 vs 
14.7 ± 15.6 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-1-0-0-1 
OPVS: 0-3-2-0-1-1-1-1 
B 
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Li, W. et al 
(1998) 
Acupuncture vs 
Western 
medication 
Acu: n = 70 
WM: n = 32 
▲ 
N/A Yes 
 
Treatment: 37 / 70, 
52.9% 
Control: 15 / 32, 46.9% 
Jadad: 1-0-0-0-0  
IVS: 0.5-0-0-0-0-0.5 
OPVS: 0-3-2-0-1-1-0-1 
C 
Chen, X.S. 
(1997) 
Acupuncture vs 
Western 
medication 
Acu: n = 45 
WM: n = 30 
■ 
6 months No 
Treatment: 30 / 45, 
66.7% 
Control: 16 / 30, 53.3% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-1-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 
B 
Acupuncture plus other TCM therapies vs Western medication 
Shao, Y., et al 
(2005) 
Electronic 
acupuncture plus 
massage VS 
Western 
medication 
Acu: n = 35 
WM: n = 33 
▲ 
6 months No 
Short-term: 
Treatment: 26 / 35, 
74.3% 
Control: 25 / 33, 75.8% 
After 6 months 
Treatment: 26 / 35, 
74.3% 
Control: 17/33, 51.5% 
Jadad: 1-0-0-0-1 
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 
C 
Lu, Z.Q. 
(2004) 
Acupuncture plus 
massage vs 
Western 
medication  
Acu: n = 54 
WM: n = 30 
■ 
6 months Yes (16) 
Treatment: 35 / 46, 
76.1% 
Control: 12 / 26, 46.2% 
Jadad: 1-0-0-0-0 
IVS:  0.5-0-0.5-0-0-0.5 
OPVS: 0-3-2-0-1-1-0-1 B 
Wang J.L., et al 
(2004) 
Acupuncture plus 
Chinese medicine 
injection vs 
Western 
medication 
Acu: n = 60 
WM: n = 60 
■ 
6 months No 
Treatment: 37 / 60, 
61.7% 
Control: 19 / 60, 31.7% 
Jadad: 1-0-0-0-1 
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-0-0-1 C 
Liu Y., et al 
(2002) 
Acupuncture plus 
acupoint injection 
vs Western 
medication 
Acu: n = 54 
WM: n = 52 
■ 
8 weeks No 
Treatment: 41 / 54, 
75.9% 
Control: 32 / 52, 61.5% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0.5-0--0-1 
OPVS: 0-3-2-0-1-1-0-1 B 
Acupuncture plus other therapies vs Western medication 
Wang, L.Q.,   
et al (2004) 
Acupuncture plus 
hyperbaric oxygen 
vs Western 
medication 
Acu: n = 63 
WM: n = 28 
● 
1 year No 
Treatment: 53 / 63, 
84.1% 
Control: 33 / 56, 58.9% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 B 
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Liu X.L., et al 
(2002) 
Acupuncture plus 
hyperbaric oxygen 
vs Western 
medication 
Acu: n = 256 
WM: n = 158 
■ 
N/A No 
Treatment: 103 / 256, 
40.2% 
Control: 50 / 158, 31.6% 
Jadad: 1-0-0-0-1  
IVS: 0.5-0-1-0--0-1 
OPVS: 0-3-2-0-1-1-0-1 C 
Zhang, Y.K. 
(2005) 
Acupuncture plus 
medication vs 
Western 
medication 
Acu: n = 60 
WM: n = 60 Headache 
index No No 
Treatment: 9.1 ± 2.07 
Control: 11.7 ± 3.04 
Jadad: 1-0-0-0-1 
IVS: 0.5-0-0.5-0-0-1 
OPVS: 0-3-2-0-1-1-0-1 
 
B 
＊ Acu: acupuncture, WM: Western medications 
＃ ▲  refers to four categories of self-defined “global response” named “cured”, “marked improvement”, “improvement” and “no effect”. According 
to the definition, the participants in the “cured” and “significantly improved” categories had more than 50% improvement when compared with the 
baseline and were considered as respondents in this review. ■ refers to three categories self-defined “global response”, named “cured”, “effective” 
and “ineffective”. According to the definition, the participants in the “cured” category had more than 50% improvement, and were considered as 
respondents in this review. ● refers to four categories of self-defined ”global response”, named “cured”, “marked improvement”, “improvement” and 
“no effect”. According to the definition, the participants in the “cured”, “significantly improved” and “improved” categories had more than 50% 
improvement, and were considered as respondents in this review. 
※  A: indicates adequate concealment of the allocation (e.g. by telephone randomisation, or use of consecutively numbered, sealed, opaque 
envelopes). B: indicates uncertainty about whether the allocation was adequately concealed (e.g. where the method of concealment is not known). C: 
indicates that the allocation was definitely not adequately concealed (e.g. open random number lists or quasi-randomisation such alternate days, 
odd/even date of birth, or hospital number). D: indicates the score was not assigned, i.e. not used.  
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5.4.3   Quality Assessment  
The median Jadad score was 2 (range 1-2) out of a possible score of 5; the median IVS was 
2.0 (range 1.5 - 2.5) out of 6; and the median OPVS was 8 (range 7 - 9) out of 16. None of the 
17 studies had more than 60% of a maximum score of Jadad, IVS or OPVS.  
 
All 17 trials were described as randomised studies. Six studies in which the method of 
randomisation was briefly mentioned used the order of admission or date of birth to allocate 
participants. These six studies can be considered as quasi-randomised, hence “C Inadequate” 
was coded for the six studies. The remaining twelve studies were in Category B because it is 
unclear if and how the allocation concealment was conducted. Detailed information about 
allocation concealment was absent in eleven studies, one trial merely stated the sortition 
method was used (Lao and Lai, 2002). 
 
Furthermore, no study reported details regarding the process of blinding. The participants 
were not blinded to the treatment allocation because Western medications were the control 
intervention. The blinding of assessors was not reported in any of the studies. All studies 
gained one point for reporting drop-outs. In two studies, a drop-out rate of less than 10% was 
reported (Lu and Yan, 2004, Li et al., 1998). The remaining studies did not have any 
drop-outs.  
 
Only two trials (Liu et al., 2001, Zhang, 2005) presented mean and standard deviations of the 
outcome measures and were awarded one point for data presentation in OPVS.  
 
In contrast to the poor reporting quality of study designs, most of the studies achieved 
satisfactory results in STRICTA, reporting quality of intervention, which is not assessed by 
any other measurements. All 17 trials gave detailed information for acupuncture rationale, 
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needling techniques, treatment regimes, co-interventions and the control interventions; 
however, none of the studies gave details of practitioner backgrounds (Table 12). 
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Table 12: Study and control interventions of included studies.  
Author and 
date 
Study 
Intervention 
Type of Acupuncture 
Treatment 
Acupuncture points & 
Needling 
Other 
treatment 
Treatment 
Regime 
Practitioner 
Background Control Intervention 
Acupuncture vs Western medication 
Zhou, J.H. 
(2005) 
Acupuncture 
alone 
Formula acupuncture 
(dredging meridian and 
activating Qi and blood) 
GB8, GB19, TE20 
De Qi mentioned No 
1 / day for 30 
days N/A 
Nimodipine (Ca channel 
blocker) 40 mg, tid 
Cui, R., et 
al (2004) 
Acupuncture 
alone 
Formula acupuncture 
(regulating the liver) 
GB8, GB20, GB39, GB41, LI4, 
LR3, RN12 
De Qi mentioned 
No 6 / week for 3 
weeks N/A 
Nimodipine 40 mg, tid and 
oryzanol 20 mg, tid 
Wang, B. 
(2004) 
Acupuncture 
alone 
Formula acupuncture 
(dredging meridian and 
activating Qi and blood) 
DU15, DU16, DU17 
Split the distance from DU16 to 
GB12 into 6 spaces, needling on 
the cut-points. 
De Qi mentioned 
No 1 / 3 days for 30 days N/A 
1. Cafergot 2 tabs for acute 
migraine attacks; if not 
effective within 30 mins, 
take another 1 - 2 tablets. 
Maximal dose 6 tab/day. 
2. Nimodipine 30 mg bid for 
30 days 
Feng S.L., 
et al (2003) 
Acupuncture 
alone 
Formula acupuncture 
plus complementary 
point based on TCM 
syndrome differentiation 
Empirical points: 1st point: 0.5 
cun above GB8; 2nd/3rd points: 
1 cun left or right to the 1sr 
point. 
Complementary points: BL23, 
KI3 ,LR3 or SP9 , ST8, ST40 or 
GB20, GB34,  LR3, 
De Qi mentioned 
No 5 / week for 8 
weeks N/A Nimodipine 40 mg, tid 
Lao, J.X. 
(2003) 
Electronic 
acupuncture 
alone 
Formula acupuncture 
(regulating the liver) 
plus complementary 
point based on TCM 
syndrome differentiation 
GB4, TE23 
Complementary points: 
Ex-HN5, GB20, LU7, or KI3, 
LR3 or LI4, LR2 or GB8, ST40 
De Qi mentioned 
No 
1 / day for 10 
days, then rest 5 
days. Totally 
repeat 3 times 
N/A 
Rotudin 30 mg tid for 10 days, 
then rest 5 days. Totally 3 
repeat 3 times 
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Zhou, L.S. 
(2003) 
Acupuncture 
alone 
Formula acupuncture 
(regulating the liver) 
GB8, GB41, GB44, TE3, TE5, 
TE19 
De Qi mentioned 
No 1 / day for 40days N/A 
Ergotamine 1mg for acute 
migraine attacks. If not 
effective, take another 2 mg 
after 30 mins. Maximal dose 6 
mg/day 
Zhang, 
Y.C., et al 
(2002) 
Acupuncture 
alone 
Formula acupuncture 
(dredging meridian and 
activating Qi and blood) 
TE21 
De Qi mentioned No 
1 / day for 5 
days N/A 
Flunarizine (Antihistamines) 
10 mg, qd for 5 days. 
Liu, K.Y., et 
al (2001) 
Acupuncture 
alone 
Formula acupuncture 
(regulating the liver) 
Ex-HN5, GB8, GB20, GB34, 
GB 41, LR3, ST36, TE5, start 
and end points of lower sensory 
area in Head acupuncture 
De Qi mentioned 
No 1 / day for 30 days N/A 
Nimodipine 30 mg, tid for 30 
days 
Li, W. et al 
(1998) 
Acupuncture 
alone 
Formula acupuncture 
(regulating the liver) 
plus complementary 
point based on painful 
points 
DU20, GB20, GB39, LR2 
Complementary points:   Ashi 
points 
De Qi mentioned 
No 6 / week for 3 
weeks N/A 
Carbamazepine 
(Anticonvulsants) 100 mg, tid 
for 21 days 
Chen, X.S. 
(1997) 
Acupuncture 
alone 
Formula acupuncture 
(regulating the liver) 
Ex-HN5, GB20, LR3, ST8, 
TE5, 
De Qi mentioned 
No 1 / day for 20 days N/A 
Nimodipine 30 mg, tid. for 20 
days 
Acupuncture plus other TCM therapies vs Western medication 
Shao, Y., et 
al (2005) 
Electronic 
acupuncture 
plus massage 
Formula acupuncture 
(regulating the live) 
Ex-HN5, GB4, GB20, GB38, 
GB41, LR3, PC6 ,  TE23, 
De Qi mentioned 
Tuina along the 
gallbladder 
Meridian on the 
head for 15 min 
1 / day for 10 
days, then rest 3 
days, totally 3 
phases. 
N/A 
Flunarizine 5 mg, q.d. Acute 
migraine attack, take 
ibuprofen 1-2 tablets 
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Lu, Z.Q. 
(2004) 
Acupuncture 
plus massage 
Formula acupuncture 
(dispelling wind) plus 
complementary point 
based on TCM 
syndrome differentiation 
Ex-HN5, DU14 DU20, GB20 
Complementary points: LI4, 
ST40 or KI3, LR3 or LI4, SP6 
or LU9, ST36 
De Qi mentioned 
Tui na 
(pressuring 
DU2 ，
EX-NH5， 
ST35， ST39 for 
36 times and 
DU16 or 16 
times) after 
acupuncture 
1 / day for 30 
days N/A 
1. Ergotamine 1 - 2 mg for 
acute migraine attacks, If not 
effective, take another 2 mg 
after 30 mins. Max 6 mg/day. 
2.  Indomethacin (NSAID) 
25 mg bid for 30days 
Wang J.L., 
et al (2004) 
Acupuncture 
plus 
intravenous 
injection of a 
purified 
Chinese herb 
Formula acupuncture 
(dispelling wind) 
Ex-HN5, GB8, GB20,  LI4, 
LR3, TE3 
De Qi mentioned 
Ligustrazine 
Hydrochloride 
(川芎嗪)100ml 
i.v.drip  q. d for 
15 days 
1 /day for 15 
days N/A Flunarizine 5 mg, qd 
Liu Y., et al 
(2002) 
Acupuncture 
plus acupoint 
injection 
Formula acupuncture 
(dispelling wind) 
DU20, Ex-HN5, GB8, GB20, 
LI4, LU7, ST8, TE23, 
De Qi mentioned 
Acupoint 
injection using 
stauntoniae (野
木瓜皂甙) on 
Ex-HN5 or 
GB16 2 ml for 8 
weeks 
1 / day for 10 
days, then rest 2 
day, lasting 8 
weeks 
N/A 
Flunarizine 5 mg, qd for 8 
weeks. Cafergot for acute 
migraine attacks 
Acupuncture plus other therapies vs Western medication 
Wang, L.Q.,   
et al (2004) 
Acupuncture 
plus 
hyperbaric 
oxygen 
 
Formula acupuncture 
(regulating the liver) 
plus complementary 
point based on TCM 
syndrome differentiation 
GB4, GB20, SJ19,  SJ23 
Complementary points: BL17, 
SP10 or BL12, BL60, or SP6, 
ST40, or BL23, KI3 
De Qi mentioned 
Hyperbaric 
oxygen 
1 / day for 10 
days N/A 
1. Cafergot (1-2 tabs for first 
symptoms) 
2. Nimodipine 40 mg tid and 
Flunarizine (Antihistamines) 5 
mg, tid for 10 days 
Liu X.L., et 
al (2002) 
Acupuncture 
plus 
hyperbaric 
oxygen 
Formula acupuncture 
(dredging meridian and 
activating Qi and blood) 
Ex-HN5, LI4, LI11, LU4, 
De Qi mentioned 
Hyperbaric 
oxygen 
1 / day for 10 
days N/A 
Somiton (a combination of 
analgesics and unnamed 
nature herbs) 500 mg, tid, 
oryzanol 10 mg, tid, and VB1 
10 mg, t.i.d. for 7 days 
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Zhang, Y.K. 
(2005) 
Formula 
acupuncture 
plus 
medication 
Formula acupuncture 
(dredging meridian and 
activating Qi and blood) 
GB8, GB20, LI4, LR3 
De Qi mentioned 
Brufen 400 mg, 
tid for 30 days 
1 / day for 30 
days N/A Brufen 400 mg, tid for 30 days 
 
 
bid.: twice per day 
tid.: three times per day 
qd.: four times per day 
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5.4.4   Acupuncture Intervention   
Twelve trials used formula acupoints. One trial employed formula acupoints plus Ashi points 
(Li et al., 1998). The remaining four trials used semi-structured acupuncture treatment, 
including formula plus complementary acupoints based on traditional Chinese medicine 
(TCM) syndrome differentiation (Feng and He, 2003, Lao and Lai, 2002, Lu and Yan, 2004, 
Wang and Chen, 2004). The principles of acupuncture point selection were clearly stated in 
16 studies, including dispelling wind (Liu et al., 2002b, Lu and Yan, 2004, Wang and Gao, 
2004); dredging meridian and activating qi and blood (Liu et al., 2002a, Wang, 2004, Zhang 
and Song, 2002, Zhang, 2005, Zou, 2005); and regulating the liver (Chen and Wang, 1997, 
Cui et al., 2004, Lao and Lai, 2002, Li et al., 1998, Liu et al., 2001, Shao et al., 2005, Wang 
and Chen, 2004, Zhou, 2003). Deqi, (a feeling of numbness, heaviness, distension or 
irradiation) was reported in all 17 studies. 
 
The median treatment period was 30 days (range 5 - 56 days) with an average of 30 treatment 
sessions (range 5 - 40). In 13 studies, participants were treated with acupuncture daily. Three 
studies gave five or six treatment sessions weekly (Feng and He, 2003, Li et al., 1998, Cui et 
al., 2004) and in the remaining one study, treatment was given once every three days (Wang, 
2004).  
 
The top five acupoints used in the 17 trials were GB8 Shuigu, GB20 Fengchi, LI4 Hegu, LR3 
Taichong, and Ex-HN5 Yintang.  
 
5.4.5   Control Intervention  
All 17 trials used Western medications as the control intervention. Participants took 
prophylactics daily. These drugs were categorized as Ca++ channel blocker (Nimodipine), 
antihistamines (Flunarizine), anticonvulsant (Carbamazepine) and analgesics (Rotudin, a 
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combination of analgesics and unnamed natural herbs). In two studies, participants were 
instructed to use NSAIDs (Indomethacin and Brufen) daily (Lu and Yan, 2004, Zhang, 2005), 
which is not a standard Western pharmacotherapy for prophylactic treatment of migraine. 
These latter two studies were excluded from the meta-analysis.  
 
In six trials, Ergotamine, Cafergot or Ibuprofen was used for acute attacks in the control group 
only (Li et al., 1998, Lu and Yan, 2004, Shao et al., 2005, Wang, 2004, Zhou, 2003, Liu et al., 
2002b, Wang and Chen, 2004).  
 
5.4.6   Outcome Measures  
All studies reported the use of at least one of the clinical-related outcome measures, such as 
frequency, intensity, and duration of migraine. However apart from two studies which 
presented the means and standard deviations of clinical data (Liu et al., 2001, Zhang, 2005), 
the remaining fifteen studies reported the number of participants in the “cured”, “marked 
improvement”, “improvement” and “no effect” categories. None of the studies mentioned the 
use of a diary to record patients’ migraine.  
 
As a result, we extracted data of the “global response” to treatment. Response was defined as 
at least a 50% improvement in our review. We estimated whether a 50% improvement was 
met from the description provided by the authors. For instance, Lao (2002) recorded the 
reduction of migraine index (MI) during the third month after the end of the treatment. The 
MI reduction between 90% and 100% was considered as “cured”, between 55% and 89% as 
“marked improvement”, between 20% and 54% as “improvement” and less than 20% as “no 
effect”. The participants in the first two groups were considered to be respondents in our 
review. Most studies did not report the immediate and the long-term effects separately. For 
instance, Zhou (2003) defined “improvement” as a more than 50% reduction of MI in the 
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three months after the end of the treatment. Consequently, the 50% improvement in our 
review refers to the global response to acupuncture at 0 - 12 months after the treatment, and is 
not specific to either the immediate effect or the long-term effect. Relative risks and their 95% 
confidence intervals were calculated.  
 
5.4.7   Follow-up 
Follow-up was not clearly mentioned in three studies, and one trial did not include a 
follow-up period. Fourteen studies had a follow-up period ranging from one month to one 
year after treatment with a median of 4.5 months. Performance of the participants during the 
follow-up period was not reported separately from that immediately after acupuncture.   
 
Side effects of acupuncture and Western medications were not reported.  
 
5.5    Analysis 
5.5.1   Acupuncture VS. No Treatment 
There was no study available offering this comparison. 
 
5.5.2 Acupuncture VS. Sham/Placebo Acupuncture 
No study was available in this comparison. 
 
5.5.3   Acupuncture VS. Western Medications 
In total, ten studies with 1094 participants were included in this analysis. All 10 studies 
reported positive results (Figure 17), however, the I2 statistic (61.4%) indicated significant 
heterogeneity. Thus, a random-effects model was applied in the data analyses. The results 
significantly favored acupuncture as an intervention (RR 1.55; 95% CI 1.27 to 1.88). Only 
one study (Liu et al., 2001) presented the details of frequency and duration of migraine in 
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mean and SD (frequency per month: 0.3 ± 1.4 vs 2.6 ± 1.6; duration in hours: 2.54 ± 1.37 vs 
14.7 ±1 5.6). This study also provided the number of participants in the sub-groups of “cured”, 
“marked improvement”, “improvement” and “no effect”. The number of respondents in the 
study was chosen for the meta-analysis.  
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Figure 17: Global responses to the treatments - acupuncture alone versus Western medications 
  121 
5.5.4   Acupuncture plus Western Medication VS. Western Medication  
There was only one study in this category. Zhang (2005) compared acupuncture plus Western 
medication with the same Western medication alone. In total, 120 participants were 
randomised into two groups with 1:1 ratio. After 30 treatment days, the acupuncture group 
(9.1 ± 2.07) was found statistically significantly better than the Western medication alone 
group (11.7 ± 3.04) in headache index, a combined measure of frequency and intensity of 
headache.  
 
5.5.5 Acupuncture plus other TCM Therapies VS. Western Medications 
Four studies compared a combined therapy of acupuncture and other Chinese medicine (CM) 
therapies, including acupoint injection (Liu et al., 2002b), intravenous injection of a purified 
Chinese herb (Wang and Gao, 2004) and Tuina (Lu and Yan, 2004, Shao et al., 2005) 
respectively with Western medications. Lu (2004) combined acupuncture with Chinese Tuina 
to compare with treatment by Indomethacin (NSAID) (25 mg twice a day for 30 days), an 
invalid pharmacology treatment for migraine. In fact, frequent use of NSAIDs could lead to 
migraine from medicine overuse (Bigal et al., 2004). Consequently, this study was not 
included in the meta-analysis.  
 
Shao (2005) is the only study that presented both short-term data and the six-month follow-up 
data. The results indicated that acupuncture with massage produced a long-term effect, 
although the short-term effect was not better than Western medications. To be consistent with 
the data extracted from other studies, the follow-up data was included in the meta-analysis.  
 
The fixed-effects model was used because the I2 statistic was 43.1%. Figure 18 shows that 
acupuncture plus other CM therapies were significantly better than Western medications 
control (RR1.48, 95% CI 1.22 - 1.81).   
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Figure 18: Global responses to the treatments - acupuncture with other traditional Chinese medicine versus Western medicatio
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5.5.6   Acupuncture plus Other Therapy VS. Western Medication 
Two studies of 503 participants combined acupuncture with hyperbaric oxygen to compare 
with Western medication (Liu et al., 2002a, Wang and Chen, 2004). Significant heterogeneity 
was indicated by I2 statistic (84.7%), and a random-effects model was applied. Figure 19 
indicates that the combined therapy was not statistically significantly better than the Western 
medication controls (RR 1.22; 95% CI 0.87 to 1.7).  
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Figure 19: Global responses to the treatments - Acupuncture and other therapy vs. Western medications 
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5.6    A Comparison of Our Reviews of Literatures Identified in English 
Databases and That in Chinese Databases 
A comparison of findings from our reviews based on the English databases and Chinese 
databases is presented in Table 13. In general, studies published in China were of poorer 
quality, had acupuncture treatment more frequently and had pharmacotherapy controls only. 
All studies included in the Chinese review emphasised that Deqi sensation was achieved 
during treatment. Only nine out of 15 trials reported Deqi in the English review.  
 
Twenty three percent of the Chinese trials (four out of 17 studies) used semi-standardised 
acupuncture treatment based on Chinese medicine syndrome differentiation. In comparison, 
67% of the trials reported in the English literature adopted this method. 
 
Trials published in English languages used sham / placebo acupuncture, waiting list, Western 
medicine or physiotherapy as the control interventions; blinding of participants was common 
in the sham-acupuncture controlled trials. All of the 17 Chinese studies used Western 
medications as a control. Except for two studies (Lu and Yan, 2004, Zhang, 2005), all drugs 
used in these 17 trials were recommended migraine medications (Lance and Goadsby, 2005), 
and were similar to those in trials included in the other SR. 
 
As mentioned above, 15 of the total 17 Chinese studies self-defined the outcomes and 
reported the number of participants in the “cured”, “marked improvement”, “improvement” 
and “no effect” categories, without presenting the data in mean and standard division. Hence, 
only dichotomic meta-analysis could be conducted using the respondent rate. ‘Respondent’ 
was defined as a 50% or more improvement from the baseline data in frequency, intensity or 
duration of migraine. In contrast, all English literatures summarised the data into mean (SD), 
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although a few studies prior to 1990’s did not report the detailed data. Furthermore, in some 
studies, authors defined the respondent rate as a 40% or 50% improvement. 
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Table 13: A comparison of our review (overall data) and two other SRs of acupuncture for 
migraine.  
 Current Chinese Review Our English Review (Chapter Four) 
Sample size 
(median) 
91 81 
Frequency of 
treatment (session per 
week) 
5 - 7 Once per month to once per week 
mostly 1 - 2 
De qi sensation 17 / 17 trials reported 9 / 15 trials reported 
Jadad, Median (range) 2 (1 - 2) 3 (1 - 5) 
IVS 2 (1.5 - 2.5) 4 (1.5 - 6) 
Acupoint selection 
23% of the studies chose 
acupoints according to Chinese 
medicine individual syndrome 
differentiation 
67% of the studies chose acupoints 
according to Chinese medicine individual 
syndrome differentiation or location of pain 
Control intervention Western medications 
Waiting list 
Sham/placebo acupuncture 
Western medications 
Respondent rate 50% N/A 
Relative risk 
(acupuncture vs 
Western medications) 
 1.55 (1.27 - 1.88) 
Favour acupuncture 
1.19 (0.98 to 1.46) 
Relative risk 
(acupuncture vs 
sham/placebo 
acupuncture) 
N/A 1.07 (0.93 to 1.25) 
Relative risk 
(acupuncture vs 
waiting list) 
 N/A 
P < 0.01 in frequency and intensity of 
migraine 
Favour acupuncture 
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5.7    Discussion 
This review of East Asian literature was conducted to determine the effect of acupuncture on 
migraine when compared with sham acupuncture, no treatment and other therapies. No 
Japanese or Korean studies met the inclusion criteria. No relevant studies were identified for 
the first two comparisons. There is moderate evidence from Chinese literature supporting the 
value of acupuncture for preventing migraine when compared with Western medications. 
Furthermore, combining acupuncture with other modalities of Chinese medicine is superior to 
Western medications.  
 
The major limitation of our SR was that we were not able to identify papers published prior to 
the 1980’s because the date of inception for the two databases used, Vi Pu (重庆维普) and 
Wan Fang (万方数据), were 1989 and 1982 respectively. These two databases are the most 
comprehensive Chinese e-databases and include all academically credible journals and theses 
published in China in the area of science and technology. Although studies published before 
the 1980’s are not included in these databases, it is unlikely we have missed many published 
papers in this area. Apart from two of the 17 papers being published in 1997 and 1998, the 
remaining fifteen studies were published after 2001.  
 
The second limitation of our SR was that due to language barriers, we had to rely on other 
researchers to search Japanese and Korean data. It is possible that individual variations in data 
searches and selection existed. However we provided a standard protocol for conducting 
searches and the researchers involved were all experts in the area of systematic reviews. 
Therefore such variations are not likely to have contributed to a lack of literature being 
identified from these two countries.  
 
  129 
None of the 17 studies in our review were included in the two other published SRs (Melchart 
et al., 2001, Scott and Deare, 2006) or our SR based on English databases (Chapter four), 
indicating a large body of research was not considered when the conclusion of the pervious 
SRs was drawn. Given that the Chinese studies have larger sample sizes than those conducted 
in Western countries, potentially yielding a higher weighting in a meta-analysis, it is of 
significant importance to include such studies.    
 
A search indicated that only one journal (Zhongguo Zhenjiu) included in our review was 
indexed in Pubmed (from 2005). Three studies (Liu et al., 2001, Zhang and Song, 2002, Cui 
et al., 2004) in our review were published in this journal before 2005 and so were not included 
in Pubmed. This confirms the view expressed by the authors of the other two SRs that there is 
a lack of access to Asian medical literature in Western reviews (Melchart et al., 2001, Scott 
and Deare, 2006). 
 
In this review, we encountered the same difficulty that faced the authors of the other two SRs. 
Ideally, researchers should use the number of days with migraine per month or changed 
intensity or duration of migraine at the end of the treatment as the main outcome measure for 
quantitative analyses as recommended by the IHS (Dowson et al., 2002). Only two papers 
presented means and standard deviations of these outcome measures (Liu et al., 2001, Zhang, 
2005). Due to detailed clinical data being unavailable, the number of respondents was used 
for meta-analyses. There are differences in the definition of respondents; 50% was used in our 
and Melchart et al’s reviews, and 33% in Scott and Deare’s review. Such a reduction of data 
limits our understanding of the exact effects of acupuncture on the frequency, intensity and 
duration of migraine.  
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Similar pharmacological treatments were used as the control interventions in our reviews and 
in Scott and Deare’s (2006). The effect size identified in our review (1.55) is comparable with 
the value reported by Scott and Deare (1.38) and by English literature in Chapter four (1.19). 
Considering the different definitions for the respondents, Chinese trials have a higher success 
rate. It is unknown whether the higher success rate is due to publication bias reported by 
Vickers and colleagues (1998), lower quality, or the differences in acupuncture treatment 
protocol.  
 
The reporting quality and internal validity of the Asian literature was generally poor, as 
confirmed with three different scales. All 17 studies compared acupuncture with Western 
medications, and participants could not be blinded to treatment allocation. Furthermore, no 
trial described whether the acupuncturists were blinded to outcome assessment or whether an 
independent assessor/evaluator was employed. No trials reported the detailed process of 
randomisation or the reasons for drop-outs.  
 
Another major shortcoming of the Chinese literature is the assessment of the outcomes. First, 
the effect of acupuncture on acute attacks was not investigated. Second, the Chinese trials 
neither presented detailed clinical data nor separated the immediate effect from the long-term 
effect. As a result, we cannot determine the duration of the effect of acupuncture on migraine. 
Third, although many included studies claimed that they assessed the time-profile and 
intensity of migraine, none of the studies described either the use of a diary, a method 
recommended by the IHS (2000), or how the data was recorded. The poor reporting quality 
and lower internal validity might have contributed to the over-estimation of the effect size.  
 
Most Chinese trials implemented nearly daily treatment, which is much more frequent than 
the treatments provided in studies included in the other two previous SRs (Melchart et al., 
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2001, Scott and Deare, 2006) and our English SR. It is unknown whether frequent treatment is 
associated with better results. Except for one study using empirical points alone, the 
remaining 16 trials selected traditional acupoints and provided the basis for point selection. 
All of them are in accordance with the classic literatures of TCM. From the available data, we 
cannot conclude how frequent the treatment should be and which formula is the best. The 
ideal acupuncture treatment, in terms of frequency of treatment and acupoint selection, should 
be investigated in future. 
 
5.8    Conclusion 
5.8.1   Implications for Research 
Acupuncture shows promising effects on migraine. There is moderate evidence that 
acupuncture alone or combined with Western medications is more effective than Western 
medication alone for the prevention and treatment of migraine. However, the poor quality of 
the available studies and a lack of detailed data greatly reduced the level of overall evidence. 
Future studies should improve the reporting quality and trial design and present detailed data 
of the outcome measures. Profiles detailing the side effects of acupuncture should also be 
recorded. Furthermore, it is important to include trials published in Asian languages in 
meta-analyses. There is an urgent need to conduct acupuncture clinical trials in Japan and 
Korea, two of the three countries where acupuncture is commonly used.   
 
5.8.2   Implication for Clinical Practice 
Acupuncture might be an effective prophylactic treatment for migraine. It can be used either 
alone or in conjunction with Western medications.  
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5.9    Additional Notes 
Before submitting the thesis, the databases were searched again. Six new studies were found. 
These studies should be assessed for future SRs. The studies are listed below (Table 14): 
 
Table 14: New published studies which was not included into current systematic SR 
Author Treatment Intervention 
Control 
Intervention Findings 
(Zhou et al., 
2007) Electroacupuncture Ergotamine 
Acupuncture is as effective as 
Western medication in stopping 
acute attack, but can last longer 
than Western medication. 
(Li, 2008) Acupuncture and herbal formula Nimodipine 
The combination of acupuncture 
and herbal formula is more 
effective than Western medicine 
measured via headache index. 
(Gao et al., 
2008) 
Acupuncture and 
Tuina Flunarizine 
The combination of acupuncture 
and tuina can achieve more 
long-term effects in preventing 
migraine, when compared with 
Western medication. 
(Shen, 2006) 
Acupuncture and 
blood-letting 
puncture 
Flunarizine This combination therapy is more 
effective than Western medication. 
(Zhang, 
2007) 
Acupuncture plus 
intravenous 
injection of a 
purified Chinese 
herb (Ligustrazine 
Hydrochloride) 
Flunarizine This combination therapy is more 
effective than Western mediation. 
(Li et al., 
2007) Acupuncture NSAID 
Acupuncture is more effective 
than Western medication in 
reducing frequency, intensity and 
duration of migraine 
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 CHAPTER SIX: METHOD OF CLINICAL TRIAL 
 
This is a prospective, randomised, patient/assessor blind, sham-acupuncture controlled 
clinical trial. The project was conducted with the approval of the Human Research Ethics 
Committee of the RMIT University (Project No. 16/05). It was filed with the Australian 
Government’s Therapeutic Goods Administration under Clinical Trial Notification Scheme 
(CTN No. 08/07/2005), as well as the Australian New Zealand Clinical Trials Registry with 
the reference No. ACTRN12605000314628. 
 
6.1    Participants 
All participants were volunteers suffering from migraine and were recruited from the local 
community around Melbourne.  
 
6.1.1   Diagnostic Criteria for migraine 
All participants were screened based on the classification of migraine according to the 
International Headache Society (IHS) (2004), see (Appendix 1). 
 
6.1.2 Inclusion Criteria 
Participants must meet all of the criteria as follows. 
A. Aged between 18 and 80 years and with a current history of migraine for at least 12 months; 
B. Have a minimum of five days with migraine per four weeks; 
C. Agree to avail themselves for the period of the study; and   
D. Provide a written consent for participation. 
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6.1.3   Exclusion Criteria 
Volunteers having any of the following conditions were excluded from the study: 
A. Current pregnancy or malignancy;  
B. Had experience of acupuncture treatment in the face, the hands, the legs and the front of the body 
in the previous six months. Volunteers who had received needling at sites that could not be seen by 
the volunteers, such as the back of the trunk, were included;   
C. History of head injury or whiplash; 
D. Severe arrhythmia or heart failure, brain tumor or epilepsy;  
E. Hemophiliac; 
F. Had participated in another clinical trial in the past six months; 
G. Had tension-type headache more than six days a month; 
H. Unable to distinguish between migraine attacks and additional tension-type headache; or 
I. Did not comprehend English. 
 
6.2    Procedure of Recruitment 
Participants were recruited from the local community using a series of media releases 
including a story on MX (a free pick up newspaper in the CBD of Melbourne), The Age, 
Herald Sun and Leaders (a community local newspaper). Advertisement for the study was 
also distributed to all RMIT University students and staff via RMIT email and to all the 
members of the Australia Acupuncture & Chinese Medicine Association (AACMA) via 
emails and the AACMA newsletter. Television and radio interviews of the main researchers 
by Channel Nine (a TV station) and ABC radio of Melbourne were also conducted. Some 
examples of media advertisement are listed in the Appendix 3. 
 
Volunteers who were interested in the study phoned the investigator (YYW) for further 
information. During the telephone enquiries, the investigator conducted the initial screening 
for the symptoms of migraine (Appendix 4). Volunteers with tension-type headache only or 
other types of headache were excluded. Potential participants were sent a plain language 
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statement (PLS) (Appendix 5) and the Expression of Interest Form (Appendix 6) together 
with a pre-paid envelope. Based on the returned information, those who met the selection 
criteria were invited to attend an interview, during which further eligibility assessment was 
conducted according to the inclusion and exclusion criteria. Eligible participants were then 
given the opportunity to reconsider their participation and sign the informed consent form 
(Appendix 7). 
 
6.3    Trial Design 
6.3.1   Randomisation 
Block randomisation was used to ensure a similar number of participants were allocated to the 
real acupuncture (RA) treatment and the sham acupuncture (SA) control groups, respectively. 
Eight participants were in each block. Random numbers were generated using a 
computer-generated sequence of numbers by an independent researcher. Each number was 
printed on a piece of paper, which was then concealed in a sealed envelope. Before 
conducting the first treatment, participants were asked to select a sealed envelope containing a 
unique random number. Only the acupuncturist knew the assignment group. 
 
6.3.2   Blinding 
A double-blind, placebo-controlled clinical trial is considered as the gold standard for 
evaluating the therapeutic effects of a treatment (Feinstein, 1984). However, it is not feasible 
for acupuncture studies, as the acupuncturist cannot be blinded. In the current clinical trial, 
performance bias of the participants was minimised by employing sham acupuncture as the 
controlled-intervention. Furthermore, independent assistants in charge of data entry or 
assessing PPT were unaware of the treatment allocation. Any discussion related to treatment 
between the participants and the acupuncturist was restricted to a minimum of necessary 
explanations in order to ensure the allocation concealment. Describing this procedure as a 
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dummy or modified double-blind (patient/evaluator) trial is acceptable when the intervention 
characteristics preclude investigator blinding (Jadad et al., 1996).  
 
After the first treatment week, credibility of the sham acupuncture procedure was assessed 
with a questionnaire (Appendix 8) completed by the participants. 
 
6.3.3 Drop-Outs 
Participants were informed that they could withdraw from this study at any time. The time of 
and the reason for drop-out and the allocation of drop-out participants were recorded. 
 
6.4    Materials  
6.4.1   Selection of Needles 
Individually wrapped, sterilized, disposable needles with guide tubes (Hwato, Suzhou 
Medical Instrument Factory, China) were used. This brand of needles is listed by the 
Therapeutic Goods Administration (TGA) of Australia. All the needles used on local (head) 
and distal (limb) areas were 0.25 mm in diameter. According to the location of the acupoints, 
the length of the needles used was either 30 mm or 40 mm. Furthermore, short needles of 
13mm in length with 0.22 mm in gauge were used for sham acupuncture, so that only a short 
body part of the needle was above the skin (for detailed information, see section 6.4.4 Sham 
Acupuncture for Control Groups). Similar number of needles was used in both groups (RA: 
10-12 needles; SA: 8-10 needles), as the SA group had less needling in the head than the RA 
group. Medical swabs were used for sterilization and used needles were placed into a sharps 
disposal bin.  
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6.4.2   Pressure Algometer 
A handheld pressure algometer (Wagner, Electronic Engineering Corporation of India) 
(Figure 20) was used to measure pressure pain thresholds twice, before and after the treatment 
(the 4th week and 24th week from baseline). The apparatus consists of a 1-cm in diameter hard 
rubber tip, attached to the plunger of a pressure (force) gauge. The dial of the gauge is 
calibrated in kg/cm2. The reliability and validity of algometer have been demonstrated by 
several studies (List et al., 1989, Nordahl and Kopp, 2003). Furthermore, the reliability is 
enhanced when PPT is assessed by one examiner (Antonaci et al., 1998).  
 
 
Figure 20: The algometer used to test the pressure pain threshold 
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6.4.3   Real Acupuncture (RA) Treatment  
For RA, needles were inserted either transversely, obliquely or perpendicularly to a depth of 
10-30 mm depending on the specific locations of acupoints. The treatment consisted of local 
and distal points. De Qi sensation was induced, which is a patient’s feeling of soreness, 
numbness, distension, heaviness or even an electric shock either around the needles or going 
up or down along the meridian, elicited by the acupuncture needles. Needles were retained for 
25 minutes, with further stimulation given every 10 minutes.  
 
The location of acupoints adopted in the present study followed the Standard Acupuncture 
Nomenclature published by the World Health Organization (1993).  
 
The same acupuncturist, registered with the Chinese Medicine Registration Board of Victoria, 
Australia, performed all acupuncture treatments consistently throughout the trial. 
 
6.4.3.1   Mandatory Acupoints 
Mandatory acupoints included bilateral Fengchi (GB20) and bilateral Taiyang (EX-HN5) as 
well as Shuaigu (GB8), and Hegu (LI4) at the side with pain or the side with pain in last 
migraine attack. These acupoints were used for all the participants and were illustrated in the 
following diagram (Figure 21). 
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Figure 21: Location of mandatory acupoints 
 
6.4.3.2   Supplementary Acupoints 
The selection of the supplementary acupoints was based on the diagnosis according to 
Chinese medicine theory. In terms of syndrome differentiation, there are four types of 
migraine, namely Ascending Hyperactivity of Liver Yang, Deficiency of Qi and Blood, 
Phlegm Retention, and Blood Stasis. Table 15 shows the typical symptoms and signs of these 
different syndromes and selected supplementary acupoints. Figure 22 illustrates the location 
of each supplementary acupoint. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15: Typical symptoms and supplementary acupoints for different syndromes 
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SYNDROMES TYPICAL SYMPTOMS 
SUPPLEMENT 
ACUPOINTS 
Ascending 
Hyperactivity of 
Liver Yang 
Irritability; dizziness; distending pain; 
lassitude in the lower back and legs; 
feeling heavy in the head; bitter taste 
in mouth; red tongue body and yellow 
dry coating; string-taut or rapid pulse 
Baihui (DU20), Xingjian 
(LR2), Taichong (LR3), 
Taixi (KI3), Xuanzhong 
(GB39), Sanyinjiao (SP6) 
Deficiency of 
Both Qi and 
Blood 
Pale or sallow complexion; shortness of 
breath after slight physical exertion; weak 
limbs; pale tongue with white and thin 
coating; deep, thready and feeble pulse 
Baihui (DU20), Shangxing 
(DU23), Zusanli (ST36), 
Sanyinjiao (SP6) 
Wind Phlegm 
blocking the 
meridians 
Chest distress; corpulence tongue body 
with tooth-prints; white and greasy 
tongue coating; deep and taut or deep 
and slippery pulse 
Fenglong (ST40), 
Zhongwan (CV12), 
Yinlingquan (SP9) 
Blood Stasis 
Stabbing pain; cyanotic lips and nails; 
purplish tongue body with thin white 
coating; deep, thready or 
thready-sluggish pulse  
Sanyinjiao (SP6), Xuehai 
(SP10) and Ashi point 
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Figure 22: Location of supplementary acupoints 
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6.4.4   Sham Acupuncture (SA)  
For sham acupuncture treatment, a combined insertion and non-insertion procedure were used, 
and is illustrated in Table 16.  
 
Table 16: Method of sham acupuncture 
 Distal sham acupuncture Local sham acupuncture 
Sham point 
1-2 cm away from the real individual 
distal supplementary points 
according to the syndrome 
differentiation 
1-2 cm away from the real 
acupoint of DU20 and 
GB17, on both side 
Technique 
Minimal acupuncture, 2 mm depth 
insertion 
Non-invasive, using a 
blunted cocktail-stick 
Stimulation No needling manipulation The stick was tapped 
 
For distal acupoints needles were inserted gently into the distal sham points, which were 1-2 
cm away from the exact acupoint locations. Depth of insertion was about 2 mm, which was 
just sufficient to make the needle stand vertically (Vincent, 1989b). For sham needling, short 
needles of 13 mm in length were used, such that after insertion only a short body part of the 
needle was above the skin, giving an impression of much of the needle having been inserted. 
Such method was named minimal acupuncture and illustrated by Figure 23. No needling 
manipulation was carried out for sham points. A non-invasive technique was carried out for 
local sham points in the head, (1-2 cm away from the real acupoint of DU20 and GB17). A 
blunted cocktail-stick was tapped on the site to produce some discernible prick to simulate 
needling sensation. Table 17 compares the methods applied in the RA and SA, respectively.  
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Figure 23: The method of minimal sham acupuncture 
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Table 17: Treatment methods for real and sham acupuncture groups 
 Real group Sham group 
Point selection 
Standard acupoints plus 
supplementary acupoints 
according to differentiation of 
syndromes 
1-2 cm away from the standard 
acupoint. 
Stimulation 
Needling to obtain “De Qi” 
sensation 
For distal points, needles were 
inserted about 2 mm depth 
without manipulation. For local 
points, a blunted cocktail-stick 
was used to simulate needling 
sensation 
Duration 
25 mins with stimulation every 10 
minutes 
25 mins without stimulation. But 
the acupuncturist visited 
participants every 10 minutes. 
Frequency 
Twice per week for four weeks 
followed by once per week for 
another four weeks, then once per 
fortnight for four weeks, then once 
per month for another two months 
Twice per week for four weeks 
followed by once per week for 
another four weeks, then once per 
fortnight for four weeks, then 
once per month for another two 
months 
Number of 
needles 
10-12 8-10 
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6.5    Outcome Measures 
6.5.1   Primary Outcome Measures 
The primary endpoints were 1) Frequency: number of days with migraine per four weeks 
(assessed with headache diaries); 2) Intensity: mean severity of average migraine per four 
weeks (assessed with headache diaries); and 3) Duration: hours of migraine per four weeks. 4) 
Respondent rate; 5) Numbers of accompanying symptoms, including nausea, vomiting, light 
sensitivity, sound sensitivity, pain with movement and other specific symptoms that were 
described by individual participants. All of these were assessed using a Headache Diary 
(Appendix 9).  The daily Headache Diary took about five minutes to complete. In the first 
interview, the investigator taught the participants how to complete the Diary step-by-step. 
During baseline and the treatment period participants were requested to complete the diary 
every day and hand the completed form to the investigator (or a research assistant) fortnightly. 
During the three-month follow-up I and another one-month follow-up II period, the diaries 
were required to be posted back to the investigators every four weeks.  
 
Frequency of Migraine: In the headache diary, participants were required to indicate whether 
they had migraine or not every day. The number of days having migraine every 4-weeks were 
calculated. 
 
Intensity of Migraine: The intensity of migraine was assessed with measurements that 
consisted of two parts, the 10-cm Visual Analogue Scales (VAS) which designates “no pain” 
and “pain as bad as it could be” at the two ends. Three VASs were conducted for rating 
highest, lowest and average migraine of that day. The other measurement is the Likert Scale 
of Headache Severity, which has six numbers (0-5) to describe the pain. 0 means no headache, 
5 means intense, incapacitating headache. Means of the VAS value and the Likert Scale per 
four weeks were calculated.   
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Duration of Migraine: Participants were required to indicate the times and duration of each 
migraine headache on a 24-hour scale. In some cases, patients reported to have two headaches 
per day, as the first headache could be eliminated by medication, and onset again once the 
effect of medication ran out. The total hours of the two headaches represented the duration of 
migraine on that day. Mean hours of migraine per four weeks were calculated.  If a 
participant had 3 days with migraine of different duration within a 4-week period, we 
calculated the mean duration of the migraine attacks during the 4-week period. 
 
Respondent Rate:  The 50% or greater improvement in the days with migraine per four 
weeks compared with the baseline period was considered as positively responding to the 
treatment.  
 
Accompanying Symptoms: Some common symptoms that accompany migraine were listed 
for the participants to choose, such as light sensitivity, vomiting, and nausea. Furthermore, 
participants were asked to write down the signs and symptoms they experienced if they were 
not listed.   
 
6.5.2   Secondary Outcome Measures 
Secondary outcome measures included anti-migraine and pain relief medication consumption 
(assessed with the diary), severity and quality of migraine assessed with the McGill pain 
questionnaire (MPQ) (Appendix 10), quality of life assessed with Migraine Specific Quality 
of Life questionnaire (MSQOL) (Appendix 11) and pressure pain threshold (Appendix 12). 
MPQ and MSQOL were given to the participants every four weeks. Pressure pain thresholds 
were tested twice, prior to the first and last treatment sessions.  
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Medication Quantification: The name and dosage of any migraine medication for daily use 
or for acute attacks were recorded by the participants, such as Sandomigrain and Noten for 
prophylaxis; and Tramal and Nurofen for acute pain.  These medications were divided into 
three groups for analysis, namely, medication for acute pain, migraine specific medication and 
prophylaxis medication. The medications for acute pain are quite complex with different drug 
classes, dosage and detriment weight, hence, the Medication Quantification Scale (MQS) 
version III was used. The sum of four-week scores of MQS was calculated for further analysis. 
As to the latter two subgroups, the mean pill count per four weeks was adopted for 
comparison.  
 
The score of each acute pain medication in MQS was calculated through multiplying 
individual detriment weight and a score for dosage level. The detriment weights range from 
1.1 to 4.5 (Appendix 13).  A score of dosage level ranges from 1 to 4 (Table 18), as stated in 
the drug manufacturer package inserts or the physicians desk reference (PDR, 2004).  
 
Table 18: Relative dosage scores 
Score Dosage 
1 Subtherapeutic dose or occasional use 
2 Low 50% of the therapeutic dose rang 
3 Upper 50% of the therapeutic dose rang 
4 Supratherapeutic dose 
 
Take Aspirin and Tramal as examples, whose detriment weights were 3.4 and 2.3 respectively. 
If a migraine patient took 15 tablets of Aspirin (325 mg / tab) per day and 50 mg Tramal for 
the migraine relief, the score of dosage was given four to Aspirin and one for Tramal, 
according to Table 4. The score of MQS of that day is indicated in Figure 24. 
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MQS III 
Drug 
Dosage 
(Mg/day) 
Dosage 
level 
* 
Detriment 
weight 
= 
MQS 
Score 
Aspirin 
15 tab/day 
325 mg * 15 
4 * 3.4 = 13.6 
Tramal 100 mg 1 * 2.3 = 2.3 
Total score 15.9 
 
Figure 24: Sample MQS III computation sheet.  
 
Adverse Events (AEs) of Acupuncture: Participants were asked to record in Headache and 
Medication Diaries any AEs associated with acupuncture treatments and the management of 
these AEs at the end of each week throughout the treatment period. They were also asked to 
indicate the severity of AEs by selecting one of the three words “mild”, “moderate” or 
“severe”. Participants have been notified about the common adverse events including fainting, 
infection, dizziness, bruising, pain and lethargy. During analysis, AEs were classified into 
three types: by event, by risk and by causation according to the WHO Draft Guidelines for 
Adverse Event Reporting and Learning Systems (WHO, 2005). For instance, the wrong 
diagnosis and wrong practices belong to “event”, such as pneumothorax; infection, bruising or 
pain caused by needling can be classified as “risk”; and tingling sensation belongs to 
“causation”. Any disagreement on the classification was solved by discussion among 
researches. 
 
Quality of Pain was assessed with the McGill Pain Questionnaire, which consists of three 
major categories of word descriptors – sensory, affective and evaluative. These words 
describe patients’ subjective experience of pain. There are 20 subclasses with three to six 
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words in each subclass. Participants were requested to pick one word only from each subclass. 
The scoring method of the MPQ questionnaire followed the instructions described in 
Melzack’s study (1975b). Four types of data are obtained from the questionnaire.  
Pain rating index (PRI) was calculated based on the rank values of the words-PRI. In this 
scoring system, the word in each subclass implying the least pain (first word) was given a 
value of 1, the next word was given a value of 2, etc. The values of the words chosen by a 
patient were then added up to obtain a score for each dimension. The score of subclasss 1-10 
to assess sensory components (PRI-S); 11-15 to assess affective components (PRI-A); 16 
assess evaluative components (PRI-E); 17-20 to assess miscellaneous components (PRI-M) 
and PRI–T to investigate the overall performance, subclass 1-20.  
 
Quality of Life was measured by Migraine Specific Quality of Life Questionnaire (MSQOL), 
which is designed specifically to assess the health related quality of life of migraine sufferers 
during the previous four weeks. It consists of three dimensions, namely, role 
function-restrictive (FR) (questions 1-7), role function-preventive (FP) (questions 8-11) and 
emotional function (EF) (questions 12-14). Each dimension is scored from 0-100 and a higher 
score indicates better health.  
 
Pressure Pain Threshold was assessed with a manual algometer. Eleven points were tested 
and these are illustrated in Figure 25. They included the point A: located 2 cm inferior to the 
external occipital protuberance and 2 cm lateral from the midline, on both side; point B: 
bilateral GB20: in a depression between the upper portion of the sternocleidomastoid muscle 
and the trapezius; point C: bilateral points at 2 cm lateral to GV20: which is located on the 
head, 5 cun directly above the midpoint of the anterior hairline; point D: bilateral EX-HN5 
(Taiyang): at temple, in a depression about 1 cun posterior to the midpoint between the lateral 
end of the eyebrow and the outer canthus of the eye; point E: bilateral ST6: one finger width 
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anterior and superior to the angle of the mandible at the belly of the masseter muscle with 
teeth clenched and point F: EX-HN3 (Yintan), which is located midway between the medial 
ends of the eyebrows. When testing for the pain threshold, the blinded investigator placed the 
rubber tip on the selected point and applied a steady gentle pressure at a rate of 1 kg/cm2/sec 
(Nussbaum and Downes, 1998). The participants were informed that the investigation was 
aiming to determine pain threshold, but not pain tolerance. Participants were asked to tell the 
investigator when pain was induced. A reading was made and recorded. The procedure was 
repeated twice and the mean of the two ratings represented the pressure pain threshold (PPT) 
of the point. The difference between the two groups in PPT after treatment was calculated. 
 
 
Figure 25: Location of measuring points of PPT 
 
6.6    Procedure of the Trial  
The overall procedure is illustrated in Figure 26. 
Selecting potential participants via checking the 
Expression of Interest Form Excluded 
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Figure 26: A diagram of the procedure of the clinical trial 
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6.6.1   Initial Examination and Assessment 
After receiving the Expression of Interest Form (EIF) from potential participants, the assessor 
and investigator went through the forms together based on the selection criteria to identify the 
eligible participants. This step was followed by individual phone calls to those potential 
participants for a face-to-face interview.  
 
The first interview was conducted at the Chinese Medicine Clinical Trial Laboratory, 
Bundoora Campus of RMIT University. During the first interview, the following procedures 
were undertaken. 
 
The assessor and investigator together greeted the potential participants, and then explained 
the procedure of the trial as well as the right of the participant to withdraw at any time. The 
assessor / investigator assessed the migraine situation of the potential participants according 
to the IHS criteria to ensure they were eligible for the trial. Any questions were 
comprehensively answered prior to the signing of the Consent Form (CF).  
The Consent Form (CF) was signed and witnessed by a third person. A copy of the signed CF 
was provided to the participants for their own record. Another two forms, “Attitude to 
Acupuncture” (Appendix 14) and “Knowledge of Acupuncture” (Appendix 15) were given 
and participants were asked to complete these at that time. 
Assessor / investigator explained to the participants how to complete the diary, MPQ and 
MSQOL.  
 
6.6.2   Run-in Period 
After explaining the instructions for the diary, a four-week baseline Headache Diary was 
given to the potential participants. During this stage, they were asked to record their migraine 
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condition as well as the medication dosage daily in the diaries. These baseline diaries were 
brought back on their next visit.  
 
6.6.3   Treatment Stage 
Before conducting the treatment, the investigator checked the four-week baseline diaries to 
calculate the days with migraine. Potential participants, who had less than five days with 
migraine during the baseline period, were excluded from this trial. The remaining eligible 
participants were then randomly allocated to either RA group or SA group and treated for a 
total of 16 sessions during the following twenty weeks. As described in Section 6.5 Outcome 
Measures, the frequency, duration and intensity of migraine as well as the pain medication, 
adverse events of acupuncture, quality of pan and quality of life were monitored.  
 
6.6.4   Follow-up Stage 
After completion of the treatment period, the participants were asked to record their migraine 
condition using the daily diaries for three months. MPQ and MSQOL were completed every 
four weeks for three months. The follow-up procedure was designed to evaluate any potential 
long-term effect of acupuncture for migraine.  
 
6.7    Data Collection and Analysis 
6.7.1   Sample Size Calculation    
For this clinical trial, the sample size was calculated based on an acupuncture trial on 
migraine compared with sham acupuncture and waiting list (Linde et al., 2005b) of which 
statistical significance was achieved with 221 participants of two groups (treatment n = 145, 
waiting list n = 76) based on the frequency of headaches. The mean frequency (standard 
deviation) of headaches in the treatment and control groups were 1.5 (1.2) and 2.3 (1.1). 
Using this data, we calculated the following: 
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ES (Effect Size) = (Mean of acupuncture – Mean of control) / pooled SD  
Pooled SD =  )n(n / )SD * 1)-n( SD *1)- (n 21222211 ++  = 1.17 
ES = 
17.1
3.25.1 −
 = -.68 
Significance level α = (Two-tailed) = 0.05 
β = 1-power = 0.2, i.e. power was set at 0.80 (80%) 
Hence, using sample size tables (David, 1995)  it was estimated that the trial required a 
sample size of 33 per group for each of the two groups with statistical power of 80%. As the 
intention-to-treat analysis was used, no additional participants were needed to compensate the 
drop-outs. Consequently, a total of 66 participants was needed in this study. 
 
6.7.2   Data Collection and Treatment of Missing Data  
The diaries were returned and then passed on to one of the independent research assistants for 
data entry. Whenever the research assistant found there was a report of an adverse event of 
acupuncture, the adverse events sheet was allowed to be provided to the acupuncturist to 
ensure safe practice. 
 
The research assistants entered all raw data into Excel spreadsheets. Mean values per four 
weeks were then calculated and saved in a separate Excel spread sheet, which was then 
exported to Statistical Package (SPSS, version 15.0 for Windows) for data analysis. The MPQ 
and MSQOL were calculated according to the relevant manuals. 
 
Any missing data in the Headache Diary was replaced by using the Missing Value Analysis 
function in SPSS. As to the Six-Point Likert Scale for assessing the intensity, if more than one 
box are marked, the higher one was chosen. Moreover, the data missed in the MPQ and 
MSQOL were dealt with according to the instructions for these two questionnaires, 
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respectively. In MPQ, the missing data are replaced with the median values of the total 
sample (Stevinson et al., 2003). As to MSQOL, in the event that responses on one or more 
items within a dimension are missing, the missing item values are estimated using the average 
of the other items within the same dimension (Medical Outcomes Trust, 1998). 
 
6.7.3   Data Analysis 
All the data were summarised as mean (standard deviations, SD). Intention-to treat analysis 
was performed for all the outcome measurements. Per protocol (PP) analyses of primary 
outcome measurements were conducted with data from participants who completed the 
20-week treatment. 
 
Chi-square or t-test was adopted to test the comparability between two groups in 
socio-demographic characteristics and primary and secondary outcome measure data. Tests 
for short-term effects of acupuncture employed repeated measures of General Linear Model 
(ANOVA) to test the main effects of treatment group of time and group by time interaction. 
Paired-samples t-test and independent-sample t-tests with Bonferroni correction were used for 
post-hoc analyses. The long-term effects were analysed using the paired sample t-tests. The 
scores of sub-categories of MPQ and MSQOL were analysed separately. The number and 
percentage of AEs were summarised and analysed using Chi-square to investigate the safety 
of acupuncture. 
 
When the probability value achieved 0.05 or less, the difference was considered to be 
statistically significant. In the event when more than one comparison was made, significant p 
value was calculated by dividing 0.05 with the number of comparison. 
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CHAPTER SEVEN: SHORT TERM EFFECTS OF 
ACUPUNCTURE ON MIGRAINE AND DISCUSSION 
 
This chapter presents the analysis of data obtained from the 20-week treatment period of the 
study. Per protocol analysis was employed to analyse both the primary and secondary 
outcomes. Results in the study have demonstrated a statistically significant short-term 
prophylactic effect of acupuncture, as well as improvement with respect to severity, 
medication consumption and quality of life, when compared with sham acupuncture. 
Furthermore, there were no any serious adverse events that necessitated withdrawal of 
participants from the trial. The incidence and severity of minor adverse effects were 
comparable between two groups. 
 
7.1    Short-term Results 
7.1.1   Subject Recruitment 
Between October 2005 and April 2007, a total of 179 phone calls were received from the 
public to express an interest in participating in this clinical trial. Fifty-nine respondents were 
excluded because they did not meet the selection criteria. The Plain Language Statement and 
Expression of Interest Form were sent to the remaining 120 respondents. A total of 95 of 
these completed and returned the Form. Furthermore, 37 respondents were excluded for 
reasons outlined in Table 19. The remaining 58 potential participants were invited to RMIT 
University for a face-to-face interview. Four potential participants did not attend the 
interviews. One was excluded because he had a mixed migraine and tension-type headache 
and he could not distinguish between the two types of headaches. Finally, a total of 53 
respondents signed the informed consent form and entered into the run-in period of the study, 
in which they completed the migraine diaries to record the frequency, intensity and duration 
of migraine. At the end of four weeks, all volunteers returned for further assessment and 
treatment. Three were excluded as they had less than 5 days with migraine in a four-week 
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run-in period. A total of 50 participants were randomly allocated into either the real 
acupuncture (RA) or the sham acupuncture (SA) groups. The whole process is illustrated in 
Figure 27. 
 
Table 19: Number of potential participants being excluded from the trial.   
Item Reason 
Number of 
participants 
1 Not met the IHS definition of migraine. 9 
2 Had less than five days with migraine in four weeks 25 
2 
Had acupuncture experience for headache in the last six 
months 
2 
4 Preparing to get pregnant 1 
Total  37 
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Figure 27: A flowchart illustrating the process of recurring participants 
Contact by phone from people who were interested in this 
study, n = 179
Sending Plain Language Statement, n = 120
Patients who returned Expression of Interest Form, n = 95
Phone call to make a face to face interview, n = 58
Further assessments @RMIT Chinese Medicine Research 
Clinic, n = 54
Included in clinical trial, n = 50
Excluded, according 
to inclusion criteria, 
n = 37
Excluded, n = 59
n = 25, did not 
return form back
Signed informed consent
Four weeks baseline diaries were handed out, n = 53
Excluded, as attack 
days< 5 @baseline 
n = 3
Excluded, as cannot 
distinguish tension-
type headache, n = 1
Did not attend 
interview, n = 4
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7.1.2    Allocation of Participants 
Among the 50 participants, 26 were randomly allocated to receive RA and 24 to receive SA. 
Forty-eight participants completed the treatment, with one withdrawing from each treatment 
group. One in the RA group could not tolerate acupuncture needling; one in the SA group had 
work commitments preventing him from receiving treatment regularly. One more participant 
in the SA group withdrew during the follow-up period without giving any reason. The number 
of participants at each stage of the clinical trial is illustrated in Figure 28. Intention-to-treat 
(ITT) analysis was used when comparing the treatment groups on all variables. 
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Figure 28: Number of participants in different stages of trial 
12 weeks follow-up period
n = 25
16 sessions of treatment during a 20-
week period:
2/wk for 4wks →1/wk for 4wks 
→1/2wks for 4wks →1/4wks for 8wks
Treatment: n = 25
Dropout: n = 1 (can not tolerate 
acupuncture needling)
Treatment: acupuncture
n = 26
16 sessions of treatment during a 20-
week period:
2/wk for 4wks →1/wk for 4wks 
→1/2wks for 4wks →1/4wks for 8wks
Control: n = 23
Dropout: n = 1 (work commitments)
Control: sham acupuncture
n = 24
12 weeks follow-up period
Dropout: n = 1
n = 22 
Allocation
Follow-Up
Participants were randomly assigned to either 
treatment or control group 
n = 50
Treatment
ITT analysis n = 26
PP analysis n = 25
ITT analysis n = 24
PP analysis n = 23Analysis
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7.1.3    Socio-demographic Data 
The 50 included participants had an age range from 19 to 68 years with a mean age of 42.6 
and a standard deviation of 14.10 years. Thirty-seven of the participants were females and 13 
were males. The migraine history of all participants corresponded to a mean time of 19.7 
years with a standard deviation of 12.90 years. Thirty-seven of the 50 participants were 
currently married or partnered. Twenty-six participants had an acupuncture experience more 
than six months ago, and these 26 participants were nearly evenly allocated into the two 
groups, 12 in RA and 14 in SA. The education level of participants was high with 22 having a 
degree or higher education; 26 having 9 years formal education; one having less than nine 
years education and the remaining one not providing relevant data.  
 
The socio-demographic data of each treatment group are presented in Table 20. There were no 
significant differences between the RA and SA groups with respect to age, migraine history, 
gender, acupuncture experience, marital status and education level.  
 
As to the knowledge and attitude to acupuncture, 82% of the participants agreed that 
acupuncture should be used as a complementary medicine; and 74% of the participants 
indicated that they felt more anxiety about using acupuncture than taking medication 
indicating a lack of knowledge of acupuncture. Moreover, 48% of the participants consulted 
with their doctors about acupuncture before joining this study. 62% of participants had heard 
about acupuncture from friends or relatives. Overall, on the 18 questions regarding the 
attitude to acupuncture and the 14 questions investigating the knowledge of acupuncture, the 
two treatment groups showed no significant differences.  
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Table 20: Comparisons of demographic variables at baseline in the RA and SA groups 
Demographic  Intention-to treat analysis 
Variables 
RA 
n = 26 
SA 
n = 24 
χ
2 or t - 
value p - value 
Age (yrs) 
(Mean ± SD) 41.6 (14.91) 43.8 (13.40) -.55 .58 
Migraine History (yrs) 
(Mean ± SD) 18.4 (12.67) 21.1 (13.28) -.74 .47 
7  
(26.93%) 
6  
(25%) Gender 
(n, %) 
Male  
 
Female  19  
(73.07%) 
18  
(75%) 
.02 .88 
14 
(53.85%) 
10 
(41.67%) Acupuncture Experience (n, %) 
 No 
Yes 12 
(46.15%) 
14 
(58.33%) 
.74 .39 
17 
(65.38%) 
17 
(70.83%0 Marital Status 
Partnered (n, %) 
Single (n, %) 9 
(34.62%) 
7 
(29.17%) 
.17 .68 
12 10 
14 12 
0 1 
Education level (n) 
H: University or higher 
 
S: 9 or more years of 
formal education 
 
 
 
L: less than 9 years 
 
 
M: Miss data 
0 1 
2.26 .52 
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7.1.4    Clinical Characteristics Between RA and SA Groups at Baseline 
Baseline clinical characteristics of the RA and SA groups are presented in Table 21. The two 
groups are comparable in the frequency, duration, intensity and accompanying symptoms of 
migraine. A typical participant had migraine attacks for 12 days per four weeks with each 
attack lasting for more than eight hours, the highest pain intensity being 5.5 out of 10 on a 
10-cm VAS and 3 on a Six-Likert scale and with more than two accompanying symptoms, 
such as nausea and photophobia. Per protocol analysis with 48 participants who completed 
the study confirmed this finding. 
 
The two groups were also comparable on four items of the MPQ, QoL scales and medication 
consumption measured with MQS and pill count. 
 
Eighteen of 50 participants were diagnosed as Ascending Hyperactivity of Liver Yang 
according to differentiation of syndromes in Chinese Medicine. Sixteen were in the 
Deficiency of Qi and Blood sub-group. Ten and six participants had the diagnosis of Phlegm 
Retention and Blood Stasis, respectively. No group difference regarding the Chinese 
Medicine syndromes was detected (Table 22).  
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Table 21: Comparison of baseline clinical characteristics variables of participants 
 
RA 
Mean 
(SD)[range]  
SA 
Mean(SD) 
[range]  
t - 
value 
95% CI for 
difference 
p - 
value 
Attack days (Number 
of days with migraine 
per 4 weeks) 
11.81 (5.76) 
5, 28] 
12.41 (6.40) 
[5, 28] -.35 (-4.07, 2.85) .73 
Duration 
(Hours /attack) 
8.99 (3.57) 
[1.7, 15.43] 
8.86 (4.82) 
[0.92, 22.71] .11 (-2.27, 2.53) .91 
Highest of Pain-VAS 6.03 (1.08) [3.63, 8.17] 
5.30 (2.04) 
[1.27, 9.66] 1.64 (-.17, 1.64) .11 
Lowest of Pain-VAS 3.12 (1.82) [.18, 7] 
2.66 (1.90) 
[0, 7.64] .88 (-.60, 1.53) .39 
Average of Pain-VAS 4.62 (1.35) [1.94, 7.5] 
4.01 (1.99) 
[.17, 8.32] 1.28 (-.35, 1.57) .21 
Severity of Pain 
(Six-point Likert Scale) 
3.20 (.39) 
[2.11, 3.89] 
3.24 (.62) 
[2.02, 4.20] -.27 (-.34, .26) .79 
Accompanying 
symptoms (Number of 
symptoms per attack) 
2.70 (0.96) 
[1, 8] 
2.32 (0.96) 
[1, 7] 1.41 (-.16, .93) .16 
PRI-S 21.26 (7.5) 18.27 (8.87) 1.29 (-1.67, 7.64) .20 
PRI-A 6.68 (3.20) 5.40 (2.74) 1.51 (-.42, 2.98) .14 
PRI-E 3.63 (1.12) 3.51 (1.34) .34 (-.58, .82) .73 
McGill 
PRI-M 7.59 (3.22) 6.74 (2.95) .97 (-.91, 2.61) .34 
FR 46.70 (18.93) 54.17 (17.23) -1.45 (-17.79, 2.86) .15 
FP 61.73 (20.64) 71.04 (18.97) -1.66 (-20.61, 1.99) .10 MSQOL 
EF 48.50 (24.15) 54.72 (24.77) -.85 (-20.99, 8.55) .40 
MQS 87.01 (110.15) 93.76 (81.11) -.25 (-62.14, 48.64) .81 
Medication Pill 
Account 7.27(13.50) 13.50 (20.27) -.62 (-12.70, 6.74) .54 
 
PP: indicates the data are based on the per protocol analysis 
PRI-S: sensory components 
PRI-A: affective components 
PRI-E: evaluative components 
PRI-M: miscellaneous components 
FR: Function-restrictive in Migraine Specific Quality of Life questionnaire 
FP: Function-preventive in Migraine Specific Quality of Life questionnaire 
EF: Emotional function in Migraine Specific Quality of Life questionnaire 
PPT: Pressure Pain Threshold 
MQS: Medication Quantification Scale 
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Table 22: Chinese medicine differentiation syndromes 
Syndrome RA SA Total χ
2
 - 
value 
p - value 
Ascending Hyperactivity 
of Liver Yang 
7 11 18 
Deficiency of Both Qi 
and Blood 
11 5 16 
Phlegm Retention 4 6 10 
Blood Stasis 4 2 6 
Total 26 24 50 
4.13 .25 
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7.1.5    Effects of Acupuncture on the Primary Outcomes During the Treatment Period 
All of the primary outcomes data sampled between Week 17 to 20 (last phase of treatment) 
were analysed using the Independent-Samples t-test, and the results are summarised in Table 
23.  
 
Table 23: Primary outcome measurements between Week 17 and 20. 
 
Note: * statistical significance assessed at 0.05/6 = 0.0083 (Bonferroni Correction) for both 
intention to treat and per protocol analysis 
 
 
 
 
 
 
 
RA 
Mean (SD) 
SA 
Mean (SD) 
t - 
value 
95% CI for 
difference 
p - 
value 
Attack days (Number 
of days with migraine 
per 4 weeks) 
5.17 (5.02) 10.08 (7.11) -2.80 
(-8.45, 
-1.37)  
.008* 
Duration 
(Hours /attack days) 
5.96(3.30) 7.99 (4.49) -1.83 (-4.26, .20) .073 
Highest of Pain-VAS 4.96 (1.76) 4.48 (1.89) 1.61 (-.17, 1.64) .35 
Lowest of Pain-VAS 2.34 (1.92) 2.47 (1.73) -.24 (-1.16, .92) .82 
Average of Pain-VAS 3.01 (1.82) 3.24 (1.80) -.45 (-1.26, .80) .65 
Severity of Pain 
(Six-point likert Scale) 
2.18 (1.05) 2.93 (.61) -3.05 (-1.24, -.26) .004* 
Accompanying 
symptoms (Number of 
symptoms per attack) 
2.03 (1.41) 1.86 (.87) .52 (-.49, .84) .60 
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7.1.5.1   The Effect of Acupuncture on the Frequency of Migraine 
The data regarding migraine frequency collected from six phases, including baseline and five 
phases of treatment were analysed with the General Linear Model (GLM) for repeated 
measures. There was a significant time effect [F (5, 240) = 18.372, p < .001] and treatment 
group by time interaction [F (5, 240) = 4.53, p = 0.002] indicating that the number of days 
with migraine was reduced in both groups over the 20-week treatment period and the 
reduction was faster in the RA group than in the SA group (Figure 29). During the first eight 
weeks of treatment, the number of attack days was reduced quickly in the RA and continued 
to reduce throughout the rest of the treatment period. In contrast, the frequency of migraine in 
the SA group did not change greatly through the whole 20 weeks treatment period.  
 
Post-hoc analyses were conducted using Independent sample t-tests with a Bonferroni 
correction. The significance level was adjusted at α = 0.0083. A significant difference in the 
number of days with migraine was found between the two groups (p = 0.008) at the end of the 
20-week treatment. 
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Figure 29: The number of days with migraine per four weeks in each group across all treatment 
time points (Mean and SEM) 
Tw4, Tw8, Tw12, Tw16 and Tw20 correspond to the treatment week 1-4; week 5-8; week 
9-12; week 13-16 and week 17-20 respectively * indicated that at the end of treatment, the 
mean number of attack days 5.92(0.66) in RA was significantly less than those in SA, 7.99 
(0.92).  
 
At the end of 20-week treatment, the number of participants who achieved more than a 50% 
reduction in the days with migraine is summarised in Table 24. A significant group difference 
(p = 0.002) was detected, which indicates that more participants in the RA group responded to 
the RA treatment than those in the SA. .  
 
Table 24: The number of participants responded to the treatment 
 
RA 
(n, %) 
SA 
(n, %) 
Total χ2- value p - value 
Respondent 19 
(73.08%) 
7 
(9.17%) 
26 
Non-respondent 7 
(16.92%) 
17 
(70.83%) 
24 
Total 26 24 50 
9.64 .002 
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Table 25 lists the number of participants in each of the four categories of Chinese medicine 
syndromes. The Chi-square test indicates there was no significant difference between the 
treatment groups (p = 0.248). Table 26 lists the number of respondent and non-respondents in 
each category of Chinese medicine syndromes. Spearman correlation indicates that was no 
significant correlation between the two sets of data, (p = 0.387). 
 
Table 25: The number of participants in each of the four categories of Chinese medicine 
syndromes 
Chinese Medicine diagnosis RA SA 
Ascending Hyperactivity of Liver Yang 12 13 
Deficiency of Both Qi and Blood 18 7 
Phlegm Retention 6 8 
Blood Stasis 7 3 
Chi-square (df) 4.132 (3,50)* 
P  .248 
*3 cells (37.5%) have expected count less than 5. The minimum expected count is 2.88. 
 
 
Table 26: The number of respondent in each of the four categories of Chinese medicine 
syndromes 
Chinese Medicine diagnosis Respondents  Non-respondents  
Ascending Hyperactivity of Liver Yang 7 11 
Deficiency of Both Qi and Blood 11 5 
Phlegm Retention 4 6 
Blood Stasis 4 2 
Chi-square (df) 4.132 (3,50)* 
P  .248 
Spearman Correlation -.125 
P  .387** 
* 3 cells (37.5%) have expected count less than 5. The minimum expected count is 2.88. 
** Based on normal approximation. 
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7.1.5.2   The Effect of Acupuncture on the Duration of Migraine 
GLM analysis was conducted, and the result revealed a significant time effect of duration [F 
(5, 240) = 3.77, p = 0.006], demonstrating that during the 20-week treatment period, the 
duration of each migraine attack was reduced in both groups. However, no significant 
difference was detected between the two groups in terms of duration of time [F (5, 240) = 
2.11, p = 0.082] (Figure 30).  
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Figure 30: The reduction of migraine duration in each group across all treatment time points 
(Mean and SEM) 
Tw4, 8, 12, 16 and 20 correspond to the treatment week 1-4; week 5-8; week 9-12; week 
13-16 and week 17-20 
 
7.1.5.3   The Effect of Acupuncture on the Intensity of Migraine 
The means of highest, lowest and average pain for every four weeks were measured using 
VASs. The average pain was also measured with a Six-Point Likert Scale. 
 
GLM analyses revealed that the highest, average and lowest pain were reduced during the 
treatment period (time effect: highest pain [F (5, 240) = 6.80, p < 0.001]; average pain [F (5, 
240) = 10.13, p = 0.082]; lowest pain [F (5, 240) = 0.74, p = 0.55]). However there was no 
significant difference between groups by time interaction in the three measures of the 
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intensity of migraine during the 20 weeks. The time course of the intensity of migraine 
measured with VASs are illustrated in Figure 31. 
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Figure 31: The time course of the highest, lowest and average levels of pain measured with 
VASs over the five treatment phases (Mean and SEM) 
Tw4, 8, 12, 16 and 20 correspond to the treatment week 1-4; week 5-8; week 9-12; week 
13-16 and week 17-20 
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On the other hand, when pain was measured with the Six-point Likert Scale (Figure 32), 
GLM analysis indicated there was a significant time effect difference for average pain [F (5, 
240) = 10.15, p < .001] induced by the active treatment group by time interaction [F (5, 240) 
= 3.14, p = 0.02] indicating that the RA group experienced a faster reduction of migraine pain 
when compared with the SA group.  
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Figure 32: The time course of the average pain measured with a Six-point Likert Scale over the 
five treatment phases (Mean and SEM) 
Tw4, 8, 12, 16 and 20 correspond to the treatment week 1-4; week 5-8; week 9-12; week 
13-16 and week 17-20 * indicated that at that time point, the mean of average pain measured 
with Six-point Likert Scale in RA was significantly less than those in SA using a Bonferroni 
correction on the t-test  
 
7.1.5.4   The Effect of Acupuncture on the Reduction of Accompanying Symptoms of 
Migraine 
The number of accompanying symptoms per attack was analysed with the GLM, and there 
was a time effect [F (5, 240) = 5.80, p < 0.001], however, without a treatment group by time 
interaction [F (5, 240) = 0.69, p = 0.58] (Figure 33), indicating the number of accompanying 
symptoms decreased in both RA and SA groups to a similar degree.  
  173 
1
2
3
Baseline Tw4 Tw8 Tw12 Tw16 Tw20
N
u
m
be
r 
o
f a
cc
o
m
pa
n
y 
sy
m
pt
o
m
s RA
SA
 
Figure 33: No significant difference in number of accompanying symptoms was detected 
between two RA and SA groups in treatment period 
Tw4, 8, 12, 16 and 20 correspond to the treatment week 1-4; week 5-8; week 9-12; week 
13-16 and week 17-20 
 
7.1.6    The Effect of Acupuncture on the Secondary Outcomes During the Treatment 
Period 
All the secondary outcome data at the last phase of treatment (week 17 to week 20) were 
analysed using Independent-sample t-tests, and the summary is presented in Table 27. 
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Table 27: Secondary outcome measurements at the week 17 to 20 (last phase of treatment) 
 
RA 
Mean (SD) 
SA 
Mean (SD) 
t - 
value 
95% CI for 
difference 
p - 
value 
PRI-S 13.07 (8.80) 
15.83 
(11.55) 
-953 (-8.57,3.06) .35 
PRI-A 3.96 (3.01) 4.79 (2.75) -1.02 (-2.48, .81) .32 
PRI-E 2.08 (1.26) 2.83 (1.46) -1.96 (-1.53, .02) .056 
McGill 
PRI-M 5.62 (3.39) 6.13 (3.49) -.52 (-2.47,1.45) .60 
FR 72.20 (16.37) 
57.98 
(21.00) 
2.68 (3.56, 24.89) .010 
FP 77.12 (16.80) 
68.33 
(22.73) 
1.54 (-2.70, 20.27) .130 MSQOL 
EF 
78.31 (19.25) 
60.53 
(25.55) 
2.79 (4.98, 30.58) .007* 
MQS 20.81 (46.43) 
68.92 
(81.19) 
-2.60 
(-85.35, 
-10.87) 
.012 
Medication 
Pill 
Account 
4.54(12.21) 
10.54 
(19.31) 
-1.32 (-15.12, 3.11) .192 
 
Note: * statistical significance assessed at 0.05/6 = 0.0083 (Bonferroni Correction).  
PRI-S: sensory components 
PRI-A: affective components 
PRI-E: evaluative components 
PRI-M: miscellaneous components 
FR: Function-restrictive in Migraine Specific Quality of Life questionnaire 
FP: Function-preventive in Migraine Specific Quality of Life questionnaire 
EF: Emotional function in Migraine Specific Quality of Life questionnaire 
PPT: Pressure Pain Threshold 
MQS: Medication Quantification Scale 
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7.1.6.1   Pain Assessed with McGill Questionnaire 
The MPQ contains four domains, and a low score reflects a milder level of pain. GLM 
analysis showed that time effects were detected in all four sub-categories (PRI-S [F (5, 240) = 
7.41, p < 0.001]; PRI-A [F (5, 240) = 8.87, p < 0.001]; PRI-E [F (5, 240) = 10.34, p < 0.001] 
and PRI-M [F (5, 240) = 4.50, p = 0.001]). However, a treatment group by time interaction 
was found in PRI-A [F (5, 240) = 2.82, p = 0.017] only (Figure 34).  
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Figure 34: The trend over time of four domains of MPQ over five treatment phases 
Tw4, 8, 12, 16 and 20 correspond to the treatment week 1-4; week 5-8; week 9-12; week 
13-16 and week 17-20 
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Post-hoc analysis was conducted using a t-test to examine the effects on PRI-A in the 
treatment week 8 and last treatment phase. However, no significant differences between two 
groups were detected (TW8: p = 0.40; TW20: p = 0.32). 
 
7.1.6.2   Quality of Life 
Three dimensions of MSQoL, namely, role function-restrictive (FR), role function-preventive 
(FP) and emotional function (EF) were analysed individually with the GLM for repeated 
measures.  
 
There were statistically significant time effects in FR [F (5, 240)= 8.60, p < 0.001] and EF [F 
(5, 240) = 10.83, p < 0.001] and treatment group by time interaction (FP [F (5, 240) = 2.97, p 
= 0.023] and EF [F (5, 240)= 596, p < 0.001]). Both groups improved on FR and EF, however 
EF and FP showed faster improvement in the RA group when compared to those in the SA 
group (Figure 35). 
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Figure 35: Comparisons of MSQOL between two groups at baseline and last phase of treatment 
(Mean and SEM) 
* indicated that at the end of treatment, the EF of MSQOL 78.31 (19.25) in RA was 
significantly better than those in SA, 60.53 (25.55).  
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7.1.6.3   Medication Consumption 
Medication used by the participants included those for reducing acute migraine headache and 
those for prophylactic purposes. Their consumption was recorded by the participants in the 
Headache Diaries during the whole study period.  Medications for acute pain, including 
Aspirin, Brufen, Cafergot, Codiene, Deseril, Panaderine, Panaderine Forte and Tramal, etc, 
were quantified using MQS. The number of pills of preventive medication including specific 
anti-migraine and prophylactic drugs, such as Endep, Noten, Sumatripton, Sandomigrain, 
Valium, Imigrain and Zomig was analyzed. The numbers of participants who took medication 
during the baseline period and at the end of treatment are listed in Table 28 and Table 29 
respectively.  
 
Table 28: Number of participants took different types of medication during the baseline period 
 
RA  n=26 
(n) 
SA  n=24 
(n) 
χ2 - value p - value 
Number of participants who took 
pain killers 
23 22 .14 .71 
Number of participants who took 
specific anti-migraine drugs 
3 4 .27 .60 
Number of participants who took 
prophylactic drugs 
11 12 .30 .59 
 
Table 29: Number of participants took different types of medication at the end of treatment 
 
RA  n=26 
(n) 
SA  n=24 
(n) 
χ2 - value p - value 
Number of participants who took 
pain killers 
9 18 8.2 .004* 
Number of participants who took 
specific anti-migraine drugs 
1 4 2.28 .13 
Number of participants who took 
prophylactic drugs 
7 9 .64 .42 
* indicated that there was a significant group difference. 
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There was no statistically significant difference between two groups with respect to the 
numbers of participants adopting anti-migraine drugs, preventive control drugs or using pain 
killers during baseline period. However, at the end of treatment fewer participants in the RA 
group took pain-killers than the SA group did (p = 0.004).  
 
The MQS was reduced in both groups during the treatment period (time effects [F (5, 240)= 
7.14, p < 0.001]). Furthermore, there was a trend for a quicker reduction in the RA group 
when compared with the SA group (treatment group by time interaction [F (5, 240)= 2.54, p = 
0.064]) (Figure 36). Results of the post-hoc t-tests demonstrated that at the end of treatment, 
the participants in the RA group took less pain killers for acute pain than SA group did. 
Although the group difference achieved significant level (p = 0.012), as under the Bonferroni 
Correction test, the p value less than 0.05/6 = 0.0083 was considered as a result that showed 
statistical significance. 
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Figure 36: The changed trend of MQS over five treatment phases 
Tw4, 8, 12, 16 and 20 correspond to the treatment week 1-4; week 5-8; week 9-12; week 
13-16 and week 17-20 
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There were neither time effects [F (5, 240)= 1.53, p = 0.18] nor treatment group by time 
interaction [F (5, 240)= 0.85, p = 0.52] in the pill account (Figure 37). The number of tablets 
of preventive medication was slightly reduced in both groups, without reaching statistical 
significance when comparing the two treatment groups. 
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Figure 37: Comparisons of pill account between the two groups 
 
7.1.7   Summary of the Short-term Effects of Acupuncture 
In summary, at the end of the 20-week treatment period, the frequency of migraine was 
significantly reduced in both groups. Moreover, there was a more rapid reduction in the RA 
than in the SA group. In the first eight weeks of treatment, the number of attack days was 
reduced more quickly in the RA, and this effect was maintained during the remaining 
treatment period.  
 
The two groups were similar in the reductions of the duration and intensity of migraine when 
measured with VASs or MPQ and accompanied symptoms. However, the RA group reported 
a more rapid decline of the intensity of migraine measured with a Six-point Likert Scale, and 
also improved emotional function and role function-preventative. 
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Real acupuncture treatment effectively reduced the medication consumption for acute pain 
when compared with SA, but not preventive medication or specific anti-migraine 
medications. . 
 
7.1.8   Adverse Events of Acupuncture 
Fifty participants completed 774 sessions of treatment, comprising 400 RA sessions and 374 
SA sessions. Fifty adverse events (AE) were recorded, 36 in the RA group and 14 in the SA 
group. The rates of AE incidences per treatment in the two groups were 9% and 3.74%, 
respectively. The most frequently reported AE by the RA group was the tingling sensation, 
recurrent headache followed by cold and sweaty feelings (Table 30). In the SA group, cold 
and sweaty feelings and then dizziness were more frequent than other AEs.  
 
Most of the AEs were reported as mild or moderate, except for one case. One participant in 
the RA group experienced severe tingling sensation after a needle was inserted into Hegu (LI4) 
on the right hand. The participant described that the tingling could be felt on the right side of 
the face, lasted for one hour, and disappeared after some rest. She withdrew from the study. 
AEs reported by other participants disappeared after rest. There was no incidence in which 
special medical management or intervention was required or causing withdrawal of 
participants from the trial except for the case mentioned above.   
 
Among the total 50 AEs, 37 cases had dizziness, cold and sweaty feelings, bruising, needling 
pain or headache. These AEs were likely due to being nervous, treatment position or low 
blood sugar, and acupuncture was defined as risk of these patients. Twelve cases involved 
tingling sensation, and acupuncture was classified as being the cause. In one case, the 
participant developed mild spasm in the calf muscle induced by tapping on the thigh after. 
This AE was classified as not assessable for cause. 
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 Table 30:  The adverse events reported by participants in each treatment group.  
RA SA 
Degree of Severity of Adverse Events Degree of Severity of Adverse Events Type of event 
Mild Moderate Severe Total Mild Moderate Severe Total 
Dizziness 3 1   1 2   
Bruising 1 2   1    
Pain 1 2   2    
Cold and sweaty 4 4   3 2   
Tingling 8 2 1  1    
Recurrent 
Headache 
5 2   2    
Others  1       
Total incidents 
of A.E. 
   36    14 
Total treatment    400    374 
Accidences per 
treatment 
   9%    3.74% 
 
7.1.9   Credibility of Blinding Process 
 
Credibility of the blinding process was assessed with the Participants’ Perception of 
Acupuncture Treatment at the end of the first treatment week. All 50 participants completed 
this three-item questionnaire, which was designed to detect whether the participants could tell 
the allocation of groups. Data from the two groups are presented in Table 31. No statistically 
significant differences were detected between the two groups (p = 0.88), indicating the 
blinding was successful. 
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Table 31: Number of participants’ perception of treatment in each group at the end of first week 
of treatment 
 
Guessing in the 
RA (n, %) 
Guessing in the 
SA (n, %) 
Do not know  
(n, %) 
Total 
RA group 
n = 26 
14 
(53.85%) 
4 
(15.38%) 
8 
(30.77%) 
26 
SA group 
n = 24 
11 
(45.84%) 
4 
(16.67%) 
9 
(37.5%) 
24 
Total 25 8 17 50 
x
2
 0.34 
p 0.88 
 
The participants were asked the reason for their guess. Seventeen participants who could not 
tell which group they were in and did not select any reason. The majority of the remaining 33 
participants made the guess based on the result of the treatment or the manner, attitude or the 
words of other personnel in the research (Table 32). There was no group difference in the 
reasons.  
 
Table 32: The reason of guessing group location 
 
RA group 
n = 26 
SA group 
n = 24 
Total χ2 - value p - value 
No selection 9 8 17 
Manner, attitude or words of 
acupuncturist 
3 4 7 
Manner, attitude or words of 
the personnel in the clinic 
5 6 11 
Results of the treatment 8 4 12 
Others 1 2 3 
Total 26 24 50 
1.88 .76 
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7.1.10   Results of Media Promotion and Participants Recruitment 
From October 2005 to September of 2006, a series of methods were used to promote the trial 
and to recruit the participants.  In October 2005, the first media story was released in the MX 
newspaper in Melbourne. News about the Division of Chinese Medicine and the current trial 
were published in the major newspapers including the Age and the Herald Sun. Interviews of 
the main investigators were broadcasted or published on television (Channel Nine), radio 
(3LO) and local newspaper interviews (Leaders Newspapers). News about the trial was also 
distributed to the RMIT University staff and students via RMIT internet and to all the 
members of the Australian Acupuncture and Chinese Medicine Association (AACMA) 
through email, and the newsletter of AACMA. Advertisements were placed in the local 
Leader newspaper. The numbers of participants who were enrolled into this study through the 
above methods are listed in Table 33 and Figure 38. Taking “Radio and MX” as an example, 
these two promotions were released at the same time. Sixty phone calls were received after 
that, 26 volunteers returned the Expression of Interest Form after reading the Plain Language 
Statement. Fourteen participants met the selection criteria and were included into the study.  
 
In this research study, interviews and news in the newspaper and interview with the local 
radio station are the most effective way to recruit participants. 
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Table 33:  Participants allocation of media release 
 
Radio 
and MX 
The Age 
Leader 
newspaper 
(interview) 
Herald 
Sun 
RMIT 
website 
Channel 
Nine 
and 
others 
AACMA 
newsletter 
Leader 
(Ads) 
Referred by 
other 
participants 
Total 
Phone Enquiries 60 10 32 25 5 15 0 30 1 178 
Returned the 
Questionnaires 
26 5 18 13 1 10 0 21 1 95 
Included 14 3 10 7 1 5 0 9 1 50 
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Figure 38:  The numbers of participants recruited through various media sources   
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7.2    Discussion 
7.2.1   Population Sample 
Participants of the study were volunteers, recruited from the local community around 
Melbourne, and identified as the migraine with aura and without aura, the two major 
sub-groups of migraine patients. Furthermore, these participants all experienced at least five 
days of migraine or more during the four-week baseline period. No upper limit on the 
maximum migraine days or attacks per month was set. This population sample of high 
migraine attacks was chosen because the effect of acupuncture on migraine of such high 
frequency has not been studied previously. Current published migraine trials included patients 
with 2-6 migraine attacks per month (Diener et al., 2006, Alecrim-Andrade et al., 2008); 2-8 
migraine attacks per month (Streng et al., 2006, Linde et al., 2005a) and 2 attacks per month 
(Allais et al., 2002, Alecrim-Andrade et al., 2006, Vickers et al., 2004a). Part of them reported 
the mean of days with migraine, ranged from 5 (Linde et al., 2005) to 6.1 days (Diener et al., 
2006). The mean attack days at baseline in the current study was about 12 days per four week, 
much higher than previous published studies.  
 
Among the 50 participants, 37 were females and 13 were males. This conforms with other 
clinical studies (Demirkirkan et al., 2006, Alecrim-Andrade et al., 2006) and epidemiological 
studies (Rasmussen, 1999, Aygul et al., 2005), which have shown that migraine is more 
prevalent in women than in men. This gender difference might also be a consequence of that 
women seek medical care for headaches more often than men do (Celentano et al., 1990). The 
migraine history of all participants was 19.68 (12.90 in SD) years, which is similar to other 
studies (Alecrim-Andrade et al., 2006, Vickers et al., 2004b, Alecrim-Andrade et al., 2008). 
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The participants of current study aged between 19 and 68 years old, and with the mean of 
42.64 (14.10 in SD) years, consistent with a survey conducted in the USA that the peak 
prevalence of migraine occurs between ages 25 and 55 years (Lipton et al., 2001). The marital 
status of migraine sufferers has not been widely reported (Abramson et al., 1980, Lafata et al., 
2004). In the current study 68% participants of the study were partnered. Similar percentage 
was also reported by one other study (Aygul et al., 2005). 
 
7.2.2   Blinding Procedure 
Randomised, double blind and controlled study is recognised as the gold standard design for 
clinical study. However, blinding the acupuncturist has been proven unfeasible for 
acupuncture studies. Employing independent assistants who are in charge of randomisation, 
data entry and checking was recommended to minimize bias (Margolin et al., 1998). 
Describing this procedure as a modified double-blind (patient/evaluator blinded) trial is 
acceptable when the intervention characteristics preclude investigator blinding (Jadad et al., 
1996). In this study, independent assistants were employed for randomisation, data entry and 
assessing pressure pain thresholds.  
 
Furthermore, two sham procedures were conducted to ensure the success of sham acupuncture 
and to minimize the non-specific effects of needling. This is discussed in the following 
Section 10.3. In addition, the success of blinding was measured. From the literature, there are 
two methods to assess this item in acupuncture studies. The first operates as a surrogate for 
testing blinding, and tests for psychological impact of the real and sham interventions. The 
credibility of the interventions is assessed by questions, such as whether the participant would 
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recommend the treatment to other friends (Vincent and Lewith, 1995). The second method, 
employed by the current study, asks the participants directly, which group they think they 
were in. In order to minimize the perception from the treatment effects, we chose the second 
week of the treatment period to assess the credibility of the intervention. The result showed 
that blinding of participants was successful, as there was no difference between the two 
groups in the participants’ perception of group allocation and reasons.  
 
7.2.3   Sham Acupuncture Control  
The purpose of employing control intervention in a clinical trial is to elicit the belief in 
participants that they have received a real intervention. Various strategies were adopted in the 
trial to mimic real acupuncture procedure and make sham acupuncture indistinguishable from 
real acupuncture by participants. 
 
7.2.3.1   Selection of Acupuncture Points  
Sham points were 1-2 cm away form the real acupuncture points to avoid stimulating the 
meridians. This method attempts to mimic acupuncture technique and minimize afferent 
stimulation along the same meridians with the real acupoints. This method has been used by 
acupuncture trials on various diseases (Xue et al., 2004, Vincent, 1989a, Xue et al., 2007), 
including migraine studies (Linde et al., 2005a). A systematic review reported almost half (27 
out of 47) studies employed this technique (Dincer and Linde, 2003). Because the head has a 
high density of real acupoints, therefore, in the present trial only two sham points were used 
in the head. In some trials, no head sham points were chosen (Diener et al., 2006). 
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7.2.3.2   Selection of Needles  
The thickness of needles is considered as an important factor for inducing therapeutic effect in 
acupuncture, as the stimulus strength would increase with the thickness of needles (Marcus, 
1994). Therefore needles used in the sham acupuncture group are often thinner and shorter 
than those used in real acupuncture group (Xue et al., 2002). Although, some trials still 
employed same needles in two acupuncture groups (Alecrim-Andrade et al., 2006), in the 
present study, thinner needles with 0.22 mm in diameter were used in the SA group rather 
than the needles with 0.25 mm in diameter used in the RA group, in order to minimize the 
specific effects of sham acupuncture.  
 
7.2.3.3   Selection of Stimulation Mode  
In acupuncture trials, it is difficult to establish a true placebo intervention, as sham 
acupuncture is not an inert treatment (Le Bars et al., 1991), and may produce non-specific 
effects (Birch, 2006), such as the analgesic effects produced via diffuse noxious inhibitory 
control (DNIC) by simply piercing the skin (Le Bars et al., 1991). Even though conducting 
standardised sham needling method on non-acupoints by the same acupuncturist, it is 
impossible to eliminate the non-specific effects of sham acupuncture, because there are other 
variables considered as potential modifiers of needling effects, such as depths of insertion, 
manipulation of the needle, etc. For these reasons, sham acupuncture often involves shallow 
needing and without eliciting Deqi, which is a level of stimulation essential to traditional 
Chinese acupuncture. The results of previous clinical trials supported that success was higher 
in patients who reported feeling of Deqi (Lundeberg et al., 1988). 
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Two methods of stimulation were employed in the current study. For distal points on the arms 
and legs, needles were shallowly inserted to a 2 mm depth as the depth of insertion is 
considered as an important factor for inducing therapeutic effect in acupuncture, and has been 
demonstrated to be in proportion to the stimulus strength (Marcus, 1994). It is the most 
popular method of sham acupuncture (Dincer and Linde, 2003).  
 
For the two sham points on the head, blunt acupuncture without insertion of needles into the 
skin was used.  This method of non-invasion is reported as the second popular sham 
technique in acupuncture trials by a review (Dincer and Linde, 2003) and used by other 
acupuncture studies for migraine (Linde et al., 2004) and for tension-type headache (Karst et 
al., 2001). Especially, in some trials for pain related conditions, where penetration of the skin 
is commonly thought of as the single most important mechanism, the blunt acupuncture 
method was widely employed (Linde et al., 2004, Streitberger and Kleinhenz, 1998). The 
validity of this method has been demonstrated by White’s study (2003). Furthermore, a 
systematic review showed that shallow invasive sham needling within the dermatome of the 
diseased area was almost as effective as RA (Sánchez Aranjo, 1998), indicating non-invasive 
procedure should be used on the head points when studying the effect of acupuncture on 
headache.  
 
Finally, in order to ensure the credibility of the sham acupuncture, participants with few 
acupuncture experience were recruited, therefore they could not identify the sham 
acupuncture according to the past experience. Such criterion has been used in most 
acupuncture studies (Berman et al., 2004, Xue et al., 2007, Alecrim-Andrade et al., 2008). 
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7.2.4   Acupuncture Protocol 
Number and frequency of treatment sessions are of considerable concern as they may be 
reasons for negative outcomes of acupuncture studies (White et al., 2001). Although, to date 
there is no standard treatment protocol available for acupuncture studies. A systematic review 
on chronic pain revealed that studies in which participants received six sessions or more were 
significantly more likely to have positive findings than the studies with fewer sessions did 
(Ezzo et al., 2000). Ceccherelli and his colleagues (2000) suggested that the study with twice 
per week treatment was more successful than those with weekly treatment. This option was 
supported by the result of the systematic review of Chinese literature (Chapter Five). 
 
In the current clinical study, twice per week treatment was applied for the first four weeks, 
then frequency of treatment gradually reduced to once per month. This gradual reduction in 
treatment frequency is commonly used in clinical practice to consolidate the effects achieved 
by the first eight weeks, and to avoid recurrent headache from abrupt withdrawal of 
acupuncture. Totally, 16 sessions of treatment were delivered in 20 weeks, which is a quite 
long treatment period. 
 
This method has been used in an acupuncture study for osteoarthritis in the knee (Berman et 
al 2004), which consisted of a total of 23 treatments during 26 weeks (eight weeks of twice 
treatments per week, then once per week for another two week followed by four weeks of 
once per fortnight, then monthly treatment for another 12 weeks). However, such long 
treatment period was seldom applied by other acupuncture studies for migraine except for one 
study (Allais et al., 2002). For instance, in Linde (2005a) and Alecrim-Andrade’ studies 
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(2008), 12 and 16 treatment-sessions were conducted in 8 and 12 weeks respectively. In 
Allais’ study (2002), 24-week treatment period was used, and acupuncture was compared 
with western medication and their study findings revealed acupuncture was adequate for 
migraine prophylaxis. One limitation of Allais’ study is that once-a-week treatment was 
conducted for the first 8 weeks, which may weaken the effect of acupuncture compared with 
twice per week treatment.  
 
Point selection is also important element in successful treatment. Commonly acupuncturists 
should make the treatment plan based on individual situation, including the choice of points, 
or method of stimulation (Sun, 1998). However the superiority of individual treatment in 
comparison with formula acupuncture has not been demonstrated in clinical trials (White et 
al., 2001).  
 
In the present study the treatment method adopted a semi-structured acupuncture prescription 
which included four mandatory acupoints plus up to six aupplementary acupoints chosen 
according to the individual’s syndrome differentiation based on signs and symptoms. All four 
mandatory acupoints are most commonly used points for migraine as identified from 
systematic review of Chinese literature (Chapter Five), and three of them are in the top five 
frequently used acupoints of the systematic review of English literature (Chhapter Four). 
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7.2.5   Effectiveness of Acupuncture 
7.2.5.1   The Effect of Acupuncture on the Frequency of Migraine 
The results of the present clinical trial show that acupuncture could reduce the frequency of 
migraine during the treatment period. Accordingly, the numbers of respondents was higher in 
the RA group than that in the SA group. During the first eight weeks of treatment, the number 
of attack days reduced quickly in the RA group and continued to reduce throughout the rest of 
the treatment period, which is in agreement with those of Alecrim-Andrade (2008) in their 
study on acupuncture for migraine. However, In Alecrim-Andrade’s study, the respondent 
rate which is more than 50% improvement in the frequency, was used. Such outcome measure 
is not so sensitive as the mean and SD. According to the Guidelines for Controlled Trials of 
Drugs in Migraine (2000), respondent rate is a relatively insensitive measurement. It can only 
be used to identify a subgroup of respondents in post hoc analysis. 
 
The findings on migraine frequency of the current study demonstrated that the RA is 
significantly better than SA, which was different with some other studies (Linde et al., 2004, 
Linde et al., 2005a, Alecrim-Andrade et al., 2006). These authors reported that RA and SA 
both contributed to the reduction of frequency, thus, resulting in no significant difference in 
frequency reduction between RA and SA groups. The success of frequency reduction in the 
current study may be due to the fact that all recruits in this study had higher frequency of 
migraine per month at baseline than other studies. They had five days or more per month. A 
study with 284 migraineurs and 17 tension-type headache patients found that obvious 
improvement in the number of days with migraine appeared in the participants with more than 
four days with headache per month (Vickers et al., 2004a). Our study seems to support this 
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claim. A second reason for producing positive results may be our treatment regime. To this 
date, our study of acupuncture for migraine has the longest treatment period of 20 weeks 
among all previous studies. The treatment protocol started with higher number of acupuncture 
sessions of twice per week and then gradually decreased to once a week, then once a fortnight 
and finally once a month towards the end. Such regime is quite different from previous 
published trials of less than 12 weeks treatment-period (Streng et al., 2006, Diener et al., 
2006). Further, the sham acupuncture in this study which had been designed to optimally 
minimize non-specific effects might also contribute to the success (detailed see Section 7.2.8 
Placebo Effects).  
 
7.2.5.2   The Effect of Acupuncture on the Duration of Migraine 
Although RA acupuncture reduced duration of each migraine attack in the RA group, there 
was no group different on this measure in this study. Two studies conducted by 
Alecrim-Andrade and her colleagues (2008, , 2006) demonstrated that acupuncture reduced 
the total hours in pain per four weeks. However, these studies employed the widely used 
measurement method of Headache Index (Liguori et al., 2000, Wylie et al., 1997). Results 
obtained from Haedache Index should be considered with care because they combined the 
duration of each attack with the frequency of migraine attack. It is important to understand 
that decrease in the frequency of attack alone can contribute to a reduction of the total number 
of hours in pain per four weeks. This assessment method is different from our single measure 
of hours per attack. We chose this approach since in most cases where a decrease in total 
hours of pain is found, this is due to a decrease in frequency attacks (International Headache 
Society Clinical Trials Subcommittee, 2000). To date, there is only one other study (Hesse et 
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al., 1994) that also used the same single measurement of duration of migraine alone as in our 
study.  They also reported no significant difference in total hours of pain per four weeks 
between the two groups. This difference of results by the two different measurement methods 
clearly demonstrates possible bias due to assessment methodology. 
 
7.2.5.3   The Effect of Acupuncture on the Intensity of Migraine 
The severity of migraine tested by VAS slightly decreased in both groups, without significant 
group difference being detected. Such findings are consistent with other migraine studies 
(Linde et al., 2004, Melchart et al., 2003a, Hesse et al., 1994), as well as tension-type 
headache studies (Karst et al., 2001, White et al., 2000). However, severity assessed by a 
Six-Point Scale revealed significant group difference in current study. This anomaly in the 
results in severity between VAS and Six-Point Scale could be explained by the higher 
sensitivity and user-friendly nature of the latter scale. Generally, the six-point scale was 
described by words, such as “0” means no headache; “4” means very severe headache: I find 
it difficult to concentrate and can do only undemanding tasks. This scale is easier to use than 
the VAS. Moreover, the VAS are likely to be too complicated to use in long-lasting 
prophylactic RCTs (International Headache Society Clinical Trials Subcommittee, 2000). 
Vickers and his colleagues (2004a) used the Six-Point Scale for chronic headache patients and 
found that the scores were significantly lower in the acupuncture group. Some studies 
(Alecrim-Andrade et al., 2008, Alecrim-Andrade et al., 2006) chose a brief Four-Point Scale, 
and found no significance between the two groups.  
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7.2.5.4   Quality of Life 
Recent population-based studies have demonstrated that migraine impairs quality of life due 
to high frequency of attack and compromised physical, mental and social functioning 
(Terwindt et al., 2000). The SF-36 questionnaire is a commonly used outcome measure 
instrument for evaluating the efficacy of an intervention on quality of life. In this study, we 
used MSQOL questionnaire, based on the SF-36, but specifically for the migraine sufferers, 
assessed three aspects, namely, role function-restrictive, role function-preventive and 
emotional function. MSQOL was introduced in 1997, and has been widely used for migraine 
studies involving various therapies other than acupuncture (Shevel, 2007, Spigt et al., 2005) 
and survey based studies (Vos and Passchier, 2003), but has not been used in acupuncture 
studies for migraine.  
 
The effectiveness of acupuncture in improving QoL of pain conditions in certain aspects has 
been supported through RCTs (Jena et al., 2008, Coeytaux et al., 2005). On the other hand, 
some studies stated that acupuncture cannot achieve significant improvement when compared 
with sham acupuncture (Jubb et al., 2008, Grant et al., 1999). In the present study, the role 
function – preventive and emotional function in RA group demonstrated a significant 
improvement when compared with SA group. This may be due to the reduction of frequency 
alone. 
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7.2.5.5   Medication Consumption 
The first line of anti-migraine agents normally taken by migraine sufferers for acute pains and 
prophylaxis are the analgesics. The type of rescue medication took by migraineurs are 
analgesia for acute pain, anti-migraine agents normally taken when the first symptoms of 
migraine occur. Alecrim-Andrade (2008) pointed out that most migraineurs used more than 
two types of medication. In the current study, 90% participants took either simple or 
compound analgesics, which is consistent with figures in other migraine studies (Streng et al., 
2006) which reported 76% with simple and 19% with compound analgesics.  
 
Our study is among the few acupuncture studies using the MQS to measure consumption of 
analgesics, rather than by pill counts or by number of patients who take analgesics. At present, 
there are numerous different types of pain killers with various analgesic strengths. Therefore, 
simple pill counts of analgesics do not tell the types of medication nor the total medication 
weight. Thus, the patient’s strength of medication consumption is not truthfully reflected. In 
our study real acupuncture treatment achieved reduction of analgesics more quickly for acute 
pain as assessed by MQS, than did sham acupuncture. Similar findings were also detected by 
other studies (Allais et al., 2002, Vickers et al., 2004b) in which treatment effects were 
measured by pill counts and MQS respectively. This reduction included all types of 
medications. This can be explained by our finding that the frequency of attack was 
significantly reduced in the RA group. Consequently, a lower number of days with migraine 
would result in a reduced demand for medication consumption, simple or compound 
analgesics included.  
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Around half of participants took anti-migraine drugs or prophylactic drugs in this study. 
However, we could not compare our results with other relative migraine studies, as these 
published studies did not report the consumption of each type of medications as discussed 
above. 
 
7.2.6   Safety 
The safety of acupuncture treatment is an important consideration in the practice of Chinese 
medicine (White, 2004). Some surveys (Ernst and White, 2001, Melchart et al., 2004b) have 
shown that acupuncture is well tolerated and that serious complications are rare events. 
Although a number of AEs like pneumothorax have been reported by other studies, such 
events are rare and generally associated with poorly trained and unlicensed acupuncturists 
(Birch, 2004).  In our study only minor AEs were encountered. The type of AEs and their 
incident rate of 9% in the RA group is lower than the 15% reported in a survey conducted in 
the United Kingdom, further confirming that acupuncture is a relatively safe form of 
treatment technique (MacPherson et al., 2001). 
 
Apart from the common AEs associated with acupuncture such as needling pain and bruising, 
a peculiar AE, a recurrent headache in the first couple of treatment sessions, was reported nine 
times by our participants. The headache, however, did not lead to a real migraine onset, and 
disappeared after resting. Such AE phenomenon was also reported by one other acupuncture 
study for migraine (Allais et al., 2002). Furthermore, according to the record of diary, some 
participants actually experienced more migraine attacks in the first four-weeks after 
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acupuncture. Whether this observation was a reaction to acupuncture or simply a coincidence 
of the individual’s migraine development is unclear.  
 
7.2.7   Drop-out Rate 
Although our study has the longest acupuncture treatment period compared to other migraine 
prophylactic studies (Streng et al., 2006), the drop-out rate was low at 6%, a figure similar to 
a recently published study of acupuncture for migraine (Alecrim-Andrade et al., 2008). This 
result indicates that a long-term treatment protocol can be well tolerated and accepted by most 
of the patients.  
 
7.2.8   Placebo Effect 
Some improvements in the SA group had been observed in certain outcome measures during 
the treatment period although this response did not negate the overall statistical significance 
group difference. This SA improvement is most likely the consequences of the placebo effects 
and non-specific effect of acupuncture, such as the analgesic effect resulting from skin 
piercing. Pervious studies have argued that needling the sham points located outside of 
merdian but within the same dermatome as the treatment acupoints have some treatment 
effects, as even the shallow insertion can activate the diffuse noxious inhibitory control 
(DNIC) (Berman, 2001). Linde et al.(2005a) used invasive sham acupuncture in migraine 
patients, and found that the results showed a meaningful improvement of pain, although 
statistically insignificant. And most trials comparing real acupuncture with such sham 
acupuncture technique (i.e., needling slightly away from the active acupoint, but within the 
same dermatome) have very often yielded negative results between the RA and SA groups for 
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various conditions. This may lend support to the argument to the involvements of DNIC. 
Furthermore, Sanchez Aranjo (1998) reviewed 100 clinical trials and revealed that putting 
needling close to active acupoints but outside of the meridians can produce greater placebo 
effect than putting needles on different nerve segment, or dermatome. On the other hand, if 
sham acupuncture without puncture were employed, acupuncture clinical trials showed 
positive results more frequently (Richardson and Vincent, 1986). The current study has 
adopted the non-puncture method by using blunt needling for the sham points in the head. 
Undoubtedly, such blunt sham method could minimize the non-specific effects of invasive 
needling even though no scientific evidence is yet available to support that it is inert. 
Nevertheless, it must be pointed out that, the participants’ belief in positive results of the 
acupuncture treatment, the regular visits to the acupuncturist and the subjective belief of the 
magic power of the non-conventional therapies may all be the contributing factors to placebo 
effect and all could enhance the therapeutic effect. In the current study, nearly 30% SA 
participants responded positively to the sham treatment. This is comparable to data by other 
studies (Linde and Rossnagel, 2004, Diener et al., 2002, Brandes et al., 2004). Furthermore, 
there is some evidence that medical devices induced a much higher placebo effect than 
medications did (Kaptchuk et al., 2000). Especially the subcutaneous placebo had higher 
efficacy (34%) than oral application does (26%) (Diener, 2001). Even the blunt needling was 
still greater than placebo pills (Kaptchuk et al., 2006). A systematic review reported that there 
was a 46% placebo response for pain relief and 21% for pain-free in pharmacological 
pediatric migraine trials (Fernandes et al., 2008). 
 
  203 
However, these placebo effects also exist in the RA group. Our significant results were based 
on difference between the two groups. Therefore, the placebo effects do not invalidate our 
conclusion of statistically significant positive outcomes. 
  
7.2.9   Limitations and Implications for Future Studies  
There are several limitations in the present study, which need to be addressed in future 
studies. 
 
The main limitation is the small sample size. Inadequate sample size can skew the findings 
(Moher et al., 1994) and this has been a common problem for acupuncture trial (ter Riet et al., 
1990, Melchart et al., 2001). The originally targetted sample size of the present study was a 
total of 66 participants, based on a migraine study which achieved statistical significance 
between acupuncture and waiting list groups on the frequency of headaches. In the end, our 
study only managed to recruit fifty participants. There are several reasons, which may 
contribute to the difficulties of recruiting participants. First of all, with the increasing 
popularity of acupuncture, it is difficult to enroll participants who have no previous 
acupuncture experience. Surveys reveled that headache sufferers accounted for about 10% of 
visits to acupuncturists is in USA (Burke et al., 2006), and more than 25% in Germany 
(Endres et al., 2007b). In order to ensure the success of the blinding of participants, we 
recruited only subjects who had not received acupuncture treatment for headache in the last 
six months. Secondly, our criterion of recruiting only participants who had five days or more 
of migraine per month excluded many interested migraine sufferers who had a lower 
frequency of attack, thus limiting our recruitment capability. Finally, the long-treatment 
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period might also be an obstacle or impediment. Some people were unwilling and or unable to 
commit themselves for such a long period of time. 
 
The Oxford Pain Validity Scale, which is designed to assess the quality of clinical trial for 
pain conditions, has defined trials with 40 or more participants as satisfactory sample size. 
Nevertheless, a small sample size is still possible if more disease-specific primary outcome 
measures, such as frequency or intensity of migraine headaches, are chosen (Melchart et al., 
2001). Consequently, in the current study, there was still sufficient power to detect significant 
changes in frequency and intensity of migraine. 
 
In addition, sham acupuncture method is still a controversial issue. So far no universal 
agreement on an inert method of sham acupuncture is available (Birch, 2006). The 
non-specific effects produced by shallow needling may reduce the difference in effect size of 
real and sham acupuncture. 
 
Another potential limitation is that frequent migraine sufferers might have a higher 
expectation for acupuncture than normal migraineur do. Previous studies have shown that the 
expectation caused greater activation than skin prick (Pariente et al., 2005). In this project all 
participants were volunteers. One of the reasons that they joined the study was that they learnt 
from others’ experience that acupuncture was helpful. 62% participants are in this category. 
They might have expected a good treatment response. Although one would argue that the 
same expectation also occurred in the sham acupuncture group. The exact contribution of this 
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factor is unknown in the present study. Future studies should include a measurement of 
expectations. 
 
In conclusion, acupuncture is potentially effective in preventing migraine attacks in short term. 
Its long-term effect is presented and discussed in the following chapter.  
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CHAPTER EIGHT: LONG TERM EFFECTS OF 
ACUPUNCTURE TREATMENT ON MIGRAINE 
 
This chapter presents the analysis of data collected during the 12-week follow-up I period of 
the study and the 12-month follow-up II period. Independent-sample t-tests were used to 
detect the differences between the two groups in weeks 4, 8 and 12, and at the end of 12 
months. Furthermore, paired-sample t-tests were used to compare data sampled in weeks 4, 8 
and 12 of follow-up I, as well as data from the end of follow-up II, with data from the end of 
treatment. This data was used to assess the long-term effects of acupuncture. The significant p 
value was set at 0.05/3=0.0167 with Bonferroni correction.  
 
For the follow-up I data, ITT analyses were used. The data of three drop-out participants was 
replaced using the Missing Value Analysis function in SPSS, except for MPQ and MSQOL. 
A detailed description of data handling is presented in section 6.7.3. In total, 50 participants 
were included.  
 
For follow-up II, the data of 25 participants who sent their dairies back was analyzed. Thus 
per protocol analyses were employed. 
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8.1    Results of Twelve-week Follow-up I Period  
8.1.1   The Effects of Acupuncture on the Primary Outcomes During the Follow-up 
Period 
The results of the primary outcomes data during the last phase of follow-up I are presented 
below in Table 34.  
 
Table 34: Primary outcome measurements at the end of the 12-week follow-up I period 
 
RA 
Mean (SD) 
SA 
Mean (SD) 
t - 
value 
95% CI for 
difference 
p – 
value 
Attack days (Number of 
days with migraine per 4 
weeks) 
5.12 (3.67) 9.47 (6.20) -2.99 (-7.20, -1.40) .005* 
Duration 
(Hours /attack days) 
8.17 (2.81) 8.81(4.05) -.65 (-2.61, 1.33) .52 
Highest of Pain-VAS 4.79(1.39) 4.66 (2.03) .25 (-.86, 1.11) .80 
Lowest of Pain-VAS 2.55 (1.10) 2.62 (1.65) -.18 (-.86, .72) .86 
Average of Pain-VAS 3.90 (1.03) 3.60 (1.89) .72 (-.55, 1.16) .48 
Severity of Pain 
(Six-point Likert Scale) 
2.63 (.39) 2.87 (.56) -1.76 (-.52, .04) .087 
Note: * indicates statistically significant difference at the 0.05 level (2-tailed) 
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8.1.1.1   The Effect of Acupuncture on the Reduction of Frequency of Migraine 
During the 12-week follow-up I period, the RA group had fewer numbers of migraine days 
when compared with the SA group. At the end of this follow up period, the RA group had 
5.12 (3.67) days with migraine, which was significantly less than the SA group 9.47 (6.20) 
days with migraine (p = 0.005).  
 
Within-group analysis using the paired-sample t–tests showed the numbers of days with 
migraine in the RA or SA did not change significantly during the 12-week follow-up period 
when compared with the end of treatment (Figure 39). This  indicates the effects of 
acupuncture were maintained throughout the follow-up period. 
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Figure 39: The time course of the number of days with migraine in the two groups during the 
follow-up I period (Mean and SEM) 
Pw4, 8 and 12 correspond to the post-treatment week 1-4; week 5-8 and week 9-12 
* indicates that at the Pw4, Pw8 and Pw 12, the mean number of attack days 5.87 (1.07), 5.62 
(0.88) and 5.12 (0.73) in RA was significantly less than those in SA, 9.85 (1.45), 9.32 (1.2) 
and 9.47 (1.27). 
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At the end of the 12-week follow-up period, the number of participants who achieved more 
than a 50% reduction from the baseline, i.e., the respondent is listed in Table 35. Significant 
group difference was revealed (p = 0.002) with the RA having more respondents.  
 
Table 35: The number of participants who respondent to the treatment at end of follow-up 
period 
 
RA 
(n, %) 
SA 
(n, %) 
Total χ2- value p - value 
Respondent 
17 
(65.38%) 
5 
(20.83%) 
22 
Non-respondent 
9 
(34.62%) 
19 
(79.17%) 
28 
Total 26 24 50 
10.05 .002* 
* indicates there was a significant difference between the two groups 
 
The numbers of respondents at the end of follow-up I period in each category of Chinese 
medicine diagnosis is listed in Table 36. The Spearman correlation indicates the significant 
relationship between the respondent rates at the end of follow-up I and the different Chinese 
medicine syndromes (p = 0.034). The participants who experienced migraine from Ascending 
Hyperactivity of Liver Yang had the poorest response rates. 
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Table 36: Number of participants who respondent to the acupuncture in each group of Chinese 
medicine syndrome at the end of follow-up period I 
 
Chinese Medicine diagnosis Respondent Non-respondent 
Ascending Hyperactivity of Liver Yang 4 14 
Deficiency of Both Qi and Blood 9 7 
Phlegm Retention 5 5 
Blood Stasis 4 2 
Chi-square (df) 5.84 (3,50)* 
P  .12 
Spearman Correlation -.30 
P  .034** 
* 3 cells (37.5%) have expected count less than 5. The minimum expected count is 2.64. 
**Based on normal approximation. 
 
8.1.1.2   The Effect of Acupuncture on the Reduction of Duration of Migraine 
No significant difference in the duration of migraine was detected between the two treatment 
groups at the end of the 12-week follow-up period (p = 0.52). 
 
Paired-sample t–tests showed that the duration of migraine in the RA group increased rapidly 
during the follow-up period, from 5.96 (3.31) hours at the end of the treatment to 8.17 (2.81) 
hours at the end of the follow-up period. There was a significant difference in the duration 
measured at the end of the follow-up period when compared with the data from the end of 
treatment (p < 0.001). Contrary to this, the changes in the SA group were not statistically 
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significant during the same period [7.99 (4.49) to 8.81(4.05) hours] (Figure 40). Such data 
illustrates the reduction of duration of migraine observed during the treatment period in the 
RA group was maintained for eight weeks after treatment. 
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Figure 40: The trend of duration of migraine in two groups during follow-up period (Mean and 
SEM) 
Pw4, 8 and 12 correspond to the post-treatment week 1-4; week 5-8 and week 9-12 
+ indicates that, the mean of duration of migraine attacks at the end of Pw 12 was 8.17 (0.56) 
in RA was significantly more than those at the end of Tw20 5.92 (0.66). 
 
8.1.1.3   The Effect of Acupuncture on the Reduction of Intensity of Migraine 
There were no significant differences between the RA and SA groups in terms of highest (p = 
0.80), lowest (p = 0.86) and average (p = 0.48) VAS pain and the average pain on the 
Six-Point Likert Scale (p = 0.087) at the end of the follow-up period. 
 
In the RA group, the highest and lowest level of pain on VAS, and average pain in the 
six-point Likert Scale, slightly fluctuated without reaching statistical significance during the 
follow-up period (p = 0.45; 0.49 and 0.027 respectively) when compared with the last phase 
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of treatment. The average pain levels measured using VAS significantly increased (p = 0.006) 
after the termination of the acupuncture treatment.  
 
In the SA group, no significant differences were detected with respect to any of the highest, 
lowest and average levels of pain on VAS, or the average value pain on the six-point Likert 
Scale at any stage of the follow-up period when compared with the end of treatment data. See 
the following graphs in Figure 41 
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Figures 41: The intensity of migraine of the two groups during the 12-week follow-up period, 
presented using mean (SEM) 
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Continued Figures 41: The intensity of migraine of the two groups during the 12-week 
follow-up period, presented using mean (SEM) 
Pw4, 8 and 12 correspond to the post-treatment week 1-4; week 5-8 and week 9-12 
+ indicates the intensity of migraine significantly changed within the RA group at the Pw12 
3.90 (0.21) when compared with Tw20 3.01(0.36) (p < 0.0167). 
 
  214 
8.1.1.4   The Effect of Acupuncture on the Reduction of Accompanying Symptoms of 
Migraine 
There were no significant differences between the RA and SA groups at the end of the 
follow-up period. Results of paired-sample t-tests showed that there were no significant 
changes in either group during any stage of the 12-week follow-up period (Figure 42). 
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Figure 42: The number of accompanying symptoms of the two groups during the 12-week 
follow-up period, presented using mean (SEM) 
Pw4, 8 and 12 correspond to the post-treatment week 1-4; week 5-8 and week 9-12 
 
  215 
8.1.2   The Effect of Acupuncture on the Secondary Outcomes During the Follow-up 
Period 
All the secondary outcomes data from the last phase of follow-up were analysed and are 
presented in Table 37. 
 
Table 37: Secondary Outcome measurements at post-treatment weeks 8 to 12 (last phase of 
follow-up period) 
 
RA 
Mean (SD) 
SA 
Mean (SD) 
t - 
value 
95% CI for 
difference 
p - 
value 
PRI-S 11.13 (4.24) 14.09 (8.99) -1.47 (-7.07, 1.13) .15 
PRI-A 3.30 (2.13) 4.36 (3.10) -1.42 (-2.56, .44) .163 
PRI-E 1.58 (.86) 2.59 (1.32) -3.23 (-1.64, -.38) .002* 
McGill 
PRI-M 5.50 (.86) 5.85 (2.85) -.46 (-1.92, 1.21) .651 
FR 74.18 56.31 3.19 (6.52, 29.21) .003* 
FP 80.77 63.13 2.87 (5.08, 30.21) .007* MSQOL 
EF 79.33 58.80 3.08 (7.06, 33.99) .004* 
MQS 10.99 54.27 -3.19 (-69.79, .002* 
Medication 
Pill 3.46 (9.84) 10.10 -1.63 (-14.93, 1.64) .113 
Note: * indicates statistically significant difference at the 0.05 level (2-tailed) 
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8.1.2.1   Pain Assessed with McGill Questionnaire 
For MPQ, the only significant difference between the two groups was PRI-E measured at the 
end of the follow-up period (p = 0.002). (Table 38), 
 
Table 37: Pain assessed with MPQ in each group at the Tw 20 and Pw 12 
Treatment week 20 Post-treatment week 12 
RA 
n = 26 
SA 
n = 24 
RA 
n = 26 
SA 
n = 24 
 
Mean SD Mean SD Mean SD Mean SD 
PRI-S 13.08 8.80 15.83 11.55 11.13 4.24 14.09 8.99 
PRI-A 3.96 3.01 4.79 2.75 3.30 2.13 4.36 3.10 
PRI-E 2.08 1.26 2.83 1.46 1.58 .865 2.59 1.32 
PRI-M 5.62 3.40 6.13 3.49 5.50 2.64 5.85 2.85 
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Results of paired-sample t-tests for within group effects showed that there were no significant 
changes in either group at any stage of the 12-week follow-up period when compared with the 
end of treatment data (Figure 43). 
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Figure 43: The trend of four dimensions of MPQ in two groups during follow-up period (Mean 
and SEM) 
Pw4, 8 and 12 correspond to the post-treatment week 1-4; week 5-8 and week 9-12.  
* indicates that at the end of follow-up period I, the mean PRI-E 1.58(0.17) in RA was 
significantly less than those in SA, 2.59 (0.27). 
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Continued Figure 42: The trend of four dimensions of MPQ in two groups during follow-up 
period (Mean and SEM). Pw4, 8 and 12 correspond to the post-treatment week 1-4; week 5-8 
and week 9-12. * indicates that at the end of follow-up period I, the mean PRI-E 1.58(0.17) in 
RA was significantly less than those in SA, 2.59 (0.27). 
 
8.1.2.2   Quality of Life 
Statistically significant differences in all of the three categories were detected between the 
two groups at the end of the follow-up period (FR p = 0.003, FP p = 0.007, EF p = 0.004), 
which indicated the QoL of the participants in the RA group maintained after discontinuation 
of treatment.  
 
Paired-sample t–tests revealed a statistically significant increase in FP for the RA group, but 
not in FR or EF dimensions between the end of treatment and the follow-up periods (p = 0.03) 
(Figure 44), indicating the effect of RA on FR and EF of QoL lasted for 12 weeks. 
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Figure 44: The trend of three dimensions of MSQOL in two groups during follow-up period 
* indicates significant difference between two groups at that time point. + indicates significant 
change within the RA group at the time points when compared with tw20 (at the end of 
treatment) 
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8.1.2.3   Medication Consumption 
Mean and SD of medication consumption are presented in Table 39. Figure 45 illustrates the 
changes in medication consumption as measured with the MQS and pill counts. Whilst the 
consumption of both acute and preventative medication in the RA group was stable during the 
follow-up period, the SA use of medications for acute pain reduced. Nevertheless, there was 
no within-group difference in these two measures during the follow up periods (p > 0.0167). 
The significant group difference in MQS was revealed at the eighth week of the follow-up 
period (p = 0.013). 
 
Table 39: The medication consumption in each group at the tw 20 and pw 12 
Treatment week 20 Post-treatment week 12 
RA 
n = 26 
SA 
n = 24 
RA 
n = 26 
SA 
n = 24 
 
Mean SD Mean SD Mean SD Mean SD 
MQS 20.81 46.43 68.92 81.19 10.99 24.26 54.27 62.36 
Pill 
Account 
4.54 12.21 10.54 19.31 3.46 9.84 10.10 17.63 
 
Paired-sample t-tests did not identify any within-group difference indicating that the reduction 
of MQS observed at the end of the treatment period in the RA group continued to improve for 
12 weeks after treatment. 
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Figures 45: Trends in medication scale of two groups during follow-up period 
* indicates significant difference between two groups at that time point.  
 
8.2    Results of Follow-up Period II 
 
At the 12th month after the termination of treatment, four-week diaries were sent out to 
participants to record their migraines. Only 25 of our 47 participants sent their questionnaire 
back, 16 from the RA group and nine from the SA group. All the available data was 
summarised into mean and SD and is presented in Table 40. No significant group difference 
was detected in any outcome measures.  
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Table 40: Primary and secondary outcome measurements at the end of the one-year follow-up 
period II 
 
RA 
Mean (SD) 
SA 
Mean (SD) 
t - 
value 
95% CI for 
difference 
p – 
value 
Attack days (Number 
of days with migraine 
per 4 weeks) 
11.31 (5.47) 12.33 (5.57) -.45 (-5.77, 3.73) .66 
Duration 
(Hours /attack days) 7.51 (2.60) 7.61 (3.50) -.09 (-2.64, 2.43) .93 
Highest of Pain-VAS 5.81 (1.01) 4.91 (2.44) 1.06 (-1.75, 1.21) .71 
Lowest of Pain-VAS 2.77 (1.45) 3.04 (2.12) -.38 (-1.00, 2.82) .31 
Average of Pain-VAS 4.21 (1.08) 3.39 (2.08) 1.10 (-.83, 2.47) .29 
Severity of Pain 
(Six-point Likert 
Scale) 
3.11 (0.46) 3.31 (0.71) -.83 (-.68, .29) .42 
PRI-S 21.56 (8.11) 19.67 (10.82) .50 (-5.98, 9.78) .62 
PRI-A 6.5 (2.45) 6.22 (3.40) .23 (-2.18, 2.74) .82 
PRI-E 3.56 (1.15) 3.75 (1.18) -.40 (-1.19, .81) .70 
McGill 
PRI-M 7.25 (2.52) 8.11 (2.89) -.78 (-3.15, 1.43) .44 
FR 46.36 (15.21) 50.07 (18.97) -.54 (-18.03, 10.61) .60 
FP 61.97 (15.39) 64.28 (17.80) -.34 (-16.33, 11.71) .74 MSQOL 
EF 49.52 (16.98) 56.63 (21.05) -.92 （-23.06, 8.83） .37 
MQS 78.18 (79.06) 75.06 (50.77) .10 (-59.50, 67.74) .92 
Medication Pill 
Account 
10.56 (14.81) 7 (9.90) .64 (-7.91, 15.03) .53 
 
Furthermore, the paired-sample t-tests were conducted between the data of baseline and 
follow-up II, and revealed that no within-group difference was detected in either RA or SA 
group; this indicated the effects of acupuncture ceased after one-year (Table 41) with the 
migraine of participants returning to baseline situation. However, after 12 months, the number 
of days with migraine in the RA was slightly better than baseline data. 
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Table 41: Comparisons between baseline and follow-up II in the RA and SA groups 
 
Within RA 
Group 
Mean (SD) 
p – 
value 
Within SA 
Group 
Mean (SD) 
p – 
value 
Attack days (Number of days 
with migraine per 4 weeks) .94 (1.77) .051 .33 (1.4) .50 
Duration 
(Hours /attack days) .29 (1.01) 2.76 -.10 (.48) .57 
Highest of Pain-VAS .17 (.43) .13 .04 (.58) .83 
Lowest of Pain-VAS .10 (.67) .54 -.17 (.84) .55 
Average of Pain-VAS .29 (.87) .20 .54 (1.06) .16 
Severity of Pain (Six-point 
Likert Scale) .10 (.50) .45 -.08 (.25) .34 
PRI-S -.19 (1.22) .55 -.17 (2.19) .82 
PRI-A -.01 (1.2) .97 -.46 (1.77) .46 
PRI-E -.17 (.70) .34 -.49 (1.39) .32 McGill 
PRI-M .31 (1.0) .24 .09 (1.3) .84 
FR -.65 (6.55) .70 .57 (12.04) .89 
FP .84 (6.55) .61 2.39 (6.24) .28 MSQOL 
EF -1.77 (11.28) .54 .04 (11.11) .99 
MQS 4.23 (24.06) .49 11.39 (28.54) .26 Medication 
Pill Account -2.38 (8.87) .30 0 (3) 1 
 
8.3    Summary of the Long-term Effects of Acupuncture 
In summary, during the 12-week follow-up I period, the anti-migraine effect of acupuncture 
on the frequency of attack days and QoL was maintained for at least 12 weeks after the 
discontinuation of the treatment in both the RA and SA groups. The RA group also 
experienced a continuous reduction in the consumption of medication. The duration and 
intensity of migraine increased after the end of the treatment in both groups, and the effect 
was maintained for eight weeks only in the RA group. After the one-year follow-up II period, 
all the effects of acupuncture ceased.  
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8.4    Discussion 
Our study demonstrated the long-term effects of acupuncture lasted up to three months after 
the cessation of treatment. The effects depend on the type of measures utilized with frequency, 
medication consumption and QoL having better outcomes in the RA group. Such long-term 
effects of acupuncture are also observed in most well-designed, recently-published migraine 
studies which show a four month follow-up period reducing analgesics taken (Allais et al., 
2002) and a six month follow-up period reducing the intensity and days with migraine (Diener 
et al., 2006) respectively. Furthermore, similar findings on the long-term effect (up to 12 
months) of acupuncture in reducing frequency, analgesics taken and headache index were also 
reported in some tension-type headache studies (Tavola et al., 1992). 
 
Except for the number of days with migraine in the RA group, all the features of migraine 
went back to the baseline situation 12 months after the termination of treatment. However, 
such findings conflict with Vickers’ study (2004a) where the effect of acupuncture lasted for 
12 months in frequency, intensity and prophylactic medication consumption. Similarly, in 
Vincent’s study (1989a), the group difference in pain scores (combination of frequency and 
intensity) still remained substantial at the 1-year follow-up. Moreover, the same 
measurements were used to assess the frequency, intensity and medication in both our study 
and Vickers’ study. The larger sample size of 379 participants and “avoid acupuncture” 
control intervention of Vincent’s study may have contributed to the contrasting findings. 
 
The discrepancy in outcomes might be explained by a high drop-out rate from the follow-up 
period II in the current study. As described in Section 7.2.7, we had a low drop-out rate at 6% 
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until the end of follow-up period I. However, during the second phase of the follow-up, half 
of participants dropped-out from the study. This situation was probably due to the rebound 
symptoms of migraine, which may have disappointed participants, and patients suffering 
severe migraine might be less likely to complete the diary. In the two other studies, the 
drop-out rate at one year was 13.3% and 17.9%, respectively (Vincent, 1989a, Vickers et al., 
2004a), much lower than the current study.  
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CHAPTER NINE: PRESSURE PAIN THRESHOLD 
 
9.1    Background of Pressure Pain Threshold (PPT) 
 
Individual pain threshold and tolerance may affect people’s experience of the pain. The 
common method of assessment of threshold is pressure pain threshold (PPT) measured with 
an algometry. Many trials have demonstrated the high reliability and validity of algometry in 
assessing the PPT (Nussbaum and Downes, 1998, List et al., 1989, Nordahl and Kopp, 2003). 
This instrument has excellent inter-examiner reliability (Antonaci et al., 1998). Nussbaum and 
Downes’ trial (1998)indicates that the reliability of algometry is enhanced when measured by 
one examiner only.  
 
The correlation between PPT and migraine is not clear. Jensen and his colleagues (1988) 
demonstrated that PPT of temporal muscle did not change during the attacks of common 
migraine nor during headache-free intervals, which is contradictory to another study (Sandrini 
et al., 1994) reporting a lower PPT during migraine attacks compared to healthy people. 
Moreover, a recent study revealed significant differences in PPTs of the neck region between 
the patients with unilateral migraine and healthy volunteers, and between symptomatic and 
non-symptomatic sides (Fernández-de-Las-Peñas et al., 2008). One other study also reported 
the lower PPTs on the symptomatic side than on the non-symptomatic side in the cranial area 
of migraine patients (Smith et al., 2006).  
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The above mentioned studies had some flaws. For example, there was no consistency of 
measuring sites between studies. The values of PPTs were measured on the neck and in the 
cephalic area in 25 migraineurs (Fernández-de-Las-Peñas et al., 2008); on the temporal 
muscles in 26 patients (Jensen et al., 1988); on the frontalis muscles in 22 patients (Sandrini et 
al., 1994) and in the cranial area in 10 migraineurs (Smith et al., 2006). PPT measured at 
different areas makes it difficult to compare between studies. Moreover none of these studies 
explored the relationship between PPTs and features of migraine., Among those few PPTs 
studies on migraine, no studies assessed the effectiveness of acupuncture on PPTs for 
migraine sufferers, although some RCTs had reported acupuncture improved PPTs in 
tension-type headache patients (Karst et al., 2000, Xue et al., 2004).  
 
Therefore, there is a need to assess the PPTs on migraine patients, investigate the 
effectiveness of acupuncture on PPTs via a well-designed RCT and explore the relationship 
between the PPTs and features of migraine.  
 
9.2    Objectives 
To determine whether manual acupuncture could change the PPT of migraine sufferers;  
To determine if there was a correlation between migraine reduction and changes in PPT. 
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9.3    Methods 
9.3.1   Subjects 
In the current study, 50 participants with migraine were recruited from local community by a 
series of media release. They took part in a randomised, sham acupuncture controlled trial as 
described in Section 6.1 and Chapters 7 and 8.   
 
9.3.2   Intervention 
Subjects were blinded to the allocation of treatment groups throughout the intervention period, 
and received either real acupuncture or sham acupuncture treatment, with a total of 16 
sessions during 20 weeks (Please see Sections 6.4.3 and 6.4.4 for detailed information). 
 
9.3.3   Regional PPT Measurement Sites 
In total, PPTs at 11 sites were measured, including 7 acupoints and 4 non-acupoints. These 
points are located in the head, face and neck area, and are listed in Table 42, and have been 
illustrated in Section 6.5.2.  
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Table 42: The points used for testing pressure pain threshold 
No. 1 Left 
No. 2 Right 
2 cm inferior to the external occipital protuberance and 2 cm lateral to the 
midline 
No. 3 Left 
No. 4 Right 
GB20: In a depression between the upper portions of the 
sternocleidomastoid muscle and the trapezius 
No. 5 Left 
No. 6 Right 
2 cm lateral to GV20, which locates on the head, 5 cun# directly above the 
midpoint of the anterior hairline, at the midpoint of the line connecting the 
apexes of both ears 
No. 7 Left 
No. 8 Right 
EX-HN5: In the temple region, in a depression about 1 cun posterior to the 
midpoint between the lateral end of the eyebrow and the outer canthus of 
the eye 
No. 9 Left 
No. 10 Right 
ST6: One finger width anterior and superior to the angle of the mandible at 
the belly of the masseter muscle when teeth clenched 
No. 11  
EX-HN3: At the midpoint of the line connecting the medial ends of the 
eyebrows 
#
cun, is a Chinese word that translates to "anatomical inch". The length of one cun is 
individualized. For instance, the distance from the eyebrow to the forehead hairline is defined 
as 3 cun. . 
 
9.3.4   PPT Measurement 
PPT was measured before the first real or sham acupuncture treatment and after the last 
treatment during the trial. Within each session, PPT of each site was measured twice, and the 
mean of the two measurements represented the PPT value of that site. 
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PPT was measured in a standard sequence from the No. 1 site to the No. 11 site with 1 kg/cm2 
increasing rate. The research assistant who measured PPT was blinded to the treatment 
allocation. Detailed methods have been described in Section 6.5.2 Pressure Pain Threshold.   
 
9.3.5   Statistical Analysis 
The percentage change in the mean PPT scores at each site before and after treatment of each 
session was used for statistical analyses.  
 
Percentage change at each site = (mean PPT post-treatment – mean PPT pre-treatment) / 
(mean PPT pre-treatment)× 100% 
 
This computation was applied because of the wide variation in the PPT values, both between 
and within subjects and across the 11 measurement sites. Moreover, no standard PPT value 
exists for migraine patients at the present time, and the PPT values cannot be compared 
between studies. The General Linear Model (GLM) was used to perform analysis of variance 
of PPT percentage change scores. Post-hoc analyses using t- tests were performed when 
examining the significant treatment effects at each site. This method of analysis has been used 
in other studies to test the effects of acupuncture on PPTs (Zaslawski et al., 2003). 
Furthermore, bivariate Pearson correlation analysis was adopted for investigating the 
correlation between PPTs and other clinically related outcomes. 
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9.4    Results 
9.4.1   Baseline PPT 
The baseline values of PPT at different sites are listed in Table 43 and the two groups were 
comparable. The PPT values were also analysed with GLM via SPSS, and a significant site 
difference was detected [F (10, 480) = 37.60, p < 0.001], indicating that the mean PPTs at 
different sites varied widely. The lowest PPT values were reported at sites No.7, No.8, No.9 
and No.10. No significant site by treatment group interaction was detected [F (10, 480) = 1.74, 
p = 0.15]. Testing for group differences across the different sites showed no significant 
differences (see Figure 46). 
 
Table 43: Baseline PPT at different sites 
Site 
No. 
RA 
n = 26 
Mean (SD) 
Kg / cm2 
SA 
n = 24 
Mean (SD) 
Kg / cm2 
t - value 95% CI for difference p - value 
1 3.35 (2.13) 2.95 (1.42) .77 (-.64, 1.43) .45 
2 3.30 (2.05) 3.28 (1.74) .05 (-1.06, 1.11) .96 
3 2.70 (1.31) 2.78 (1.27) -.24 (-.82, .65) .81 
4 2.59 (1.45) 2.79 (1.38) -.49 (-1.00, .61) .63 
5 3.03 (1.72) 3.09 (1.87) -.12 (-1.08, .96) .91 
6 3.01 (1.71) 2.92 (1.64) .20 (-.86,1.04) .85 
7 1.82 (1.19) 2.20 (1.00) -1.21 (-1.00, .25) .23 
8 1.81 (1.06) 2.28 (0.90) -1.67 (-1.03, .10) .10 
9 1.52 (0.88) 1.74 (0.88) -.89 (-.72, .28) .38 
10 1.58 (0.91) 1.80 (0.89) -.88 (-.74, .29) .38 
11 2.60 (1.56) 2.38 (1.01) .59 (-.53, .98) .56 
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Figure 46: The PPT values at different sites at baseline of the two treatment groups (Mean and 
SEM, n = 26 in RA, n = 24 in SA) 
 
Meanwhile, the PPT values were also analysed using GLM via SPSS using gender as the 
grouping variable. Although females had lower PPTs than the males [F (1, 48) = 1.91, p = 
0.17], no site by gender interaction was revealed [F (10, 480) = 0.91, p = 0.45]. There was no 
statistically significant difference between males and females across all sites (Figure 47). This 
is summarised in Table 44.  
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Figure 47: PPTs measured at the 11 sites for males and females (Mean and SEM, Female n = 37, 
Male, n = 13) 
 
Table 44: A comparison of baseline PPT by gender. 
Site No. 
Female 
n = 37 
Mean (SD) 
Kg / cm2 
Male 
n = 13 
Mean (SD) 
Kg / cm2 
t - value 95% CI for difference p - value 
1 2.99 (1.80) 3.66 (1.83) -1.15 (-1.84, .50) .26 
2 3.12 (1.90) 3.79 (1.83) -1.11 (-1.89, .55) .27 
3 2.58 (1.28) 3.20 (1.19) -1.55 (-1.44, .19) .13 
4 2.48 (1.28) 3.28 (1.62) -1.80 (-1.69, .10) .08 
5 2.82 (1.76) 3.75 (1.68) -1.65 (-2.06, .20) .11 
6 2.81 (1.70) 3.42 (1.50) -1.15 (-1.68, .46) .26 
7 1.92 (1.09) 2.24 (1.16) -.91 (-1.04, .40) .37 
8 1.93 (1.02) 2.35 (0.92) -1.30 (-1.06, .23) .20 
9 1.55 (0.87) 1.84 (0.90) -1.02 (-.86, .28) .31 
10 1.60 (0.93) 1.93 (0.77) -1.13 (-.91, .26) .27 
11 2.40 (1.16) 2.79 (1.70) -.94 (-1.25, .45) .35 
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Tests of correlations were conducted on baseline data involving frequency, duration and 
intensity of migraine and PPT values at the 11 sites. Statistically significant, but very weak 
correlations were found between the duration of migraine and PPTs measured in the neck at 
site No.3 (r = -0.30, p = 0.033), No.4 (r = -0.304, p = 0.016) and No.5 (r = -0.28, p = 0.047). 
No other significant correlations were identified.  
 
9.4.2   Percentage Changes in PPT after Treatment 
Percentage changes in PPT were analysed with the General Linear Model (GLM). There was 
a significant site difference [F (10, 480) = 4.50, p = 0.026] without a site by treatment group 
interaction [F (10, 480) = 2.41, p = 0.11] indicating that the changes in PPTs varied 
significantly among the 11 sites. Generally, the two groups showed similar trends in the PPTs 
changes across the sites (Figure 48). 
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Figure 48: The percentage change of PPTs at 11 sites in the two groups after the treatment 
(Mean and SEM, RA n = 26, SA, n = 24) 
* indicates that at the end of treatment, the mean percentage changes in PPTs of site No.7 and 
8 in RA was significantly larger than those in SA. 
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Post-hoc analyses were conducted using Independent sample t-tests. The percentage changes 
in PPT are summarised in Table 45. 
 
Table 45: The percentage changes in PPTs in the two treatment groups 
Site 
No. 
RA 
Mean (SD) % 
SA 
Mean (SD) % 
t - 
value 
95% CI for 
difference 
p - value 
1 20.78 (50.99) 8.63 (39.53) .84 (-16.99, 41.30) .406 
2 16.06 (41.66) 7.16 (53.46) .66 (-18.23, 36.04) .512 
3 26.88 (67.06) 17.40 (63.66) .51 (-27.77, 46.74) .611 
4 30.09 (65.51) 10.64 (41.96) 1.26 (-11.69, 50.60) .215 
5 33.73 (67.66) 4.29 (40.34) 1.89 (-2.10, 60.97) .067 
6 42.39 (18.88) 81.50 (70.77) 1.09 (-20.06, 67.08) .283 
7 228.48 (565.45) -.66 (36.86) 2.06 (.328, 457.95) .050* 
8 92.69 (173.82) -2.52 (30.13) 2.75 (24.09, 166.33) .011* 
9 190.19 (445.64) 66.87 (202.89) 1.24 (-76.42, 323.06) .220 
10 227.77 (451.18) 65.46 (196.64) 1.67 (-34.98, 359.61) .104 
11 15.84 (55.53) 4.15 (29.83) .92 (-13.97, 37.35) .364 
* indicates significant difference between the two treatment groups 
 
After the treatment, PPTs increased at all sites in both groups except for those at sites No. 7 
and 8 in the SA group. In the RA group, mean increases in PPTs ranged from 15.84% at No. 
11 to 229.48% at No. 7. In the SA group, the range was from a decrease of 0.66% at No. 7 to 
an increase of 66.86% at No. 9.  
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A significant difference between the two treatment groups on the percentage change in PPTs 
was obtained at sites No. 7 and 8, which are the left and right EX-HN5, located at the 
temporal region of the head.  
 
No significant correlations were detected between changes in frequency, duration or intensity 
of migraine and changes of PPTs (Table 46). Two-way ANOVA was used to dected the 
difference in changces of PPTs between respondents and non-respondents. There is neither 
site difference [F (10, 480) = 1.02, p = 0.34], nor group by site interaction [F (10, 480) = 0.16, 
p = 0.77].  
 
Table 46: Correlation between changes of PPTs and frequency, duration and intensity of 
migraine 
Frequency Duration Intensity  
Pearson’s r P Pearson’s r P Pearson’s r P 
PPT1% -.20 .18 -.08 .60 .17 .23 
PPT2% -.11 .44 .06 .66 .26 .07 
PPT3% .00 .98 .06 .70 -.04 .79 
PPT4% -.24 .10 -.11 .45 .08 .60 
PPT5% -.17 .25 -.02 .91 .05 .74 
PPT6% -.14 .34 .03 .84 .06 .66 
PPT7% -.08 .60 -.07 .62 -.11 .45 
PPT8% -.08 .58 -.00 .99 .14 .33 
PPT9% .05 .74 -.03 .86 .19 .20 
PPT10% .12 .43 -.05 .73 -.10 .47 
PPT11% .15 .32 .21 .14 -.05 .76 
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9.5    Discussion 
Manual acupuncture changed PPTs of migraine sufferers in the temporal and facial muscles, 
especially in the temporal area. No correlation between migraine reduction and changes in 
PPTs was detected. As no participant had any migraine during the two sessions of test, the 
correlation between PPT during an attack and migraine features is unknown.  
 
At baseline, the four sites located on the bilateral temporalis and the belly of the masseter 
muscles, were reported to have the lowest PPTs. This finding is in agreement with Bono’s 
study which tested the PPTs of 10 symmetrical points on each side of the head and at the 
deltoid in cluster headache patients. The researcher found that the lowest PPTs were at the 
anterior and intermediate levels of the temporal muscle on the symptomatic side (Bono et al., 
1996).  
 
In our current PPT trial/tests, there are weak correlations between the PPTs on the neck and 
the duration of migraine. Given such correlation was not assessed by other migraine studies, 
no comparison can be made.  It is unknown whether the relationship can be explained by the 
finding that the most sensitive region of migraine sufferers is the nape area (Kosek et al., 
1993).  
 
In the current study, 19 of 22 PPT values in both two groups increased after the treatment. 
Furthermore, eight of total 11 PPTs in the RA group increased by 30% or more from baseline 
data; whereas only three of 11 PPTs in the SA group increased by more than 30%. 
Acupuncture seemed to increase PPTs better than SA did, although significant group 
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differences were found at two sites only. The results are somewhat consistent with one study 
(Karst et al., 2000), finding that acupuncture improved the PPTs in the temporal region of 
chronic tension-type headache than SA did. 
 
Three factors might explain why PPTs at two sites No. 7 and 8 were statistically significantly 
higher than those in the SA group. Firstly, increases in PPT varied from site to site, but the 
temporalis has been considered to be the most reliable site when the repeatability of PPT was 
assessed at a few sites, including 13 sits located in anterior, upper, posterior and temporal 
areas of the head. (Sand et al., 1997). Secondly, the significant increase in PPT might be due 
to the local effect of acupuncture since the two sites were needled in the trial. Finally, testing 
on healthy volunteers, Zaslawski and his collegues (2003) stated that PPTs changed more 
significantly on the acupoints compared with the non-acupoints. No. 7 and No. 8 are two 
commonly used acupoints for headache.  
 
It is not a co-incidence that the PPTs increased significantly at No. 7 and No. 8, namely, Tai 
Yang, which is located on either side of the temporal regions, in the m. temporalis, on the 
superficial temporal artery and vein, and near the second and third branches of the trigeminal 
nerve. The temporal artery (Lipton, 2004) and trigeminal nerve are associated with the 
development of migraine (Moskowitz, 2007). The neurovascular theory considers that the 
vasodilatation activates the stretch receptors in the wall of the temporal artery, stimulating the 
peri-vascular trigeminal nerves, and leading to neurogenic inflammation. The inflammation in 
turn activates the trigeminal nuclei and further enhances the sensitivity of the nervous system 
prior to a migraine attack (Maassenvandenbrink and Chan, 2008). Acupuncture has been 
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shown to increase pain threshold in many other studies (Zaslawski et al., 2003, Chapman et 
al., 1976, Berlin et al., 1975), however it is unknown about the relationship between the 
enhanced PPT in the temporal area and the sensitivity of stretch receptors in the wall of the 
temporal artery. It is possible that acupuncture reduces the sensitivity of these receptors, and 
therefore prevents the activation of trigeminal nerves. This hypothesis should be explored in 
the future and it might help us understand the anti-migraine mechanisms of acupuncture.  
 
Nevertheless there is no correlation between percentage increases in PPTs and the features of 
migraine. The present results suggest that the changes of laboratory-derived measurement 
PPT were unrelated to the clinical outcomes, frequency, duration and severity of migraine. 
Other studies also indicated that the reduced PPT did not correlate with illness duration and 
side of pain in cluster headache sufferers (Bono et al., 1996). However heat or cold pain 
thresholds were not assessed in the current study, and correlation between thermal pain 
threshold and migraine cannot be concluded.  
 
Our observations of baseline data confirm the findings of previous publications regarding the 
range of PPT values (Fernández-de-Las-Peñas et al., 2007) as well as the lower PPT in 
women in healthy populations (Chesterton et al., 2003, Jensen et al., 1992) and in migraine 
groups (Fernández-de-Las-Peñas et al., 2007). However, such data were from studies, 
including the current study, with a small sample size and different gender proportions, which 
is probably due to the higher prevalence in the females than the males. Gender imbalance 
could have affected our results. Therefore, further investigations of clinically relevant changes 
in PPT for both gender groups are still required (Chesterton et al., 2003) . 
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As noted earlier, this study involved 50 participants only; this small sample size may have 
underestimated the effects of acupuncture. Furthermore, participants suffering from bilateral 
migraine or unilateral migraine with side shift might also complicate the results. However 
these data were not collected in this study.   
 
In conclusion, future studies need to assess both thermal and mechanical pain thresholds in 
the neck and cranial regions, in particular the temporal area, to further understand the 
correlation between pain threshold and migraine features. More importantly, the relationship 
between the increased pain threshold in temporal area after acupuncture and temporal artery 
pressure / neurogenic inflammation should be explored.  
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CHAPTER TEN: DISCUSSION 
 
10.1    A summary  
The aims of the project were to: 1) systematically review the current state of evidence from 
English and East Asian literature of acupuncture for migraine headache; and 2) design and 
conduct a RCT that addresses the key methodological problems identified from the systematic 
reviews (SR) to determine the short- and long-term effect and safety of acupuncture for 
patients with frequent migraine headache.  
 
Fifteen English and 17 Chinese published studies were identified in two separate literature 
review through searching major English, Chinese, Japanese and Korean databases. Overall, 
findings of these two reviews supported the value of acupuncture in the treatment and 
prevention of migraine headache when compared with standard western prophylaxis 
medications, including beta blockers (Metoprolol), selective calcium channel antagonist 
(Flunarizine, Nimodipine), 5-HT1A receptor agonists (Dihydroergotamine) and anticonvulsant 
(valproic acid) (English studies: RR 1.19; 95% CI 0.98 to 1.46; Chinese studies: RR 1.55; 
95% CI 1.27 to 1.88). However, there was insufficient data for a meta-analysis to determine 
the effectiveness of acupuncture when compared with no treatment. Furthermore, conflicting 
findings were reported in respect of the specific effect of acupuncture for migraine headache 
in studies involving a comparison between real and “sham/placebo” acupuncture (English 
studies: RR 1.07, 95% CI 0.93 to 1.25). Overall it was difficult to perform a met-analysis to 
assess the efficacy of acupuncture due to the highly heterogeneous data, differences in 
outcome measures and insufficient reporting of study details. 
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A randomised, sham acupuncture controlled trial built on findings of the above literature 
reviews were conducted. Fifty participants were recruited. The results demonstrated a 
statistically significant preventative effect of acupuncture on migraine, as well as 
improvement in medication consumption and quality of life, when compared with sham 
acupuncture. The effect lasted up to three months and ceased one year after the termination of 
the treatment. The results demonstrated that manual acupuncture could be effective and safe 
prophylaxis for frequent migraine sufferers. Because the findings of the present study were 
based on self-selected and community-based participants, the results discussed here are 
limited to this specific sub-group. Furthermore, there were no adverse events that necessitated 
withdrawal of participants from the trial. The incidents and severity of minor adverse effects 
were comparable between the two groups. 
 
10.2    Strengths of This Project 
Our systematic review (SR) is the first review to assess the East Asian data of acupuncture 
RCTs for migraine. Such literature has been neglected in previous SRs (Melchart et al., 2001, 
Scott and Deare, 2006). It is surprising to find that no RCTs in acupuncture for migraine have 
been reported in Korea and Japan where acupuncture has been widely used. In comparison, 
Chinese researchers have conducted a few dozens of trials in this area. Half of them were 
however observational studies. The remaining RCTs were of poor reporting quality.  
  
Our SR is also the first study evaluating the efficacy of acupuncture in various features of 
migraine, such as intensity and the numbers of migraine attacks. This is different from two 
existing reviews in which only respondent rates were analyzed.  
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The current RCT is unique when compared with previous studies of acupuncture for migraine 
in the following four aspects. First, only patients having a minimum migraine frequency of 5 
days per month were included. Other studies typically included patients having two – five or 
two – eight migraine attacks per month. Second, it has the longest treatment period of 20 
weeks with a gradual decrease in treatment frequency. This treatment regime follows how 
acupuncture is practiced in a clinical setting, and has been shown to be effective in one 
acupuncture trial of osteoarthritis in the knee (Berman et al., 2004). The current study also has 
the longest follow-up period at one year. Third, according to the potency of analgesics, we 
used the MQS to assess medication consumption, rather than the simple pill account used in 
many other studies. This method is sensitive and more meaningful to patients. Finally, our 
sham acupuncture procedure has minimised the non-specific effect of acupuncture by using 
non-invasive procedure on the points in the cranial area.  
 
In addition, we have also conducted a study to examine the effect of acupuncture on cranial 
pressure pain threshold (PPT) and its relationship with features of migraines, such as 
headache intensity, and number of days with migraine. Such correlation has never been 
assessed before. The findings may contribute to further understanding of the mechanism of 
migraine and the anti-migraine mechanisms of acupuncture. 
 
10.3    Limitations 
Due to a lack of accessibility to databases in other languages, our search and studies were 
limited to those published in Chinese, English, Japanese and Korean. With the increased use 
of acupuncture globally, more and more migraine sufferers seek complementary therapies 
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including acupuncture for relief. A recent Italian study reported that the percentages of 
complementary and alternative medicines used in chronic migraine and episodic migraine 
sufferers were 50% and 27%, respectively (Rossi et al., 2005). RCTs published in French, 
Italian and Russian databases have not been searched and assessed. This could have impacted 
on our conclusion.  
 
As discussed in the limitation part of Chapter Seven, like many acupuncture studies, this 
study also suffers from a small sample size, a common problem due to frequent treatment 
regime, invasive needling and a lack of understanding of acupuncture by the public. A small 
sample size could over-estimate the results by 30% (Bandolier Professional, 2003). This could 
have happened in the current study.  
 
Furthermore, a high expectation to acupuncture treatment could also contribute to the 
outcome of this study. A low back pain study showed that patients with a high expectation of 
acupuncture often had a better outcome than those with a low expectation (Kalauokalani et al., 
2001). Another study that examined four acupuncture trials for painful conditions reported a 
significant association between better improvement and a higher expectation (Linde et al., 
2007b). Although not assessed in the current study, expectation is less likely to be the reason 
underlying the group differences. The participants were successfully blinded from the 
treatment allocation as indicated by the credibility questionnaire. Nevertheless such factor 
should be assessed in future studies. A newly developed Acupuncture Expectancy Scale (Mao 
et al., 2007) can be used.  
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10.4    Implications for Further Studies  
Based on the findings of the SRs and the current clinical study, further studies should be 
conducted to address the following four aspects, including trials with various control 
interventions, trials examining more real life events, understanding respondents and exploring 
the anti-migraine mechanisms of acupuncture.  
 
10.4.1   Studies with Various Comparisons 
The effect achieved by acupuncture consists of specific, non-specific and placebo elements 
(Paterson and Dieppe, 2005). The following four types of studies should be conducted to 
address the above three elements.  
 
10.4.1.1   Acupuncture VS. Standard Drugs 
Control method plays an important role in a successful acupuncture RCT. The choice of 
control is determined according to the research question. The first of all strategies in 
acupuncture research is to assess its overall efficacy (including specific, non-specific and 
placebo effects), when compared with standard pharmacology treatment. Studies assessing the 
effect of acupuncture on acute migraine attacks should be conducted as currently there was 
only one such study. A direct comparison of the cost-effectiveness of acupuncture with 
prophylactic medications should also be studied. Furthermore, most patients who are taking 
prophylactic medications might also use acupuncture. Given the mechanisms of these drugs 
such as enhancing central inhibition and dilating blood vessels that are also involved in the 
actions of acupuncture, the interactions between the two therapies need to be explored.  
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10.4.1.2   Acupuncture VS. Sham Acupuncture 
Comparison between active acupuncture and sham acupuncture is the only way to evaluate 
the specific effect of acupuncture. Identifying an ideal placebo/sham acupuncture device or 
procedure is an important initial step to acupuncture RCTs for evaluating its specific effects. 
However to date, no existing evidence supports that placebo intervention, such as mock 
TENS, placebo tablets or inactivated laser apparatus can produce the same psychological 
impact as acupuncture does (Kaptchuk et al., 2000). The commonly used sham procedure 
involves needles being inserted deeply or superficially into either inappropriate acupoints or 
sham acupoints outside of traditional acupoint / meridians. Such points are often within the 
same region within which the points used for real acupuncture treatment and the location of 
the diseases reside.  
 
A review (Sánchez Aranjo, 1998) on methodology of sham acupuncture found that placing 
needles in the same dermatome or myotome of the disease often produced a strong therapeutic 
effect. Once the needles are inserted, the spinal gate control is activated thereby producing 
pain relief in the same and adjunct spinal nerve segment. Hence, the placebo needles have 
been developed and they have been proven to be credible (White et al., 2003, Kleinhenz et al., 
1999, Park et al., 2002). Blunt needling could be used to replace the placebo needle. Lao and 
colleagues employed such blunt needling in patients with pain after oral surgery (Lao et al., 
1999). 
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To assess the specific acupuncture effect, using sham acupuncture as the control intervention 
is inevitable. It seems blunt stimulation at the region of the disease could be one of the ideal 
sham acupunctures.   
 
10.4.1.3   Comparing Different Treatment-Regime 
Treatment regime includes the length of the trial and the frequency of the treatment. The 
current clinical study revealed a marked improvement in several variables within the RA 
group occurring after eight or 12 weeks’ treatment. The effect continued to improve in the 
remaining 8 treatment weeks and in the 12-week follow-up period. Silberstein and Goadsby 
(2002) have also found that in the controlled clinical trials evaluating migraine prophylaxis, 
the efficacy was often noted in the first four weeks and continued to increase for three months. 
However, in most of the available acupuncture studies, the treatment period lasted eight to 12 
weeks only. Before the acupuncture showed its furthest effect, the treatment already ceased. 
In the future, treatments with various treatment lengths should be compared.  
 
Moreover, this clinical study is one of the acupuncture studies using a gradual decrease in the 
treatment frequency, starting with twice per week. As discussed in Chapter Four, nearly half 
of the studies conducted in Western countries treated participants once per week then the 
treatment stopped abruptly. Such regime might not be sufficient to maintain the effect of 
acupuncture on migraine. A SR of acupuncture on chronic pain conditions revealed that the 
patients who received more than six sessions were significantly more likely to show positive 
effect of the treatment than those with fewer sessions (Ezzo et al., 2000). The frequent and 
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number of treatment may contribute to the positive results of the current clinical trial. We 
suggest future researches should focus on exploring the most effective treatment regime. 
 
10.4.1.4   Assessing Combined Interventions  
In real practice, acupuncture is often combined with other Chinese medicine therapies, such as 
herbal medicine, Chinese massage (Tuina), Qi Gong or Tai Chi.. Five of the total 15 Chinese 
studies employed acupuncture plus other therapies. None of the English studies used 
acupuncture in combination with other types of Chinese medicine as the treatment. With 
appropriate design such combined intervention studies can tell us the specific effect of 
acupuncture in the combined therapy.   
 
10.4.2   Conducting “real life” Acupuncture Treatment 
In any RCTs,, there is always a trade off between internal and external validity. 
Well-designed and well-organised sham-acupuncture controlled trials limit the potential to 
assess the effectiveness of acupuncture treatment. One of the main draw back in these trials is 
being inflexible in the delivery of acupuncture.  
 
In a clinical setting, acupuncturists change the treatment according to the conditions of the 
patients on the day in addition to individualised treatment plan. Such flexibility is not 
permitted in RCTs. Treatments in RCTs have to follow the protocol as strictly as possible. For 
instance, one patient reported lower back pain in one session in the current trial. The patient 
reported that the low back pain seemed to be associated with the migraine. The trial 
acupuncturist had to decide whether to treat this acute low back pain or not, given this 
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deviation was not written in the protocol. The patient’s low back pain was treated on that day. 
In total there were three such incidents during the trial. The trial acupuncturist controlled this 
deviation to a minimum.  
 
From the trial point of view, this limitation is successful and important. However from the 
point of view of assessing the real effect of acupuncture, such limitation interferes with the 
results. Indeed, from Chinese medicine point of the view, the blockages of Qi flow in the low 
back can cause a blockage of Qi in the upper stream of meridians, causing headache or 
migraine. A review has also showed a connection between migraine/headache and low back 
pain (Hestbaek et al., 2003).  Some acupuncture trials have planned a number of non-trial 
related treatments in the protocol thus introducing some flexibility (Melchart et al., 2005).  
This practice needs to be included, documented and analysed in future trials. Associated with 
this problem is a better understanding of the comorbidity of migraine so that we can 
determine what types of conditions can be treated in an acupuncture trial for this type of 
headache.   
 
A second problem is about the holistic approach of acupuncture and its actual practice in 
clinical trials. Although in many trials, including the current study, the researchers select 
complementary acupoints according to Chinese medicine differential diagnosis, the trial 
participants are not treated holistically as in clinical practice. This is mainly due to the limited 
communication between participants and the trial acupuncturists. As shown in the current trial 
(Paterson et al., 2008), when interviewed, participants found that the whole experience was 
not like what they expected how acupuncture should have been practiced. The trial 
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acupuncturist tried to limit the communication with the participants in order to avoid 
practitioner-patient interaction. Meanwhile the participants also tried to play their part of 
being “subjects” and not asking questions to have their problem, treatment and weekly 
experienced of migraine explained.  
 
Acupuncture is a complex intervention, involving flexibility in treatment delivery, body 
contact of practitioners and patients, patients trust in needling and communication between 
the two parties. These elements of practice can work synergistically to achieve a great effect 
(Paterson and Britten, 2004). How to address these elements of practice and their complex 
interaction remains a challenge to acupuncture clinical trials. However these elements cannot 
be ignored or dismissed. Introducing some degree of flexibility in the trial and a standard 
recording system of any deviation is the first step to address these problems. 
 
10.4.3   Understanding the Respondents  
The current clinical trial has found that the RA group had a greater number of respondents 
than the SA group did.  During the follow-up period, participants who had a migraine pattern 
of Ascending Hyperactivity of Liver Yang had the lowest respondent rate. From Chinese 
Medicine point of view, such patients are prone to mental stress and their migraine is 
associated with life events and a lack of restful sleep. Could this result indicate that 
acupuncture alone is not sufficient and additional psychological interventions, Chinese herbal 
medicine, relaxation therapy, meditation or Tai Chi are needed? Furthermore, both in the 
current study and one other study, the migraine of a small proportion of patients worsened 
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after acupuncture. Unfortunately, to date, there is no way to tell who will respond to 
acupuncture and who will not. Future studies need to explore this area.  
 
10.4.4   Studying the Mechanism  
The underlying mechanism of acupuncture for its prophylactic effect requires investigation. 
Almost all of the studies in our two reviews used acupuncture points located on the temporal 
region and the nape. Both regions are innervated by the trigeminal nerves. The significance of 
the increase in PPTs in these regions observed in the current study should be examined in the 
context of migraine reduction. It is possible that acupuncture has reduced the sensitivity of 
“stretch receptors” in the wall of temporal arteries therefore preventing the activation of 
trigeminal nerves and further migraine attacks. Previous studies have shown that acupuncture 
can modulate or change the pain threshold in the viscera by stimulating the body wall (Cui et 
al., 2005). Whether this action also explains the current finding is yet to be studied. Other 
possible mechanism is its effect of sympathetic inhibition. A recent study shows that 
acupuncture reduces the sympathetic tonus in the migraine respondents (Bäcker et al., 2008), 
which might have caused a long-term vasodilatation, therefore preventing the development of 
migraine.  
 
The involvement of well-established anti-inflammation and anti-central sensitization actions 
of acupuncture in animals is yet to be confirmed in migraine prevention. 
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10.5    Implication for Clinical Practice 
Acupuncture can be used as alternative prophylaxis for frequent migraine. Practitioners are 
recommended to treat migraine sufferers twice per week for at least eight weeks. Regular 
follow-up treatments at a monthly or bimonthly interval are needed for the long-term 
maintenance. Practitioners should also encourage the impatient individuals to have at least six 
sessions of treatment before assessing whether they are respondents to acupuncture. Other 
therapies can be combined with acupuncture, in particular, when treating patients with a 
pattern of Ascending Hyperactivity of Liver Yang. Reduced medication usage is expected 
during acupuncture treatment. Patients need to be informed that acupuncture sometime 
worsens migraine.   
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APPENDICES 
Appendix 1: Diagnosis of Migraine 
 
Migraine without aura  
A At least 5 attacks fulfilling criteria B-D 
B Headache attacks lasting 4-72 hours (if untreated or unsuccessfully treated) 
C 
Headache has at least two of the following characteristics: 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe pain intensity 
4. Aggravation by or causing avoidance of routine physical activity (e.g. Walking or 
climbing stairs) 
D 
During headache at least one of the following: 
1. Nausea and/or vomiting 
2. Photophobia and phonophobia 
E Not attributed to another disorder 
 
 
Migraine with aura 
A At least 2 attacks fulfilling criteria B 
B 
Aura consisting of at least one of the following, but no motor weakness: 
1. Fully reversible visual symptoms including positive features (e.g., flickering lights, 
spots, or lines) and/or negative features (i.e., loss of vision) 
2. Fully reversible sensory symptoms including positive features (i.e., pins and 
needles) and/or negative features (i.e., numbness) 
3. Fully reversible dysphasic speech disturbance  
C 
At least two of the following:Unilateral location: 
1. Homonymous visual symptoms and/or unilateral sensory symptoms  
2. At least one aura symptom develops gradually 5 minutes or more and/or different 
aura symptoms occur in succession over 5 or more minutes 
D 
Headache fulfilling criteria for migraine without aura beginning during the 
aura or follows the aura within 60 minutes. 
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Appendix 2: Pre-planed Form for Extracting Data in Systematic Review 
 
Author and Date  
Title 
 
Sample Conditions  
Sample size  
Study Intervention  
Control Intervention  
Type of Acupuncture 
Treatment  
Acupuncture points & 
Needling 
 
Other treatment  
Treatment Regime  
Outcomes  
Follow-up  
Drop-out  
Practitioner 
Background 
 
Authors conclusion  
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Appendix 3: Examples of Media Advertisement 
Appendix 3.1: “The Age” Newspaper 
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Appendix 3.2: “Leaders” Newspaper 
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Appendix 3.3: “GoodMedicine” Magazines 
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Appendix 4: Initial Screening Form 
 
A: Yes 
B: Do not know 
Go to question 2 1. Do you suffer from migraine or have 
been diagnosed as migraine? 
C: No Exclude 
A: 18-80 years old Go to question 3 2. How old are you 
B: less than 18 or older than 80 
years old 
Exclude 
A: Yes Exclude 3. Are you current pregnant or plan to 
pregnant in the next 12 months (if you are 
female)?  B: No Go to question 4 
A: Yes Exclude 4. Do you have history of head injury or 
whiplash? B: No Go to question 5 
A: Yes Exclude 5. Do you have severe arrhythmia or heart 
failure, brain tumor, epilepsy or 
hemophiliac? 
B: No Go to question 6 
A: Yes Exclude 6. Have you used acupuncture to treat your 
migraine in the last months?  B: No Go to question 7 
A: Yes Exclude 7. Had participated in another clinical trial 
in the past six months?  B: No Go to question 8 
A: Yes Go to question 9 8. Do you also suffer from tension-type 
headache?  B: No Go to question 11 
A: Yes Go to question 10 9. If answer “ Yes” for question 8, can you 
distinguish between migraine attacks and 
additional tension-type headache?  B: No Exclude 
A: Yes Exclude 10. If answer “ Yes” for question 9, do you 
usually have tension-type headache more 
than six days per month?  B: No Go to question 11 
A: Less than five days Exclude 11. How many days do you usually have 
migraine per month?  B: five days or more Successful in Initial 
screen, sending PLS 
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Appendix 5: Plain Language Statement (PLS)          
 
Information about Acupuncture and Migraine Study 
 
Project Title: Evaluation of effectiveness and safety of acupuncture in the treatment of migraine (CM) 
 
Investigator: Ms. Yanyi Wang, Registered Chinese Medicine Practitioner, MappSc candidate 
 
Dear Volunteer, 
 
My name is Yanyi Wang, a Master of Applied Sciences (in Chinese Medicine, by research) candidate in the 
School of Health Sciences, RMIT University. My study is supervised by Dr. Zhen Zheng; Associate 
Professor Charlie Xue, Dr. Lin Dong and Prof. Robert Helme. I am the principal investigator of this 
proposed clinical trial which will determine the effectiveness and safety of acupuncture in the treatment of 
migraine. This letter is to give you relevant information about this study. 
 
1. Research Project 
 
Acupuncture is commonly used in Chinese medicine practice worldwide and is regularly used in everyday 
practice. This research is about using acupuncture for the treatment of migraine headache. The study will 
involve approximately 78 migraine participants. To date, there have been only a few clinical trials that have 
been conducted into acupuncture treatment of migraine and they have suggested effective outcome, 
although the results of these studies are not yet conclusive. Therefore, it is necessary to conduct a more 
comprehensive clinical trial to verify whether acupuncture is useful for the management of migraine 
headache.  
 
We are looking for volunteers who have a minimum of 5 or more migraines or migraine related headache 
per month. If you fall into this category, then you are invited to participate in our study together with the 
other 77 participants. However, if you have any of the following conditions you are not eligible for this 
study. Please see the following exclusion criteria: 
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a) Current pregnancy or malignancy. 
b) History of head injury or whiplash.  
c) Severe arrhythmia or heart failure, brain tumour or epilepsy. 
d) Haemophilia. 
e) Do not comprehend English. 
 
Once you are recruited into this study, you will then be assigned by chance to either a sham or real 
acupuncture treatment. That is, you will have a 50% chance of being randomly assigned to either the real or 
control group. 
 
2. Purpose of the study 
 
The aim of the study is to examine whether acupuncture reduces the intensity, frequency of migraine and 
the consumption of medications as well as improving the quality of life. 
  
3. The real or sham treatment 
 
The sham treatment is used to demonstrate if the real acupuncture treatment has a true effect for migraine. 
Theoretically the sham acupuncture should produce minimal acupuncture efficacy, apart from placebo 
effects, if any. Once you have met the inclusion criteria you will be allocated randomly into one of the two 
groups. If the results of this study show that acupuncture is effective in the treatment of migraine headache, 
then we will be happy to provide free real treatment at the completion of the study to those who were in the 
control group. 
 
4. What you will be asked to do during the study 
 
If you agree to participate in the study, which includes a four-week baseline, a twenty-week treatment 
period and three-month follow up, you will be asked to: 
 
• Come to the clinic for an initial assessment. 
• Visit the clinic for a total of 16 acupuncture treatments. 
• Complete a daily record for intensity and frequency of headache, medication consumption chart, 
and monthly record of quality of life questionnaire for 7 times. 
• Have pain thresholds tested twice, once prior to commencement of acupuncture treatment, and 
once at the completion of the study. 
• Record adverse event of acupuncture, if any. 
 
 
5. Safety issues of acupuncture 
 
Acupuncture procedure is widely used in everyday practice with an excellent safety profile. Only 
disposable needles will be used and they are much thinner than needles used for injections. However, 
acupuncture has been reported to be associated, in a very few cases, with minor risks, such as fainting, 
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infection, small bleeding and bruises. In this trial, the principal investigator is an experienced acupuncturist 
registered with the Chinese Medicine Registration Board of Victoria. Great precaution will be taken to 
minimise any possible unpleasant adverse effect. Furthermore, the acupuncturist and all staff in the 
Division of Chinese Medicine possess First Aid, level II training. 
 
6. Potential discomfort of acupuncture 
 
Some people may experience minor pricking sensations when acupuncture needle was first inserted. 
However, this sensation is only brief. Generally there is no pain or discomfort involved in acupuncture. 
 
7. Potential benefits to you and the community 
 
The benefit of participating in the study is that your migraine symptoms and well-being will be monitored 
closely. This trial will further contribute towards a growing body of scientific knowledge about the effects 
of acupuncture for the treatment of migraine. Your involvement will help to determine whether acupuncture 
might be used as an alternative drug-free treatment to the debilitating migraine condition. Any new findings 
from this study may be taken into account when planning for future studies. Furthermore, all findings will 
be made available to all participants in a summary format.  
 
8. About discontinuation and termination of your participation 
 
Involvement in this study is voluntary, and you may ask for the procedure to be discontinued at any time. 
 
9. Confidentiality of information you provide 
 
All information provided by you and the data collected through this study will be stored in a password 
protected computer program. All files are kept securely in a locked filling cabinet. Your records may be 
inspected only by authorised persons for the purpose of original data audit. In any form of publication, all 
your personal information will be removed. You have the right to view or request a copy of your personal 
data. 
 
 
 
10. Answering any question concerning the procedure of this research 
 
Any question that you may have about the procedure will be answered and explained. Please contact Ms. 
Yanyi Wang on 9925 7002 or 0423427330, if you have any question about the research. 
 
This project has been reviewed and approved by the Human Research Ethics Committee of RMIT 
University. The project is covered by RMIT University, Broadform Public Product Liability Insurance. 
 
 
 
Any Questions or complaints about your participation in this project may be directed to the 
Secretary, RMIT Human Research Ethics Committee, University Secretariat, RMIT, GPO Box 
2476V, Melbourne, VIC 3001. Tel: 9925 1745 
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Appendix 6: Acupuncture Study-Expression of Interest   
 
 
(To be completed by the patient) 
 
Dear Participants,  
 
Thank you for your interest in participating in the study of acupuncture for migraine. Please find enclosed 
some information about the study. 
 
It contains a number of questions to be completed. Your answers will help us assess whether you are 
suitable to participate in our study. 
 
In order to provide accurate information for this initial assessment, please read the information carefully 
prior to completing the forms on pages 1, 2, 3 and 4.  
 
Please return the completed Expression of Interest form in the enclosed prepaid envelope. Upon receipt of 
your information I will contact you to arrange an appointment for further assessment to confirm your 
suitability for this research. 
 
I look forward to your participation and thank you for taking time to fill in this form. 
 
Yours Sincerely 
 
Ms. Yanyi WANG 
 
Tel:  9925 7584 or 0423427330 or email: s3042947@student.rmit.edu.au 
 
            
1. Title:        Mr        Mrs        Miss     
 
2. Family Name:  ____________     First name: ________________________ 
 
3. Date of birth: _______________   Gender:      Male        Female 
 
4. Address:  Street____________________________________________________ 
 
    Suburb___________________    Postcode:____________________ 
 
    Email:___________________________________________________ 
 
5. Telephone No: (home) __________________    (work): ________________ 
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     (mobile) ___________________________________________ 
   
Best time to call you ________________________________________________ 
 
Which one do you prefer to contact with:  Home phone;    
                                   Work phone;    Mobile 
 
6. Emergency Contact: 
 
Name: ___________________________________________________________ 
 
Address: _________________________________________________________ 
 
Telephone No: (home) ___________________    (work) __________________ 
 
(mobile) ____________________________________________ 
 
7. Currently married/ partnered?          Yes                No 
 
8. Occupation (current): ______________________________________________ 
 
9. Education attained: _________________________________________________ 
 
10. Nationality: _________________    Country of Birth: __________________ 
 
11. Are you of Aboriginal and/or Torres Strait Island descent?  Yes    No 
 
If Yes, please tick one:       Aboriginal and Torres Strait 
          Aboriginal not Torres Strait 
          Torres Strait 
 
12. How long have you suffered from headache?  _________________________ 
     
13. Do you use any pain medication for headache control?   
 
        Yes                               No 
 
If Yes, please list the medication that you have used 
 
Name of Medication Dosage Frequency ( times/day or week) How long have you 
been taking it? 
    
    
    
14. Please tick (√) how many times you usually have a headache per month. 
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 1-2 times/ month 
                          
 3-4 times/month
       
  
 5-6 times/month
                        
>6 times/month
 
               
15. Please tick (√) the symptoms that happen while you have headache. y 
         
   
Unilateral location
            
Plusating quality
 
      
Aggravated by routine physical activity; or avoiding physicial activity
  
   
Nausea
                 
Vomiting
      
Light Sensitive
  
      
Sound Sensitive
         
Other
_______________________________ 
 
16. Can you visit the clinic 16 times in the future 6 months?     
   
      Yes                            No                          Not sure   
 
17. Do you plan to move to other city during the next 5 months? 
 
       Yes                                No  
 
18. Have you been diagnosed to be a haemophilia? 
 
    Yes                                No 
 
19. Are you pregnant (if you are female)?  
 
     Yes                                No 
 
20. Are you currently breast-feeding (if you are female)? 
 
    Yes                                No 
 
21. Do you suffer from any heart disease? 
 
    Yes                                No 
 
 If yes, Please specify: ___________________________________________ 
 
22. Have you been diagnosed with a malignancy? 
 
    Yes                                No 
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 If yes, Please specify: ____________________________________________ 
 
23. Have you been diagnosed with a brain tumour or epilepsy? 
 
    Yes                                No 
 
 24. Have you had head injury or whiplash before? 
 
    Yes                                No 
 
 25. Do you have any other diseases? 
 
    Yes                                No 
 
 If yes, Please specify: _______________________________________________ 
 
26. Do you have any infectious diseases? 
 
    Yes                                No 
 
If yes, Please specify: _______________________________________________ 
 
27. Have you had acupuncture treatment in the last 6 months? 
 
    Yes                                No 
 
If yes, what was the acupuncture treatment for? _______________ 
 
 28. Are you willing and able to participate in the study? 
 
    Yes                             No                          Not sure 
 
29. Are you currently participating in any other clinical trial research? 
         
    Yes                                No 
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Appendix 7: Consent Form 
RMIT HUMAN RESEARCH ETHICS COMMITTEE 
Prescribed Consent Form for Persons Participating In Research Projects Involving Interviews, 
Questionnaires, Disclosure of Personal Information, Tests and/or Medical Procedures 
 
 
PORTFOLIO OF SET 
SCHOOL OF Health Sciences 
Name of participant: 
 
Project Title: 
Evaluation of effectiveness and safety of acupuncture in the 
treatment of migraine: a randomised, single blind and sham 
controlled trial 
Name(s) of investigators: 
(1) Yanyi Wang Phone: 03-99257002 
(2) 
Zhen Zheng 
Charlie Xue 
Lin Dong 
Cliff Da Costa  
Helme Robert 
Phone: 
03-9925 7167 
03-9925 7745  
03-9925 7990 
03-9925 6114 
03-9288 4696 
 
1. I have received a statement explaining the interview/questionnaire and tests/procedures involved in 
this project. 
 
2. I consent to participate in the above project, the particulars of which - including details of the 
interviews or questionnaires - have been explained to me. 
 
3. I authorise the investigator or his or her assistant to interview me, administer a questionnaire, and to 
use with me the tests or procedures referred to in 1 above. 
 
4. I acknowledge that: 
 
(a) Having read Plain Language Statement, I agree to the general purpose, methods and 
demands of the study. 
(b) The possible effects of the tests or procedures have been explained to me to my 
satisfaction.  
(c) I have been informed that I am free to withdraw from the project at any time and to 
withdraw any unprocessed data previously supplied (unless follow-up is needed for 
safety). 
(d) The project is for the purpose of research and/or teaching. It may not be of direct 
benefit to me. 
(e) The privacy of the personal information I provide will be safeguarded and only 
disclosed where I have consented to the disclosure or as required by law.   
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(f) The security of the research data is assured during and after completion of the study.  
The data collected during the study may be published, and a report of the project 
outcomes will be provided to all participants. Any information which will identify me will 
not be used. 
 
Participant’s Consent 
 
 
Name:  Date:  
(Participant) 
 
 
Name:  Date:  
(Witness to signature) 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
 
Any complaints about your participation in this project may be directed to the Secretary, RMIT Human Research Ethics Committee, 
University Secretariat, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 1745.   
Details of the complaints procedure are available from the above address. 
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Appendix 8: Credibility of Sham Acupuncture 
 
1. Which treatment do you believe you received? 
 
    Real acupuncture 
    Sham (placebo) acupuncture 
    Unsure  
 
 
2.  If your answer is “Real acupuncture” why do you think so? 
 
   The manner, attitude, or words of acupuncturist 
   The manner, attitude, or words of the personnel in this clinic 
   The result of my treatment (eg. Feel better, or feel worse) 
   Other  ____________________________________________ 
 
 
3.  If your answer is “Sham acupuncture” why do you think so? 
 
   The manner, attitude, or words of acupuncturist 
   The manner, attitude, or words of the personnel in this clinic 
   The result of my treatment (eg. Feel better, or feel worse) 
    Others  __________________________________________________ 
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Appendix 9: Headache Diary                                                                 
 
1. Do you have migraine today?   
 
 Yes               No 
 
 If yes, please indicate the migraine period today. 
 
 
            
        6am  8    10   12pm 2    4     6     8   10   12am  2   4am   6am 
 
2. What is the lowest level of your headache today? 
(0 means “no pain”;       10 means “pain as bad as it could be”) 
 
 
 
 0                                                              10 
 
3. What is the highest level of your headache today 
(0 means “no pain”;       10 means “pain as bad as it could be”) 
  
  
 
  0                                                             10 
 
4. What is the average level of your headache pain intensity today? 
(0 means “no pain”;       10 means “pain as bad as it could be”) 
 
 
              
  0                                                              10 
 
5. Please tick (√) the symptoms that you have today. 
 
  Nausea                Vomiting               Light Sensitive        
 
   Sound Sensitive                                  Pain with movement        
 
 No symptoms        Other ____________________________  
          
 
 
6. Headache Medication Taken 
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If you take any medication for headache, please fill in the name of the medication, how many tablets do 
you take at one time, how often do you take the medication and whether the medication is effective or not. 
Please give a score between 1 and 5 where 1 means the medication is not effective and 5 means the 
medication is most effective.   
 
1 means: not effective           5 means: most effective 
 
 
 
7. Likert Scale of Headache Severity 
 
Please tick (√) only one answer in the table below, which corresponds to the headache of today. 
 
 
    0: No headache 
 
   1: I notice the headache only when I pay attention to it 
 
 2: Mild headache that can be ignored at times 
 
 3: Headache is painful, but I can do my job or usual tasks 
 
 4: Very severe headache: I find it difficult to concentrate and can do only    undemanding tasks 
 
 5: Intense, incapacitating headache 
 
Medication      
Amount      
Effectiveness Scale (in each box, enter the number that best reflects the effectiveness of your relief) from 
1(not effective) to 5 (most effective) 
 
Score 
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Appendix 10: McGill Pain Questionnaire                           
 
1. Categories 1-20 below describe your present pain. In any appropriate category circle ONLY word that 
best describes it– the one that applies best. Leave out any category that is not suitable.  
 
 
2. Please tick (√) the word or words, which you use to describe the pattern of your pain changing with time. 
 
A B C 
Brief  Rhythmic  Continuous  
Momentary  Periodic  Steady  
Transient  Intermittent  Constant  
 
 
1 Flickering 
Quivering 
Pulsing 
Throbbing 
Beating 
Pounding 
5 Pinching 
Pressing 
Gnawing 
Cramping 
Crushing 
9 Dull 
Sore 
Hurting 
Aching 
Heavy 
13 Fearful 
Frightful 
Terrifying 
17 Spreading 
Radiating 
Penetrating 
Piercing 
2 Jumping 
Flashing 
Shooting 
 
6 Tugging 
Pulling 
Wrenching 
10 Tender 
Taut 
Rasping 
Splitting 
14 Punishing 
Gruelling 
Cruel 
Vicious 
Killing 
18 Tight 
Numb 
Drawing 
Squeezing 
Tearing 
3 Pricking 
Boring 
Drilling 
Stabbing 
lancinating 
7 Hot 
Burning 
Scalding 
Searing 
11 Tiring 
Exhausting 
15 Wretched 
Blinding 
19 Cool 
Cold 
Freezing 
4 Sharp 
Cutting 
Lacerating 
8 Tingling 
Itchy 
Smarting 
Stinging 
12 Sickening 
Suffocating 
16 Annoying 
Troublesome 
Miserable 
Intense 
Unbearable 
20 Nagging 
Nauseating 
Agonizing 
Dreadful 
Torturing 
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3. Evaluate overall intensity of total pain experience. Please tick (√) in the appropriate column. 
 
0 No pain  
1 Mild  
2 Discomforting  
3 Distressing  
4 Horrible  
5 Excruciating  
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Appendix 11: Migraine Specific Quality of Life Questionnaire (v. 2.1)            
Dear Participants, 
Please fill out this questionnaire. It will help us understand the effects of migraine headache 
on your daily activities. 
 
Thank you for your time. 
 
1. In the past 4 weeks, how often have migraines interfered with how well you dealt with family, 
friends and others who are close to you? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
2. In the past 4 weeks, how often have migraines interfered with your leisure time activities, such as 
reading or exercising? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
3. In the past 4 weeks, how often have you had difficulty in performing work or daily activities 
because of migraine symptoms? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
While answering the following questions, please think about all 
migraine attacks you may have had in the past 4 weeks. 
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4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
4. In the past 4 weeks, how often did migraines keep you from getting as much done at work or at 
home? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
5. In the past 4 weeks, how often did migraines limit your ability to concentrate on work or daily 
activities? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
6. In the past 4 weeks, how often have migraines left you too tired to do work or daily activities? 
(Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
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7. In the past 4 weeks, how often have migraines limited the number of days you have felt energetic? 
(Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
8. In the past 4 weeks, how often have you had to cancel work or daily activities because you had a 
migraine? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
9. In the past 4 weeks, how often did you need help in handling routine tasks such as every day 
household chores, doing necessary business, shopping, or caring for others, when you had a 
migraine (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
10. In the past 4 weeks, how often did you have to stop work or daily activities to deal with migraine 
symptoms? (Select only one response.) 
1   None of the time 
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2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
11. In the past 4 weeks, how often were you not able to go to social activities such as parties, dinner 
with friends, because you had a migraine? (Select only one response.) 
 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
12. In the past 4 weeks, how often have you felt fed up or frustrated because of your migraines? 
(Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
13. In the past 4 weeks, how often have you felt like you were a burden on others because of your 
migraines? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
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3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
 
14. In the past 4 weeks, how often have you been afraid of letting others down because of your 
migraines? (Select only one response.) 
1   None of the time 
2   A little bit of the time 
3   Some of the time 
4   A good bit of the time 
5   Most of the time 
6   All of the time 
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   Appendix 12: Pressure Pain Threshold                                                                             
1. Do you have migraine/headache today?      
Yes
      
No
       If yes, please give a score to describe the intensity 
 
The lowest level of your pain (0 means “no pain”; 10 means “pain as bad as it could be”)  _______________________________ 
 
The highest level of your pain ____________________          The average level of your pain____________________ 
 
2. Do you have migraine/headache at the moment?                 
Yes
            
No
     
 
If yes, Please give a score to describe the intensity of your pain (0 means “no pain”; 10 means “pain as bad as it could be”)  _________ 
 
3. Pressure pain threshold  
 
 
2 cm to the midline of 2 
cm inferior to the external 
occipital 
GB20 2cm to the midline at the 
vertex EX-HN5 
The masseter muscle in 
front of the mandibular 
angle 
EX-HN3 
 left right left right left right left right left right  
1            
2            
Mean            
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Appendix 13: Pain Medication Class Detriment Weights 
Medication Class Weitht 
Topical / transdermal anesthetics, capsaicin 1.1 
Antidepressants – serotonin reuptake inhibitors 1.7 
Antidepressants - other 1.9 
Anticonvulsants - GABAergic 1.9 
Antihypertensives 2.0 
Anti – anxiety - miscellaneous 2.1 
Muscle relaxants – non-dependency producing 2.2 
Acetaminophen 2.2 
Cyclooxygenase-2 inhibitors 2.3 
Antidepressants – tricyclics / tetracyclics 2.3 
Analgesic – miscellaneous (ie, tramadol) 2.3 
Anticonvulsants – sodium channel blockers 2.8 
Sedative hypnotics 3.1 
Opioids – Schedule II 3.4 
Nonsteroidal anti-inflamatories 3.4 
Antipsychotics 3.6 
Opioids – Schedule IV 3.7 
Opioids – Schedule III 3.7 
Muscle relaxants – dependency producing 3.8 
Benzodiazepines 3.9 
Steroids 4.4 
Barbiturates 4.5 
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Appendix 14: Attitude to Acupuncture 
 
1) Do you agree that acupuncture should be used as a complementary medicine? 
 
 
Yes
           
No
                   
Don't know
     
 
2) Do you agree with the statement that modern physiotherapy and drugs make 
acupuncture unnecessary?  
 
                
Yes
            
No
                   
Don't know
 
 
3) Would you feel more apprehensive about acupuncture than physiotherapy? 
 
                
Yes
            
No
                    
Don't know
 
 
4) Do you agree acupuncture should be used as an alternative to orthodox treatments, not 
merely used when all else fails? 
 
                
Yes
             
No
                   
Don't know
 
 
5) Would you like to recommend acupuncture treatment to your friends or relatives when 
necessary? 
 
                 
Yes
            
No
                   
Don't know
 
 
6) Do you agree with the statement that acupuncture might actually cause more pain? 
 
                 
Yes
            
No
                    
Don't know
 
 
7) Would you feel more anxiety about using acupuncture than taking medication?  
 
                 
Yes
            
No
                    
Don't know
 
 
8) Do you agree that acupuncture is unscientific and will not produce a real benefit? 
 
                 
Yes
            
No
                    
Don't know
 
 
9) Do you speak to your doctor about acupuncture? 
 
                 
Yes
            
No
                    
Don't know
 
 
10) Do you believe that acupuncture should be more strictly regulated? 
 
                 
Yes
            
No
                     
Don't know
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11) Do you believe acupuncture should be regulated the same way as Western medicine? 
 
                 
Yes
           
No
                   
Don't know
 
 
12) Do you believe that acupuncture in conjunction with Western Medicine can be more 
effective than either form of therapy used alone?     
 
Yes
            
No
                  
Don't know
            
 
13) For what kind of symptoms or illness do you think acupuncture might be helpful? 
      (Tick (√) as many as you like)  
 
Cold/Flu/Sore throat
  
Dizziness
  
Eye related problems
    
Hearing related problems
      
Cancer
     
Broken limb
        
Stomach or internal problems
 
Pain
                
Chronic condition
        
Other ______________________________________________________
 
 
14) Do you believe that acupuncture treatment for migraine headache is cheaper than other 
complementary therapies? 
 
Strongly agree Agree Unsure Disagree
 
Strongly disagree
 
 
15) Do you believe that acupuncture treatment for migraine headache is more accessible 
than other therapies? 
 
Strongly agree Agree
 
Unsure Disagree
 
Strongly disagree
 
 
16)  Do you believe that acupuncture treatment for migraine headache produces faster relief 
of symptoms than other therapies? 
 
Strongly agree Agree
 
Unsure Disagree
 
Strongly disagree
 
 
17) Do you believe that acupuncture treatment for migraine headache has fewer side effects 
than other therapies? 
 
Strongly agree Agree
 
Unsure Disagree
 
Strongly disagree
 
 
18) Do you believe that acupuncture treatment is better for long-term cure of disease than 
other therapies? 
 
      
Strongly agree Agree
 
Unsure Disagree
 
Strongly disagree
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Appendix 15: Knowledge of Acupuncture                       
 
1) Have you had acupuncture treatment before? 
 
       
Yes
                
No
  
 
2) If Yes, Was the treatment helpful? 
 
        
Yes
        
No
         
Somewhat
          
Don't know
 
 
3) Have you seen acupuncture treatment performed? 
 
        
Yes
                 
No
 
 
4) What does Acupuncture involve?  
 
Needles
    
Electricity
  
Warmth
   
Cold
     
Don't know
 
  
5) How would you describe the sensation involved in acupuncture?  
 
  
No sensation
     
Some sensation
   
Painful sensation
  
Pricking Forgot Don't know
     
Other______________________________
_
 
 
6) How much pain do you think is involved in acupuncture treatment? 
(0 means “no pain”;       10 means “pain as bad as it could be”) 
 
 
      0                                               10                                    
     No pain at all                                 worst pain imaginable 
                                                                                 
 
7) Have any of your friends or relatives had acupuncture before? 
 
Yes
                   
No
                   
Don't know
 
 
8) Do you think acupuncture is more effective for some conditions, but not 
others? 
 
Yes
                   
No
                   
Don't know
   
 
9) If yes, which condition?  ____________________________________________ 
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10) What is the chance of infection following acupuncture? 
 
None
    
Low
      
High
      
Don't know
 
 
11) Can acupuncture produce long-term effects? 
 
Yes
                   
No
                   
Don't know
  
 
12) Does acupuncture restore damaged tissue? 
 
Yes
                   
No
                    
Don't know
  
 
13) Do you know how acupuncture works? 
 
Yes
              
No
        
Some
         
Don't know
 
 
14) Does acupuncture have any side effect?     
        
Fainting
         
Infection
     
Bleeding
    
Others
 
 
